Eliciting adverse effects data from participants in clinical trials. by Allen, Elizabeth N et al.
Allen, Elizabeth N; Chandler, Clare Ir; Mandimika, Nyaradzo; Leisegang,
Cordelia; Barnes, Karen (2018) Eliciting adverse effects data from
participants in clinical trials. The Cochrane database of systematic
reviews, 1 (1). MR000039. ISSN 1469-493X DOI: https://doi.org/10.1002/14651858.mr000039.pub2
Downloaded from: http://researchonline.lshtm.ac.uk/4650712/
DOI: 10.1002/14651858.mr000039.pub2
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
Cochrane Database of Systematic Reviews
Eliciting adverse effects data from participants in clinical
trials (Review)
Allen EN, Chandler CIR, Mandimika N, Leisegang C, Barnes K
Allen EN, Chandler CIR, Mandimika N, Leisegang C, Barnes K.
Eliciting adverse effects data from participants in clinical trials.
Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No.: MR000039.
DOI: 10.1002/14651858.MR000039.pub2.
www.cochranelibrary.com
Eliciting adverse effects data from participants in clinical trials (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
15DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
44DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
44ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
89APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
102CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
102DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
102SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
103DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
103NOTES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iEliciting adverse effects data from participants in clinical trials (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Methodology Review]
Eliciting adverse effects data from participants in clinical trials
Elizabeth N Allen1, Clare IR Chandler2, Nyaradzo Mandimika1 , Cordelia Leisegang1 , Karen Barnes1
1Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. 2Dept of Global
Health & Development, London School of Hygiene and Tropical Medicine, London, UK
Contact address: Elizabeth N Allen, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, K45, Old
Main Building, Groote Schuur Hospital, Observatory, Cape Town, Western Cape, 7925, South Africa. elizabeth.allen@uct.ac.za.
Editorial group: Cochrane Methodology Review Group.
Publication status and date: New, published in Issue 1, 2018.
Citation: Allen EN, Chandler CIR, Mandimika N, Leisegang C, Barnes K. Eliciting adverse effects data from participants in clinical
trials. Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No.: MR000039. DOI: 10.1002/14651858.MR000039.pub2.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Analysis of drug safety in clinical trials involves assessing adverse events (AEs) individually or by aggregate statistical synthesis to provide
evidence of likely adverse drug reactions (ADR). While some AEs may be ascertained from physical examinations or tests, there is great
reliance on reports from participants to detect subjective symptoms, where he/she is often the only source of information. There is no
consensus on how these reports should be elicited, although it is known that questioning methods influence the extent and nature of
data detected. This leaves room for measurement error and undermines comparisons between studies and pooled analyses. This review
investigated comparisons of methods used in trials to elicit participant-reported AEs. This should contribute to knowledge about the
methodological challenges and possible solutions for achieving better, or more consistent, AE ascertainment in trials.
Objectives
To systematically review the research that has compared methods used within clinical drug trials (or methods that would be specific for
such trials) to elicit information about AEs defined in the protocol or in the planning for the trial.
Search methods
Databases (searched toMarch 2015 unless indicated otherwise) included: Embase; MEDLINE; MEDLINE in Process and OtherNon-
Indexed Citations; Cochrane Methodology Register (July 2012); Cochrane Central Register of Controlled Trials (February 2015);
Cochrane Database of Systematic Reviews; Database of Abstracts of Reviews of Effects (January 2015); Health Technology Assessment
database (January 2015); CINAHL; CAB Abstracts; BIOSIS (July 2013); Science Citation Index; Social Science Citation Index;
Conference Proceedings Citation Index - Science. The search used thesaurus headings and synonyms for the following concepts: (A):
Adverse events ANDmeasurement; (B): Participants AND elicitation (also other synonyms for extraction of information about adverse
effects from people); (C): Participants AND checklists (also other synonyms as for B). Pragmatic ways were used to limit the results
whilst trying to maintain sensitivity. There were no date or sample size restrictions but only reports published in English were included
fully, because of resource constraints as regards translation.
Selection criteria
Two types of studies were included: drug trials comparing two or more methods within- or between-participants to elicit participant-
reported AEs, and research studies performed outside the context of a trial to compare methods which could be used in trials (evidenced
by reference to such applicability). Primary outcome data included AEs elicited from participants taking part in any such clinical trial.
We included any participant-reported data relevant for an assessment of drug-related harm, using the original authors’ terminology
(and definition, where available), with comment on whether the data were likely to be treatment-emergent AEs or not.
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Data collection and analysis
Titles and abstracts were independently reviewed for eligibility. Full texts of potentially eligible citations were independently reviewed
for final eligibility. Relevant data were extracted and subjected to a 100% check. Disagreements were resolved by discussion, involving
a third author. The risk of bias was independently assessed by two authors. The Cochrane ’Risk of bias’ tool was used for reports
comparing outcomes between participants, while for within-participant comparisons, each study was critically evaluated in terms of
potential impact of the design and conduct on findings using the framework of selection, performance, detection, attrition, reporting,
and other biases. An attempt was made to contact authors to retrieve protocols or specific relevant missing information. Reports were
not excluded on the basis of quality unless data for outcomes were impossible to compare (e.g. where denominators differed). A narrative
synthesis was conducted because differences in study design and presentation meant that a quantitative meta-analysis was not possible.
Main results
The 33 eligible studies largely compared open questions with checklist-type questions or rating scales. Two included participant
interviews. Despite different designs, populations and details of questioning methods, the narrative review showed that more specific
questioning of participants led to more AEs detected compared to a more general enquiry. A subset of six studies suggested that more
severe, bothersome, or otherwise clinically relevant AEs were reported when an initial open enquiry was used, while some less severe,
bothersome, or clinically relevant AEs were only reported with a subsequent specific enquiry. However, two studies showed that quite
severe or debilitating AEs were only detected by an interview, while other studies did not find a difference in the nature of AEs between
elicitation methods. No conclusions could be made regarding the impact of question method on the ability to detect a statistically
significant difference between study groups. There was no common statistical rubric, but we were able to represent some effect measures
as a risk ratio of the proportion of participants with at least one AE. This showed a lower level of reporting for open questions (O)
compared to checklists (CL), with a range for the risk ratios of 0.12 to 0.64.
Authors’ conclusions
This review supports concerns that methods to elicit participant-reported AEs influence the detection of these data. There was a risk
for under-detection of AEs in studies using a more general elicitation method compared to those using a comprehensive method. These
AEs may be important from a clinical perspective or for patients. This under-detection could compromise ability to pool AE data.
However, the impact on the nature of the AE detected by different methods is unclear. The wide variety and low quality of methods
to compare elicitation strategies limited this review. Future studies would be improved by using and reporting clear definitions and
terminology for AEs (and other important variables), frequency and time period over which they were ascertained, how they were
graded, assessed for a relationship to the study drug, coded, and tabulated/reported. While the many potential AE endpoints in a trial
may preclude the development of general AE patient-reported outcome measurement instruments, much could also be learnt from
how these employ both quantitative and qualitative methods to better understand data elicited. Any chosen questioning method needs
to be feasible for use by both staff and participants.
P L A I N L A N G U A G E S U M M A R Y
Questioning clinical trial participants about their health in order to collect information on adverse effects of drugs
Clinical drug trials or studies are usually conducted to assess how well the drug works but also whether it causes any harm (side effects
or adverse effects). Adverse effects can be detected by the trial doctor examining participants or taking some blood samples or doing
other kinds of tests. The trial staff can also ask participants about how they are feeling after taking the trial drug. However, the way
participants are asked about their health can vary from trial to trial, or even within a trial. In some trials, participants may be asked a
simple open question such as ’how have you been feeling?’, while in other trials, participants may be asked about whether they have had
any of a long list of possible symptoms (such as ’have you had a headache, stomach ache, or sore muscles?’). There has been concern
that these different kinds of questions and how they are phrased will impact on what participants report about their health during a
trial. This might then affect the trial’s results and what we know about the side effects of drugs.
We did this review to look at studies that compared different types of participant questioning methods in order to investigate these
issues. We found 33 studies comparing mainly open questions with checklist-type questions, but also some ratings scales and participant
interviews. While the studies were all very different in terms of the types of disease, drugs, and patients studied, we found in general
that, as would be expected, when a more specific type of question was asked (like a checklist), participants reported more symptoms.
What is interesting is that, in those studies that looked more closely at the types of symptoms reported, it seems that an open question
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picks up the more severe or bothersome symptoms compared to a checklist-type question. However, some studies found that even
quite severe or bothersome symptoms were not reported when a participant is asked an open question and these severe symptoms will
only be reported with the more specific question. This makes it difficult to say whether one method is better than any other and the
different questioning methods may, in fact, be complementary and therefore should be used together. It is also difficult to say what
a specific question should include, as it might take too long for a participant to have to answer a very long list. While more research
is needed to resolve the remaining uncertainties, it is very important for trials to be clear about which kind of questioning was used
when they publish their results. This will help readers understand the trial’s findings about the side effects and make it easier to make
accurate comparisons between trials.
B A C K G R O U N D
Description of the problem or issue
Manufacturers must demonstrate safety, efficacy, and quality of
their investigational drugbyway of clinical trials in order to achieve
registrationwith regulatory authorities. Thereafter, they, and other
stakeholders, continue to evaluate the product’s risk profile in
subsequent trials, particularly in under-studied population groups
(ICH 2004). Safety analyses in clinical trials largely involve iden-
tifying untoward medical occurrences after exposure. These end-
points, which are not necessarily causally related, are called adverse
events (or sometimes adverse effects) (AEs) (ICH 1996). AEs are
assessed either on an individual case basis or by aggregate statisti-
cal synthesis to provide evidence of likely adverse drug reactions
(ADRs), which are those AEs that have a reasonable possibility of
being caused by the trial drug (CIOMS 2005).
The processes involved in collecting, recording, analysing, and re-
porting AEs are generally considered more complex than those
involved in evaluating the potential benefits of a drug, and meth-
ods are relatively less developed (Huang 2011). While some AEs
may be ascertained from physical examinations or tests, there is
a great reliance on reports from the participants to detect subjec-
tive symptoms, where the participant is the only source of infor-
mation. There is no consensus on how these reports should be
elicited from participants, although it is well known that methods
involving direct questioning influence the extent and nature of
the data detected (FDA 2005). For instance, studies have found
that giving participants a checklist of potential AEs yields more
reports than posing a general enquiry about change in health (Bent
2006). However, it is uncertain whether one way of question-
ing over another is better for detecting ADRs (Wernicke 2005).
Should methods to elicit AEs be less than optimal, there is a mar-
gin for measurement error which will undermine individual trial
results and meta-analyses of multiple trials. This problem will also
occur if trials use disparate methods. This restricts the ability to
detect rare ADRs and to explore factors influencing the assess-
ment of risk (FDA 2005; Huang 2011). This situation is com-
pounded by generally poor reporting in subsequent publications
about whichmethodswere used to determine participant-reported
AEs (Ioannidis 2004).
Description of the methods being investigated
This review investigated any method used in a clinical trial to elicit
participant-reported AEs, such as a general enquiry, checklist, di-
ary, memory aid etc, whether applied face-to-face or otherwise.
Due to the lack of consensus, as described above, the details of all
methods studied were only known once the review was ongoing.
Studies that included a comparison of methods used to elicit infor-
mation on other participant-reported variables (e.g. concomitant
medications or medical histories) were also included in the review.
How these methods might work
Little is known specifically about how different methods of AE
elicitation work, although this is likely to be similar to questions
about other topics, in that response to questioning involves com-
prehension, judgement, recall frommemory, and communication
of the response (Tourangeau 1984). Our earlier qualitative study
of barriers to accurate and complete reporting of harms data sug-
gests that questioning detail and terminology influences partici-
pants’ recognition of health issues and treatments. Moreover, we
suggested that the perceived relative importance of health issues
and treatments to the participant may be a factor (Allen 2011).
Why it is important to do this review
Current heterogeneity in, and uncertainty about, the best prac-
tices for participant-reported AE elicitation in clinical trials leaves
regulatory authorities, policy makers, healthcare professionals, pa-
tients, and the public unsure about how far results are accurate and
comparable. It would therefore be useful to synthesise research that
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compares elicitation methods. This should contribute to knowl-
edge about the methodological challenges, and possible solutions,
for achieving better, or harmonised, AE ascertainment in clinical
trials.
O B J E C T I V E S
To systematically review the research that has compared the meth-
ods used within clinical drug trials (or that would be specific for
such trials) to elicit information about the AEs that were defined
in the protocol or in the planning for the trial.
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Clinical drug trials that include a comparison of two or
more methods to elicit participant-reported AEs;
• Research studies that have been performed outside the
context of a clinical drug trial to compare two or more methods
to elicit participant-reported AEs but which could be used in
clinical trials (evidenced by reference to such applicability).
Types of data
AEs elicited from participants taking part in a clinical trial. For
the purposes of this review, AEs are defined as those outcomes that
were prespecified as potential AEs to be investigated in the trial
(including expected or unexpected AEs, the latter which will not
be known, but are intended to be detected during the trial), rec-
ognizing that the trial itself might reveal that these are not actually
increased in an intervention group compared with a control group.
Concomitant medication and medical history data were also in-
cluded in this review if the eligible study also included a compari-
son of methods used to elicit those. This is because these variables
also impact on the assessment of whether an AE is likely to be
an ADR. It became apparent during the review that terminology
and definitions used for AEs were unclear or inconsistent. This is
partly due to changing perspectives on this topic over time and
partly because we included research studies outside the context of
a clinical drug trial. Thus, we included studies that reported par-
ticipant-reported data relevant for an assessment of drug-related
tolerability or harm, using the original authors’ terminology (and
definition, where available) with comment on whether the AEs
were likely to be treatment-emergent or not.
Types of methods
Any combination of elicitation methods compared within or be-
tween participants. This included, but was not limited to, unstruc-
tured or structured enquiries, checklists, or questionnaires (e.g. by
body system, symptom etc.), diaries, and memory aids.
Types of outcome measures
Primary outcomes
• The effect measure (or number, proportion) and/or nature
(e.g. characteristics, severity, causality assessment) of AEs
identified by the method of elicitation, as defined by the original
authors.
Secondary outcomes
• If relevant, the effect measure (or number, proportion) and/
or nature (e.g. characteristics, severity, causality assessment) of
AEs identified by the method of elicitation by the relevant trial
interventions;
• If relevant, the effect measure (or number, proportion) and/
or nature (e.g. medication class) of concomitant medications
and/or medical histories identified by the method of elicitation,
as defined by the original authors;
• If relevant, summary results of qualitative methods used;
• If relevant, results of inherent elicitation method validation
studies.
Search methods for identification of studies
There was no date or sample size restrictions in the searches, but
only reports published in English were searched for and included
in the review, because of resource constraints as regards translation.
Electronic searches
The searches were designed and conducted with the assistance of
an experienced information professional. A list of databases and
search strategies was finalised prior to starting the search, with
subsequent iterations fully documented. The following databases
were searched: Embase (OVID) 1980 to 2015 week 11; MED-
LINE (OVID)1946 toMarchweek 22015;MEDLINE inProcess
and Other Non-Indexed Citations, March 16th 2015; Cochrane
Methodology Register (Wiley Online) Issue 3 of 4, July 2012 (no
longer updated); Cochrane Central Register of Controlled Trials
(Wiley Online) Issue 2 of 12, February 2015; Cochrane Database
of Systematic Reviews (Wiley Online) Issue 3 of 12, March 2015;
Database of Abstracts of Reviews of Effects (Wiley Online) Issue 1
of 4, January 2015; Health Technology Assessment database (Wi-
ley Online) Issue 1 of 4, January 2015; CINAHL (EBSCO) 1981
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to March 2015; CAB Abstracts (OVID) 1973 to 2015 Week 10;
BIOSIS (Web of Knowledge) 1969 to July 2013 (can no longer ac-
cess); Science Citation Index (Web of Knowledge) 1970 to March
2015; Social Science Citation Index (Web of Knowledge) 1970
to March 2015; Conference Proceedings Citation Index - Science
(Web of Knowledge) 1990 to March 2015.
The search was designed using thesaurus headings and synonyms
for each of the following concepts: (A): Adverse events ANDmea-
surement; (B): Participants AND elicitation (also other synonyms
for the extraction of information about adverse effects from peo-
ple); (C): Participants AND checklists (also other synonyms for
themethods used to extract information about adverse effects from
people).
Ideally, the search would have been run using the following search
string: A AND (B OR C). Unfortunately, this produced an un-
manageablely large number of results, mainly because it was im-
possible for the search to differentiate between (i) studies aiming
to compare two different methods for eliciting adverse effects data
(i.e. the eligible studies for this review); and (ii) studies whichmen-
tioned in their abstract that they collected data from participants
about adverse effects (i.e. thousands of studies that would not be
eligible for this review).
The information specialist, with help from information colleagues,
used pragmatic methods to limit the search results whilst trying
to maintain sensitivity in the search. Each of these were used sep-
arately and then combined with OR:
• Frequency searching: retrieving only those records which
contained certain adverse effect-related terms at least three times
in the abstract, the rationale being that if the study is based on
the collection of adverse effects data, then associated terms would
be used at least three times in the abstract. This part of the
strategy was tested with different proximities (i.e. two times or
four times) by comparing a sample of results from each to see
what was being lost as the number increased;
• Title field: one part of the search retrieved only those
records with adverse effects terms in the title, the rationale being
that if the study is focused on collection of adverse effects data
then associated terms would be in the title. This could only be
used in the databases accessed through OVID because other
databases do not provide this functionality. Some of the other
databases provided manageable numbers of results without these
techniques; with others, the title field technique was used.
There were no date limits on the electronic searches, but the
searches were limited to the English language.
See Appendix 1 for the search strategies used in each database
(presented with the results). We used Endnote X3 to collect, de-
duplicate, screen titles/abstracts, and record decisions on inclusion
of papers.
Searching other resources
We supplemented the electronic searches by checking reference
lists of included reports, some excluded reports that were relevant
to the topic, and other reports known to the authors who are fa-
miliar with the research area (Horsley 2011), handsearching re-
cent relevant topic-area conference abstracts (International Con-
ference onPharmacoepidemiology andTherapeutic RiskManage-
ment, International Society of Pharmacovigilance annual meet-
ing) (Scherer 2007), and searching online libraries of theses/dis-
sertations.
Data collection and analysis
Selection of studies
The first author (EA) examined titles and, where available, ab-
stracts of identified citations in order to remove obviously irrele-
vant reports (e.g. non-human studies). Thereafter, two authors (EA
and NM or CL) independently reviewed the remaining titles and
abstracts for eligibility according to the Criteria for considering
studies for this review, as described in the protocol for this review
(Allen 2013b). The full texts for all reports that appeared relevant
were sought, as well as those for which the title and abstract was
insufficient to determine eligibility. Reports from the same piece
of research were linked together. The same review authors inde-
pendently assessed final eligibility, with disagreements resolved by
discussion, involving a third author (KB), as necessary). While the
review authors were blinded to each other’s assessments, they were
not blinded to any information in the titles, abstracts, or full texts.
All documents relating to this search and selection process were
recorded along with the primary reason for non-inclusion.
Data extraction and management
One review author (EA) extracted data onto a data extraction
form according to a prespecified list, with a second review author
(CL) checking 100% of fields. Disagreements were resolved by
consensus, with, if necessary, a third author (KB) consulted to
resolve disagreements. The original planned list was pre-tested
with two reports and modified before being finalised as:
• Authors;
• Date published;
• Summary of study methods including any drug(s),
indications/inclusion criteria, assessments(s), and duration of
follow-up;
• Data (AE or equivalent with original authors’ terminology
and definition, where available; medications and medical
histories if these were also outcomes of the comparison)
• Comparisons (within or between participants);
• Elicitation methods, including (if available) description of
their development and application methods. Also training/
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experience of staff, how AEs were described, whether verbatim
reports were captured, and language;
• Outcomes and results:
◦ The relative effect estimates derived from one method
of ascertainment versus the other, by study group, if relevant;
◦ The number/proportion and/or nature of AEs as
defined by the original authors of the trial, by study group, if
relevant:
◦ If relevant, the relative effect estimates/number/
proportion and/or nature of concomitant medications and/or
medical histories;
◦ If relevant, summary of qualitative results;
◦ if relevant, statistical test results (including those from
validation studies);
• References to animal or human toxicology,
pharmacovigilance databases, participants, or patient/consumer
experiences (including explanations for differential reporting,
such as qualitative results, and underlying conceptual theories or
orientations);
• Key conclusions and limitations as reported by the original
authors or as determined by us, as the reviewers.
Assessment of risk of bias in included studies
The risk of bias was independently assessed by two review authors
(EA and KB), according to the Cochrane ’Risk of bias’ tool, as
far as was feasible in terms of the actual study design encountered
(Cochrane 2011). Where this was not feasible due to the study
methodology (e.g. for reports that compared outcomeswithin par-
ticipants), the studies were critically evaluated in terms of the po-
tential impact of the study’s design and conduct on its findings
regarding selection, performance, detection, attrition, and report-
ing biases, and any other biases that we considered important.
It is acknowledged that a ’risk of bias’ assessment is dependent on
the completeness and quality of the original study report and we
attempted to contact the original authors whose email addresses
were available to retrieve protocols or specific relevant missing in-
formation (Young 2011). We did not exclude reports from this
review on the basis of quality, unless insufficient data for the com-
parison were reported.
Measures of the effect of the methods
Effect measures from different methods were compared, where
possible, by assessing an overlap in 95% confidence intervals (
Golder 2011).
Unit of analysis issues
The units of analysis were only known once the review was ongo-
ing. The way that studies presented their data varied from abso-
lute numbers of AEs, to means, medians, the proportion of par-
ticipants with AEs and some study-specific scores. This precluded
quantitative pooling of data to generate pooled estimates. How-
ever, wherever possible, data were transformed into a common
quantitative rubric.
Dealing with missing data
We sought to minimize the amount of missing data through con-
tact with original authors, as mentioned above (Young 2011).
Thereafter, any assumptions made about missing data, any statis-
tical methods used to impute them, and the potential impact of
these methods on the findings of the review, were reported.
Assessment of heterogeneity
As noted above, pooled estimates could not be calculated, so we
did not follow our plan to assess heterogeneity using the Chi2 test
and I2 statistic (Higgins 2002).
Assessment of reporting biases
As noted above, we could not calculate pooled estimates and so we
could not follow our plan to assess reporting bias using a funnel
plot (Sterne 2001).
Data synthesis
As a meta-analysis of included studies was not possible, given
differences in study designs, interventions, and presentation, we
conducted a narrative synthesis using recommendations by Popay
2006. One author (EA) first examined the included studies for any
a priori theoretical basis for how elicitation methods could differ,
in case this could contribute to the interpretation and applicabil-
ity of the review findings. We developed a narrative summary of
the scope of the study designs in order to look at aspects of study
design across studies, and the Characteristics of included studies
table was used as the starting point for organising studies for syn-
thesis. For the latter, we tabulated brief key study characteristics
and the results within two broad categories of whether outcomes
were compared between or within participants. Where studies had
not calculated an effect, we did this using raw or summary data,
where possible, in order to develop common quantitative rubrics.
We examined the tabulation for relationships within and between
the studies, with the aim of identifying variables that potentially
moderated the effects. We followed the same process, where rele-
vant, for items relating to the impact of different elicitation meth-
ods on the between-drug effects, the nature of AEs detected, and
previous or concomitant medication and medical history data re-
ported.
Subgroup analysis and investigation of heterogeneity
We did not conduct any meta-analyses and so no quantitative
subgroup analyses or investigations of heterogeneity were done.
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Sensitivity analysis
Likewise, because we did not conduct any meta-analyses, no sen-
sitivity analyses were performed.
R E S U L T S
Description of studies
See the Characteristics of included studies, Characteristics
of excluded studies and Characteristics of studies awaiting
classification tables.
Results of the search
See Figure 1 for a flow diagram of the searchmetrics and Appendix
1 for the electronic search results. Our electronic search identified
13,903 papers, decreasing to 9663 after de-duplication. An ad-
ditional 35 papers were identified for inspection from non-elec-
tronic methods after reviewing the references lists of included and
some relevant excluded reports and handsearches. We sought the
full text for 203 articles, of which 33 were eligible for inclusion.
In total, 168 articles were excluded after checking the full text; 25
were further duplicates or variations on reports already assessed
that did not add any relevant data, 10 were not in English or
had been retracted, 98 did not include a comparison of methods
for eliciting AE data, or the comparison was not possible due to
the way data were collected or presented, 23 did not report any
methods of relevance for clinical trials, seven only included an
objectively measured AE (e.g. observation by a healthcare worker
or laboratory report), or otherwise ineligible assessment, and five
were conference abstracts without an associated paper. A further
two articles are awaiting classification. See the Characteristics of
excluded studies for details of articles which some readers may ex-
pect to be included. Nineteen included studies were found from
the electronic search and 14 through non-electronic means.
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Figure 1. Study flow diagram.
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Included studies
Of the 33 eligible studies, 32 were published in full and one was
a letter to the editor (Kruft 2007).
Theoretical basis for elicitation methods
The reports of the included studies were largely not explicit, or
were unclear, about the theoretical basis for the work. Often, the
expectation was simply that data were likely to be underreported
if participants were not questioned in detail and that more spe-
cific questioning would be likely to increase the number of AE
reports although it might have missed AEs that were not explicitly
shown on the list or tool. One study, however, asserted that a the-
oretical advantage of a general enquiry was the absence of sugges-
tion, but also hypothesised that response styles (like stoicism) are
more likely to influence open-ended questioning than checklist
methods of elicitation (Rabkin 1992). Avery 1967 postulated that
participants allowed to volunteer information may conceal or fail
to recognise symptoms, while suggestible participants may report
symptoms when questioned even though there is little objective
evidence of the symptom being present. Rosenthal 1996 stated
that ’connotation of words, among many other factors’ could in-
fluence AE responses. Some authors hypothesised that the nature
of AEs detected by the different methods would be informative.
This included the consideration that extra AEs reported through
more specific questioning methods, like a checklist, were less likely
to be clinically relevant, severe/bothersome or caused by the inter-
vention than those reported spontaneously or in response to what
some call ’non-leading’ open enquiries (Barber 1995, Downing
1970, Rabkin 1992). Where hypotheses were mentioned, they
were largely based on a study or studies that we cited in this re-
view, which may or may not be supported by the evidence. Studies
that compared methods as part of a validation exercise for a new
elicitation tool aimed to measure concordance (De Vries 2013;
De Vries 2014). One study was explicit that it was conducted
retrospectively with data already collected by different elicitation
methods (Kruft 2007). Two were natural experiments, in that the
method for eliciting AE data changed during a trial (Brent 2009;
Monteiro 1987). For other studies, it was unclear whether the
comparison was an a priori objective (Hermans 1994; Nicholls
1980; O’Connell 2007; Os 1994; Wernicke 2005; Yeo 1991).
Scope of study designs and presentations
Methods
Included studies were conducted within a wide range of thera-
peutic areas (and therefore with various participants and drug in-
terventions), including cardiology (Borghi 1984, Hermans 1994,
Nicholls 1980, Os 1994, Reilly 1992, Rosenthal 1996, Török
1984, Wallander 1991, Yeo 1991), psychiatry (Avery 1967,
Brent 2009, Downing 1970, Greenhill 2004, Jacobson 1987,
Landén 2005, Monteiro 1987, Rabkin 1992), ophthalmology
(Barber 1995, Kruft 2007), diabetes (De Vries 2013, De Vries
2014), dysmenorrhoea (O’Connell 2007), gastrointestinal dis-
eases (Barrowman 1970), gonorrhoea (Wallin 1981), malaria
(Allen 2013) (a study conducted by the authors of this review),
migraine (Sheftell 2004), Parkinson’s disease (Perez-Lloret 2012),
prostatic hyperplasia (Bent 2006), rheumatology (Huskisson
1974), and anunspecified indication for antihistamines (Lundberg
1980). Three studies were not related to any specific therapeutic
area (Ciccolunghi 1975, Spilker 1987) or the therapeutic area was
not specified (Wernicke 2005).
Five studies involved healthy volunteers, students or employ-
ees (Allen 2013, Barrowman 1970, Ciccolunghi 1975, Lundberg
1980, Spilker 1987). The remainderwere conductedwith patients.
Greenhill 2004 was treating children and therefore included care-
givers in the elicitation process, some of whom received a reim-
bursement fee for taking part in the study. Two other studies were
conducted in adolescents (Brent 2009, O’Connell 2007), one in
children and adults (Wernicke 2005) and the remainder were con-
ducted in adults (or we assumed them to be in adults when age
was not explicit). However, because age ranges were missing from
several papers, we did not include age in the Characteristics of
included studies table.
Most studies were conducted in Europe (N = 17) or the United
States (N =12). Two other studies weremultinational (Kruft 2007,
Sheftell 2004), one African (Allen 2013) and the location of one
was not reported (Wernicke 2005).
Seven studies were conducted outside of a clinical trial (
Ciccolunghi 1975,DeVries 2013,DeVries 2014,Greenhill 2004,
Perez-Lloret 2012, Sheftell 2004, Spilker 1987). The remainder
were nested within, or integral to, a trial. This latter group were all
randomised trials, with either a reference drug or placebo, except
for Allen 2013; and Wallin 1981, which used single-arm designs,
and Török 1984, which used a mixture of randomised and single-
arm trials. Four studies were conducted as part of validating two
new tools for eliciting AEs: De Vries 2013 and De Vries 2014
(outside of a trial) and Jacobson 1987 and Rabkin 1992 (within a
trial).
Data
Most studies sought to elicit any AE, while others focused on
a specific AE or specific AEs of special interest. The studies of
9Eliciting adverse effects data from participants in clinical trials (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
specific AEs included occular-related abnormalities (Kruft 2007),
sexual dysfunction (Landén 2005, Monteiro 1987), depression
(O’Connell 2007), cough (Os 1994, Yeo 1991), and self-harm
(Brent 2009). However, there were significant variations in termi-
nology and definitions for the data being collected, which made
our analysis challenging. It was largely older studies that used the
terms ’side-effect’ (Avery 1967, Huskisson 1974, Lundberg 1980,
Nicholls 1980, O’Connell 2007, Os 1994, Török 1984), ’side re-
action’ (Downing 1970), ’unwanted effect’ (Borghi 1984), and
’adverse reaction’ (Wallin 1981) to describe the data collected, re-
gardless of whether it was treatment-emergent or not, or whether
a causality assessment had been performed. More recent studies
used ’adverse experience’ (Barber 1995), ’adverse health event’
(Jacobson 1987), ’adverse event’, ’adverse drug event’ or just ’event’
(Bent 2006, Brent 2009, De Vries 2013, De Vries 2014, Greenhill
2004, Hermans 1994, Kruft 2007, Landén 2005, Perez-Lloret
2012, Rabkin 1992, Rosenthal 1996, Sheftell 2004, Wallander
1991, Wernicke 2005).
As our protocol (Allen 2013b) allowed for the inclusion of meth-
ods’ studies conducted outside of a clinical trial, we expected that
not all studies would collect or report AEs according to the In-
ternational Conference on Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human Use (ICH)
definition (’any untoward medical occurrence in a patient or clin-
ical investigation subject administered a pharmaceutical product
and that does not necessarily have a causal relationship with this
treatment’). However, of the 26 comparisons nested within or in-
tegral to clinical trials, only six could confidently be considered as
reporting treatment-emergent AEs - i.e. taking baseline symptoms
or medical history into account when interpreting data collected
as a new event or worsening of a previous event (Allen 2013, Brent
2009, Hermans 1994, Landén 2005, Monteiro 1987, Os 1994,
Wernicke 2005). The reports of four other studies were clear that
they were collecting symptoms that were not necessarily treat-
ment-emergent (Ciccolunghi 1975, Reilly 1992, Spilker 1987;
and Török 1984). The remaining studies were unclear about this.
For simplicity, we used AE as the default term hereafter. Rosenthal
1996 only reported on AEs that matched those on the checklist.
Some studies looked at the nature of the AEs elicited, although the
way this was done varied. Allen 2013 included a global statement
of the investigator’s assessment of severity and causality of all AEs
collected. Other authors reported individual assessments of sever-
ity, clinical relevance, clinical action taken, seriousness, discomfort
and/or bother. Assessments were either performed by investiga-
tors (Brent 2009, Greenhill 2004, Hermans 1994, Jacobson 1987,
Perez-Lloret 2012, Rabkin 1992) or participants (Avery 1967,
Barber 1995, Ciccolunghi 1975, Downing 1970, Reilly 1992,
Sheftell 2004, Spilker 1987) using tools such as investigator-grad-
ing schemes (mild, moderate, severe etc.) and participant-reported
rating scales. It was not clear for Huskisson 1974 or Wallin 1981
who assessed severity.
Other relevant results related to the feasibility (De Vries 2013) and
acceptability (Greenhill 2004) of different questioning methods,
and De Vries 2014 measured differing recall periods. Allen 2013
collected qualitative data from in-depth interviews with selected
participants to explore reasons for differential reporting between
elicitation methods, and captured medical history and non-study
drug data in the same way as the AEs. Avery 1967;Hermans 1994;
Rabkin 1992 andReilly 1992 also elicited baseline AE or symptom
data, but there was not enough information to clarify whether
measures of effect after baseline were treatment-emergent or not.
While we generally excluded studies that involved an objective
assessment of AEs (e.g. through laboratory tests or physical ex-
aminations), it was possible to identify some participant-reported
AE data in two of these justifying their inclusion in this review
(Török 1984, Wallander 1991). For another study (Borghi 1984),
it was possible that one of themethods involved a doctor ’filtering’
participant reports (i.e. just reporting those he or she considered
ADRs). This study was also included in the review by restricting
the comparison to the other two methods that reflected partici-
pant-reported data.
Comparisons
Most (N = 25) studies compared data within participants. That
is, each participant was asked about AEs by two or more elicita-
tion methods. The remainder of the studies allocated groups of
participants to different methods for eliciting AEs. Avery 1967,
Bent 2006, Borghi 1984, Ciccolunghi 1975, and Spilker 1987
allocated methods randomly while Brent 2009, Huskisson 1974
and Török 1984 used non-random allocation. Four of the be-
tween-participant comparisons involved comparing one method
with that method plus another one (Avery 1967, Huskisson 1974,
Rabkin 1992 and Török 1984).
Most comparisons were of participant responses to open ques-
tions (O) (and/or occasionally a completely spontaneous report,
i.e. where no question was asked) and responses to what can be
summarised as a checklist or questionnaire pick-list of potential
AEs (CL). Two of these studies involved answers to an open ques-
tion written on a blank (B) form Sheftell 2004, Spilker 1987) and
one an open question on a daily diary (D) as a gold standard (De
Vries 2014). Other comparisons involved rating scales (R), such
as visual analogue scales (VAS), that used a particular change over
time to determine the incidence of an AE (e.g. the Brief Suicide
Severity Rating Scale used by Brent 2009) or was simply reported
as a mm change (e.g. Os 1994). Two studies conducted interviews
(INT) with participants (Allen 2013, Monteiro 1987). The com-
parisons other than O/B/D versus CL were: O versus R (Brent
2009, Kruft 2007, Landén 2005, Yeo 1991), CL versus another
CL (DeVries 2013, specifically the impact of using body categories
on reporting), CL versus R (Lundberg 1980, Wallander 1991), O
versus CL versus another CL (Greenhill 2004), O versus CL versus
R (Os 1994), O versus another type of O versus CL (Bent 2006),
O versus CL versus INT (Allen 2013 [in a subset of participants
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only], Monteiro 1987)), and B versus B versus CL (Ciccolunghi
1975).
The detail of questioning (e.g. phraseology of O, the number and
type of specific symptoms or body systems asked about inCL), and
how methods were developed and applied (e.g. verbal, written, or
electronic) varied widely within these comparisons. See Table 1
for more information.
Due to the variety of indications and interventions/treatments,
and whether comparisons were within clinical trials or not, the
timeline over which the elicitation methods were applied and how
often they were applied were diverse. Some studies compared data
elicited on one visit occasion only, while other studies used data
from multiple visit occasions, which were combined or reported
separately.
Outcomes
In addition to differences in participants, therapeutic areas, com-
parisons, data and follow-up period, the disparate approaches to
measuring and reporting outcomes supported our decision not to
pool results.
Number of AEs reported
Several studies reported the number or proportion of AEs, or both,
elicited by method at, or by, a particular time-point. These were
either given as a sum total of all AEs, by type of AE or the raw
data were listed by method. However, three studies only gave the
number (%) of participants reporting no versus at least one or
two AEs (Downing 1970, Landén 2005) or the mean/median
(range, standard deviation) number of AEs per participant (Avery
1967, Downing 1970). Other variations included Barrowman
1970 and Barber 1995, who calculated an average frequency of
a particular domain for participants who did not report any AEs
spontaneously (O) but indicated an AE by CL, and Huskisson
1974, who presented AEs only as a score calculated from a severity
rating scale. Kruft 2007 performed a meta-analysis of four studies
where the outcome was presented as the number and proportion
of participants reporting AEs. Os 1994 presented frequencies of
AEs for two of the three methods compared, but presented the
third method (R) as a change in VAS measurement.
Three of the within-participant comparison studies only gave the
number of additional AEs obtained through the second or third
method (i.e. capturing AEs only when they were first elicited),
rather than absolute numbers of AEs obtained by each method
(Allen 2013, Greenhill 2004,Wallin 1981). Huskisson 1974 com-
bined all AEs that were not auditory or gastrointestinal in nature
as ’irrelevant’ and reported them as a combined frequency/severity
score. Monteiro 1987 limited the comparison to participants who
had not reported an AE by CL but had reported at least one AE
either spontaneously (by O) or by INT.
Statistical tests of effect by elicitation method, where used, mostly
included Chi2 and Mann-Whitney U tests. However, De Vries
2013 also used normal curve deviate statistics (Z value) for the
measure of agreement betweenmethods, andDeVries 2014 calcu-
lated the sensitivity and positive predictive value at different Med-
DRA® reporting levels. Wallander 1991 investigated the ability
of each method to detect symptoms that changed over time and
sensitivity to change, while Perez-Lloret 2012 analysed factors re-
lated to spontaneous reporting of AEs.
Seventeen studies presented comparative data by study group,
either descriptively or through measures of effect (Avery 1967,
Barrowman 1970, Borghi 1984, Ciccolunghi 1975, Downing
1970, Hermans 1994, Huskisson 1974, Landén 2005, Lundberg
1980, Monteiro 1987, Nicholls 1980, O’Connell 2007, Os 1994,
Reilly 1992, Rosenthal 1996, Wallander 1991, Wernicke 2005).
However, the data in Monteiro 1987 could not be extracted for
both study groups. Wernicke 2005 used the ratio between the rate
of AEs reported by drug versus placebo (D/P) plotted for solicited
AEs on an x-axis against spontaneous AEs on a y-axis, and the
ratio of D/P ratios. Lundberg 1980 used an analysis of variance
for data in each method arm reported by at least 50% of the sam-
ple, however, only summary descriptions were available for the
between-method comparison results. Landén 2005 and Os 1994
also reported AEs by drug and gender for the elicitation methods
that they compared.
Nature of AEs reported, including quality of life, clinical
relevance, and action taken
The way studies analysed and presented the effect of elicitation
method on the nature of AEs reported by participants also varied.
Avery 1967 compared mean severity score on each visit occasion
(weighting symptoms by a factor derived from the degree of sub-
jective discomfort reported by the participant). Barber 1995 re-
ported the average bother, level of activity limitation, satisfaction
with medication, compliance, and global quality of life domain
scores for those participants who did not report any spontaneous
AEs (O) but did indicate on the questionnaire (CL) that they had
the AE. Downing 1970 compared the levels of intensity of AEs
identified by CL but not O, with those detected by both methods.
Ciccolunghi 1975 reported the frequency and proportion of AEs
by discomfort level, and by elicitation method; Greenhill 2004
and Hermans 1994 reported the number (%) of AEs by severity.
Huskisson 1974 assigned a score based on whether an AE was
absent, slight, moderate, or severe, thus combining frequency and
severity as the only outcome. Jacobson 1987 and Rabkin 1992
reportedmean AE severity and impairment by elicitation method.
Reilly 1992 presented the proportion bothered, the mean degree
of bother per participant, and calculated a severity index score.
Rabkin 1992 and Greenhill 2004 both considered the impact of
elicitation method on the number of participants for whom clini-
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cal action was taken and the number (%) of AEs deemed clinically
relevant.
Two studies looked at the duration of AEs detected by different
elicitation methods (Hermans 1994, Reilly 1992), while Brent
2009 measured time to onset of self-harm AEs by elicitation
method. Ciccolunghi 1975 and Spilker 1987 described the most
commonly reported AEs by elicitation method, while Jacobson
1987 and Rabkin 1992 investigated categories of AEs that were re-
ported by participants through use of different questioning meth-
ods; Rabkin 1992 specifically looked at whether certain AEs were
underreported through O (e.g. sexual dysfunction) by highlight-
ing AEs that were reported more than five times as often by CL
compared to O.
Other relevant outcome variables
Other outcomes reported for some studies related to tool valida-
tion; De Vries 2013 investigated content validity through cogni-
tive debriefing, while De Vries 2014 compared four-week versus
three-month recall periods and Jacobson 1987 investigated inter-
rater reliability between different trial staff. De Vries 2013 also ex-
amined the feasibility and acceptability of the different elicitation
methods by time to complete the CLs and asking about ease of
use. Greenhill 2004 determined the proportion of clinicians and
parents rating satisfaction with the elicitation methods using sev-
eral domains.
Allen 2013 performed a thematic qualitative data analysis in terms
of explanations given for differential reporting of AEs,medical his-
tory, and the use of non-study medications, and how participants
expressed themselves, exploring the emerging themes in relation
to broader theories.
Excluded studies
As our search was broad out of necessity, we listed only those
studies which a reader might reasonably expect to see among the
included studies in the Characteristics of excluded studies table.
As indicted in the Results of the search above, studies were ex-
cluded if they were not relevant to the topic of the review (e.g.
non-drug studies), if only abstracts were available where there was
not enough information for an assessment of eligibility (and no
relevant paper was found), if there was no relevance to clinical
trials, if there was no comparison of elicitation methods, or data
were not presented in a way that could be extracted. For the latter,
some studies at first glance appeared to make a comparison but
had to be excluded because the data collected through the different
elicitation methods were categorised differently.
Risk of bias in included studies
See Table 2, Table 3, Table 4 and Table 5.
Allocation
For all 25 within-participant comparison studies, there was a tech-
nically high risk of bias as neither random sequence generation
and allocation concealment is feasible to implement in this design.
However, this potential for bias was unlikely to have impacted
the results substantially because all participants were exposed to
all methods. For two studies, the order that participants received
the questions were randomly assigned (De Vries 2013, Jacobson
1987). For the eight between-participant comparisons, Bent 2006
used a computer-generated method and blinded personnel to the
allocation and therefore had a low risk of bias. Ciccolunghi 1975
used a predetermined allocation list and Spilker 1987 used a table
of random numbers which also reduced the risk of bias. We judged
the remainingfive studies as either at high risk of bias because it was
clear that the allocation was not random (Brent 2009, Huskisson
1974, Török 1984), or the allocation method was unclear (Avery
1967, Borghi 1984). However, where groups were determined by
site (Huskisson 1974), it may be that there was a lower risk of
bias as different staff were involved. However, the latter, in itself,
raises the possibility of inconsistent recording of AEs. Ciccolunghi
1975 had a large proportion of non-responders to the invitation
to take part in their study, which may have increased the risk of
bias because there may have been a selective non-response related
to a particular question method.
Blinding
Of the 33 studies included in this review, only one stated that the
investigator was blinded to the AE data reports being compared in
the study; Borghi 1984 reported that the investigator was neither
informed of the results of the self-reported AEs by either the self-
completed checklist or blank form, nor did they help participants
fill in the forms. It is not feasible to blind participants when they
are reporting AEs, but for those taking part in studies where the
comparison was between-participants, there may have been less
risk of bias from knowing which questioning method was used,
as it was less likely that participants were made aware of different
methods being used in different groups/sites. For the within-par-
ticipant comparisons, it was highly likely that participants were
’primed’ by the first method - i.e. they would be more likely to re-
port that same AE when the second method was applied. As such,
these were not independent comparisons. This was acknowledged
by some study authors (Allen 2013, Greenhill 2004). The risk of
bias forWallander 1991may have been the highest because partici-
pants took forms for both questioning methods home to complete
on their own (there were no details in the paper as to instructions
for their order of completion so one may have prompted what to
report in the other).
Incomplete outcome data
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Most studies had a low risk of attrition bias. However, the risk of
bias in this domain was unclear in nine studies and two were con-
sidered of higher risk as they had high dropout rates and we could
not be sure that these were not related to the questioning method
(Ciccolunghi 1975, Wallander 1991). For Wallander 1991, there
was a significant number of dropouts, which could potentially re-
late to a questioning method as participants took forms for both
questioning methods home to complete and they may have de-
cided not to bring one of the forms back due to the nature of
its questions. For Ciccolunghi 1975, there was also a significant
amount of missing data, which could potentially be related to the
method of questioning as the forms were distributed by internal
mail and staff decided whether or not they had completed the
forms. It is possible that the decision not to complete and return
a form was affected by the type of questioning (e.g. a longer form
might be less likely to be completed than a shorter one).
Selective reporting
Twenty studies had a low risk of selective reporting and the risk of
bias in this domain was unclear in 11. Two studies were deemed
high risk as they presented only a selection of data; Rosenthal 1996
presented only spontaneously-elicited AEs if they matched ques-
tions on the questionnaire that they were being compared to, and
Wernicke 2005 selected for comparison those AEs reflecting the
same symptom in the spontaneous and solicited methods (in order
to calculate ratios of the rate reported for drug versus placebo).
While there were clear reasons for these selections of data, it is
possible that data not selected may have been informative.
Other potential sources of bias
For Barber 1995, we were unclear whether the elicitation methods
were applied in the same order for all participants, while for
Os 1994, we were unclear as to how questioning methods were
applied, making it impossible to assess whether the application
could have biased these studies in some way. The application of
elicitationmethods was unclear for Borghi 1984, Huskisson 1974,
Monteiro 1987, O’Connell 2007, Nicholls 1980, Reilly 1992,
Rosenthal 1996 and Török 1984. Furthermore, there may have
been differences in the phrasing of open questioning in Allen 2013
and Barber 1995. For the between-participant comparisons used
in Brent 2009 and Huskisson 1974, it was not clear whether one
group of participants were exposed to both questioning methods.
Kruft 2007 and Wernicke 2005 were meta-analyses where there
was little information about the parent studies, so it was unclear
whether there may have been some other inherent biases. Finally,
all studies were limited by a lack of a true gold standard against
which to assess the data reported by participants.
Effect of methods
The impact of different elicitation methods on the number
of AEs reported
See Table 6 and Table 7 for details on the effects of themethods on
the number of AEs reported for between-participant comparisons;
and Table 8 and Table 9 for details on the effects of themethods on
the number of AEs reported for within-participant comparisons.
Between-participant comparisons
- Overall
For the eight studies comparing elicitation methods between
groups of participants, 12 different comparisons involving an open
enquiry (O) could be derived (one of which had three different
endpoints), resulting in 14 comparisons in total (Table 6 andTable
7). There was no common statistical rubric, but we were able to
represent some effect measures as a risk ratio of the proportion
of participants with at least one AE. This showed a lower level of
reporting for O compared to CL, with a range for the risk ratios
of 0.12 to 0.64. Using O as the reference, there was an increase
in the absolute or mean number of AEs elicited, or the number of
participants reporting at least one AE, whenever CL or R was used
(except for suicide attempts in Brent 2009, which weremore often
reported by O than CL). This increased sensitivity of CL/R was
observed regardless of the study location, therapy area, whether
the study was conducted within or outside of a clinical trial or
with patient or healthy volunteers, the duration of follow-up and
whether the outcome variable could be considered as a treatment-
emergent AE or not. The two studies that compared different types
of O (Bent 2006 and Ciccolunghi 1975) found no difference in
the number of AEs detected.
- Between study groups
Four studies presented data by study group (Avery 1967, Borghi
1984, and Huskisson 1974 within a clinical trial and Ciccolunghi
1975 outside of a clinical trial). Avery 1967 found that the trend
for more AEs through CL was sustained when the active treat-
ment group was examined while removing the placebo partici-
pants. Borghi 1984 found that there did not appear to be a differ-
ence between the methods for detecting AEs. Huskisson 1974 had
predetermined that only auditory and GI AEs would be termed
drug-related and all other AEs were deemed as irrelevant ’noise’.
Using this classification system, they showed that the reporting
of all three types of AEs increased for fenoprofen by two to three
times, although the aspirin scores were inconsistent. While in a
different context, for Ciccolunghi 1975, there was no difference
in the detection of AEs between participants taking medication
and those not taking medication when comparing the two types
of O. There was a statistically significantly greater number of AEs
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detected by CL compared toO in participants takingmedications,
but no such difference was seen in those not taking medications.
Within-participant comparisons
- Overall
For the 25 studies comparing elicitation methods between groups
of participants, 19 comparisons involved an open enquiry (O/B/
D) and a checklist-type method (CL) (although for Kruft 2007
the data for CL and R could not be distinguished). See Table 8 for
details on the elicitation of the number of AEs and Table 9 for a
summary of the results. The direction of the effect of the method
on the number of AEs was in favour of the CL in all studies except
Hermans 1994 and De Vries 2014. The former, despite finding
an increase in absolute numbers of AEs with the CL, found no
increase when looking at the percentage of participants with at
least one AE. De Vries 2014 had performed their study to validate
a CL and found low sensitivity (33%) and positive prediction
values (10 to 51%) compared to their open question diary. The
fact that the diary was completed daily is likely to have influenced
this finding.
Two studies compared different types of CL: De Vries 2013 and
Greenhill 2004. The former found that adding body categories
did not affect the frequency of AE data reports, while Greenhill
2004 found that using a body system review resulted in a greater
increase in AE reports compared to a drug-specific inquiry.
Several studies incorporated scales (R); Landén 2005, Kruft 2007,
Yeo 1991 and Wallander 1991 found that the use of R resulted in
increased AE reports. Os 1994 observed that the increase in cough
reported by R was less consistent in men compared to women.
Landén 2005 found fewer women than men reporting AEs by O
but more women than men reporting AEs by R (the latter was not
statistically significant).
Monteiro 1987 found 36% of those with drug-induced sexual
dysfunction at INT did not report this at the previous CL, despite
their concern about this AE, even if they were secretly reducing
dose of drug to overcome it.
Perez-Lloret 2012 explored the relationship of various demo-
graphic and disease-related factors with reporting at least one AE
in response to O, and the only association found was with partic-
ipants who reported more than two AEs by CL.
- Between study groups
Common findings were identified when considering if the ques-
tion method influenced the ability to detect differences between
study groups.Nicholls 1980 andRosenthal 1996 (drug-drug com-
parisons) andDowning 1970 (drug-placebo comparisons) showed
a statistically significant difference between groups when using
CL, and no such effect when using O. Hermans 1994 found the
opposite; the between-drug difference in AEs overall (and for fre-
quency of ankle oedema) was statistically significant for O, not for
CL. Wernicke 2005’s use of drug/placebo ratios for reported AEs
suggested that O is more effective in distinguishing a difference
between trial groups. However, they also found that there were
more statistically significant differences between trial groups by
CL compared to O (nine versus five AEs). Landén 2005 (drug-
drug) and O’Connell 2007 (drug-placebo) showed no difference
between groups. The two studies that compared a CL with an R
also had conflicting results: Lundberg 1980 found a difference be-
tween drugs by their CL but not by their R, while Os 1994 found
no difference between these types of tools.
The impact of different elicitation methods on the nature of
AEs reported
See Table 10 and Table 11 for details on the effects of the methods
on the nature of AEs reported for between- and within-participant
comparisons.
Between-participant comparisons
Avery 1967 found a statistically significant higher mean severity
at each visit by CL, both overall and when removing placebo data,
in contrast to Ciccolunghi 1975 who found that O was associated
with a greater severity of symptoms than CL (Table 10). Brent
2009 found no difference betweenO andR for reporting of serious
suicidal or nonsuicidal ideation AEs, but the time to onset for
both was earlier for data elicited by R compared to O. In terms of
the individual types of AEs reported, Spilker 1987 found that the
most common symptoms elicited by CL were fatigue, headache,
and nasal congestion, compared to headache, back or muscle pain,
and nasal congestion by O, so there appeared to be some overlap.
Huskisson 1974 had used a composite measure for frequency and
severity so is reported under the number of AEs section above.
Within-participant comparisons
Of the 10 studies investigating the nature of AEs reported through
questioning method, six found O more likely to detect more
severe or intense AEs, or AEs causing more bother, distress, or
limiting activity (Barber 1995, Downing 1970; Greenhill 2004,
Jacobson 1987; Rabkin 1992; Reilly 1992), although Greenhill
2004 showed that their drug-specific review CL detected more
moderate AEs compared to O (Table 11). Meanwhile, the paper
by Rabkin 1992 revealed that 61% of AEs rated severe or very
severe were elicited by the CL and 65% of AEs causing severe or
very severe dysfunction were detected by CL compared to 35%
by O. Allen 2013 reported that additional AEs detected thorough
CL or INT were rated as mild, but the severity of AEs detected by
O was not given. Hermans 1994 and Perez-Lloret 2012 found no
difference between the elicitation methods in the severity of AEs
14Eliciting adverse effects data from participants in clinical trials (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
detected, as did Sheftell 2004. However, the latter also found that
31 (7.5%) of participants who rated their AE as severe in the CL
had not reported it when previously asked by O.
Barber 1995 found that participants who spontaneously reported
AEs indicated a more negative impact of side effects and activity
imitations on quality of life, more dissatisfaction with their medi-
cation, andmore noncompliance compared to those not reporting
spontaneously; the average global quality of life scores increased as
participants reported AEs spontaneously and discontinued ther-
apy. The two studies that looked at the duration of AEs detected
by questioning method (Hermans 1994, Reilly 1992) showed no
difference.
Jacobson 1987 observed that their CL detected a greater variety
of AEs compared to O. Rabkin 1992, using essentially the same
tool, observed that the 23 AEs that were reported more than five
times as often by CL compared to O included no reports of sexual
dysfunction. The authors concluded that there was therefore no
evidence of selective underreporting of sexual dysfunction by O
compared to other AEs, such as cognitive and affective symptoms.
They suggested that the phrase used to introduce the questioning
may have inadvertently suggested to participants that the latter
were not the topic of the enquiry.
The impact of different elicitation methods on other
relevant outcome variables
Clinical action/relevance
Rabkin 1992 found that both their O and CL methods con-
tributed equally to the elicitation of AEs that, in the clinician’s
opinion, required some change in management (13% and 11%,
respectively). However, those AEs elicited by O required more
extensive changes (dose suspension or discontinuation compared
with increased surveillance or change in dose) and all of these AEs
were in the trials’ drug groups, not placebo. Greenhill 2004 also
found that a higher proportion of AEs elicited through O led to
some clinical action (31%) compared with those identified with
the CLs (12% when using a drug-specific CL and 15% a body-
system review). Of the clinically relevant AEs (N = 37), 19 (53%)
were elicited by a body system review.
Validity, feasibility, acceptability and satisfaction
De Vries 2013 found significant problems during content valida-
tion that needed to be resolved while designing their self-reported
questionnaire (CL), such asmaking it clearer to participants which
questions related to their underlying disease symptoms and which
to AEs. The final tool was a questionnaire of 252 items and ap-
proximately 50% of respondents found a body-category structure
to be helpful, while most found the tool easy to use and took less
than 60 minutes to complete. Greenhill 2004 found that while
80% of parents found their body-system review CL method ’just
right’ (71% specifically finding the duration of the process ’just
right’), 70% of clinicians considered it to be too detailed and 74%
found it took too long. Of note, however, is that satisfaction rat-
ings for the more detailed enquiry were significantly higher in
parents who received reimbursement fees compared to those who
did not. Overall, the body-system review was deemed very useful
by 66% of parents but only 28% of clinicians in that study. De
Vries 2014 found that a recall period of either four weeks or three
months did not impact the sensitivity of identifying participants
who experienced an AE through their CL tool at either a Med-
DRA® organ class or specific level. The positive predictive value
was especially low for a four-week recall period. Jacobson 1987
found good overall interrater reliability for detecting AEs using
both their O and CL methods (best when raters were both present
for the same participant consultation) but low interrater reliability
for individual AEs and measures such as duration, severity, and
functional impairment.
Qualitative
The one study (which we had conducted) that incorporated a
qualitative analysis (Allen 2013) found that the CL and INT fa-
cilitated participants’ recognition of health issues and treatments,
and consideration of what to report. Information about AEs,med-
ical history or non-study medicine use or both was sometimes not
reported because participants forgot, it was considered irrelevant
or insignificant, or they feared the consequences of reporting this.
Some medicine names were not known, and answers to questions
were sometimes considered inferior to the information that could
be obtained from blood tests for detecting ill health. There were
some differences between the two trial sites in this study that had
an impact on reporting: South African inpatient HIV-infected,
but otherwise healthy volunteers, exhibited a ’trial citizenship’,
working to achieve the researchers’ goals, while Tanzanian HIV-
positive or -negative outpatients with malaria symptoms some-
times deferred responsibility for identifying items to report to the
trial’s clinicians.
Non-study medicines and medical histories
Allen 2013 also found that using the CL and INT (the latter in
a subset of participants) after O resulted in an additional 23 and
four non-study medication reports respectively in one site, two,
and nine in the other site. The same pattern was found for past
medical history reports; an additional eight and four reports for
CL and INT respectively in one site, 245 and 15 in the other
site. These quantitative data could not, however, be pooled due to
different numbers and types of participants in each site.
D I S C U S S I O N
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Our Cochrane methodology review shows that the question of
how different elicitation methods impact the reporting of subjec-
tive AE data by drug trial participants has been considered since
at least the 1960s, and yet is still being debated nearly 50 years
later. This situation probably reflects the complexity of the topic:
namely, how to accurately represent the often unknown adverse
effects of a drug on a myriad subjective endpoints. The review
itself was complicated by the diversity in the participant popula-
tions, designs, and elicitation methods used in the included stud-
ies. It is also difficult to ensure quality in this type of methodol-
ogy research and in differentiating AE reports from disease-related
symptoms. For instance, there may have been publication biases
whereby studies that did not find any major differences between
methods may have chosen not to report this. However, our review
did provide reasonable evidence of an increase, often substantial,
in the number of AEs elicited when using more comprehensive
(specific, detailed and/or lengthy) questioning, whether a check-
list-type tool or rating scale, compared to a more open general
enquiry, whether a verbal question or blank form for self-report,
in a wide variety of indications and contexts. This finding is, of
course, intuitive.
Importantly, some of the included studies took their research be-
yond the quantitative effects and investigated the nature of the
AEs reported in response to different questioning methods. Of the
10 studies comparing elicitation methods within participants, six
found that participants reported more severe or bothersome AEs
to an open enquiry. While the studies used disparate methods to
assess these endpoints (including the detail of the questioning it-
self and whether the nature of the AE was assessed by participants
or investigators), these findings are supported by the qualitative
data from Allen 2013, whereby participants described this process
in action; the checklist had reminded them of a mild or intermit-
tent AE, or of the need to consider or report it, or both. How-
ever, some studies had different findings: Rabkin 1992 showed
that even quite severe AEs were missed by the open enquiry and
only detected by a checklist. Moreover, Monteiro 1987 found that
some debilitating sexual dysfunction AEs were not reported spon-
taneously or in response to a specific checklist and were only re-
vealed at an in-depth interview. Rabkin 1992 also suggested that
the way the instructions to participants had been phrased in their
general enquiry may have resulted in under-reporting of cognitive
and affective AEs. This signals the care required when phrasing
questions. It is, therefore, difficult to draw firm conclusions about
the impact of questioning method on the nature of AEs detected
without further research.
The research that was nested within comparative drug trials also
had mixed results when considering if the questioning method
influenced the ability to detect differences in harm between trial
groups. Nicholls 1980 and Rosenthal 1996 (drug-drug compar-
isons) and Downing 1970 (drug-placebo comparisons) showed
a statistically significant difference between groups when using a
checklist-type tool, and no such effect when using an open en-
quiry. In contrast, Hermans 1994 found the opposite: the open
enquiry appeared to detect a difference while the checklist did not.
Wernicke 2005 used a drug/placebo ratio for reported AE, which
suggested that the open enquiry is more effective in distinguish-
ing a difference between groups. However, they also found that
there were more statistically significant differences between trial
groups by a checklist approach compared to an open enquiry (nine
versus five AEs). Borghi 1984 and Landén 2005 (drug-drug) and
O’Connell 2007 (drug-placebo) all showed no difference between
questioning methods, so no conclusions could be drawn for those
studies comparing checklist-type tools with rating scales. These
mixed results may reflect several issues: problems with the host
trials relating to their power to detect a difference in the safety
outcome by drug, that a particular questioning method is no bet-
ter than another at being able to detect a difference between study
groups, or that the study groups being compared have similar sa-
fety profiles.
One response to our findings would be to suggest that all studies
use comprehensive specific enquiries in addition to an open en-
quiry, as they appear to be complementary. This would fit with
the tenet of many clinical trials, especially preregistration trials,
which aim to collect all AEs (i.e. high sensitivity with no pro-
vision for specificity relating to AE severity, bother from AEs,
or the clinical outcome or association between the drug and the
AE). However, more comprehensive enquiries are time-consum-
ing and, while Greenhill 2004 found that parents of children gen-
erally found the more detailed questioning useful, a majority of
clinicians found using a body system review too detailed and took
too long. It is also unclear as to how much questioning is com-
prehensive enough, bearing in mind that tools may range from a
short checklist to the 252 items developed byDeVries 2013.More
research is therefore needed to explore the practicalities of using
tools of different lengths and designs and to achieve a balance be-
tween sensitivity and feasibility. For instance, De Vries 2014 found
that adding body categories which filtered and therefore limited
the questions did not affect the outcome.
Another option would be to use different types of questioning
depending on what is known about the safety profile of the drug,
whichmay itself be a factor in the phase of development; withmore
comprehensive questioning early in the process and less compre-
hensive questioning as data builds about a favourable benefit:harm
profile. Provision for this is made by the US Food and Drug Ad-
ministration (FDA): manufacturers are allowed to make a case for
limiting the safety data to serious AEs, for instance (FDA 2012).
In addition, for the treatment of life-threatening illness, there may
be a case for using less a sensitive enquiry and focusing on themore
serious AEs. However, while it is unlikely that there is a perfect
questioning tool, it is difficult to recommend that researchers use
an enquiry method that may miss some clinically relevant data
or effects that are important to participants, especially those that
16Eliciting adverse effects data from participants in clinical trials (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
could impact on adherence when a drug is eventually distributed
on a large scale, post-registration. Despite what researchers and
regulatory authorities may feel is known about important ADRs,
there may be long-term or persistent mild effects that do not in-
fluence clinical action but nevertheless impact on the quality of
life of even severely ill patients. An example is persistent nausea
in oncology patients that is considered less clinically relevant by
clinicians but a debilitating disorder by patients (Edgerly 2008).
Similarly, while there is guidance about the need to enquire specif-
ically for potential ADRs that are embarrassing for participants
to talk about (such as sexual dysfunction), other drugs with the
potential for such effects may not have been identified as yet and
this ADR will only be detected after many participants have been
exposed to the drug (CIOMS 2005).
Summary of main results
Despite different study designs, populations and details of ques-
tioning methods, the review showed that more specific question-
ing of study participants leads to more AEs being reported com-
pared to a more general enquiry. A subset of six studies suggested
that more severe, bothersome, or otherwise clinically relevant AEs
were reported when an initial open enquiry was used; while some
less severe, bothersome, or clinically relevant AEs were only re-
ported with a subsequent specific enquiry. However, two studies
showed that quite severe or debilitating AEs were only detected
by an interview, while other studies did not find a difference in
the nature of AEs between elicitation methods. No conclusions
could be made regarding the impact of questioning method on
the ability to detect a statistically significant difference between
study groups, because the findings of the research we reviewed
were inconsistent.
Overall completeness and applicability of
evidence
Our review shows that, for awide variety of populations, more AEs
will be reported when participants are asked more comprehensive
questions about their health. Some of the authors of the included
studies hypothesised that such intensive questioning is suggestive,
the implication being that participants will be made to report an
AE that is not actually real. However, we did not uncover any
evidence for these concerns as there was no gold standard applied
in the studies against which tomeasure the ’truth’, although a diary
may be the closest to this (De Vries 2014). More research could be
done to harness the techniques used in patient-reported outcome
(PRO) methods to understand and validate AE context-specific
question tools, as is being done for oncology (Basch 2014). As
a minimum, there is a need for more studies using interviews to
understand reporting behaviour in a variety of contexts.
Another observation from our findings is that few tools other
than checklists and scales were used, aside from one study that
tested a diary. This could be an issue of our methodology, resulting
in studies comparing such tools being missed. Alternatively, it
could be that there are trials that use such tools but without any
related methodology research, or that they are seldom used to
elicit AEs. While there has been significant technological growth
in innovative ways to engage with trial participants about a range
of experiences and endpoints, including health-related quality of
life measures, the methods for eliciting AEs are lagging behind.
Until there is progress, authors should be encouraged to be clear
within their teams as to the rationale for, and application of, the
questioning method used, which will contribute to consistency
in trial conduct. As important is the need to provide sufficient
detail of the elicitation method when reporting results, so as to
lead to a better understanding by readers about how this may have
influenced individual results and help in the conduct of systematic
reviews and meta-analyses.
Few studies considered the impact of the elicitation method on
other variables such as previous or concomitant medications and
medical histories. These are important for determining whether
AEs areADRs (andmay impact on eligibility criteria). This finding
may be because the primary outcome of this review focused on
AEs and we did not identify other studies that focused exclusively
on those other variables.
Quality of the evidence
We did not use the Grading Recommendations, Assessment, De-
velopment and Evaluation (GRADE) approach in this review be-
cause it was not possible to conduct any meta-analysis. The quality
of evidence was limited by the heterogeneity of studies included,
the design limitations inherent for this kind of methodology re-
search and also limitations in the application of study methods
and incomplete reporting in individual studies. Aside from dif-
ferences in therapeutic areas, drug interventions and the actual
questioning methods applied, some studies were conducted with
students or staff (Ciccolunghi 1975 and Spilker 1987) as opposed
to trial participants or patients. While there was merit in our being
inclusive in anticipation that the number of eligible studies may
be low, these differences did limit our ability to make recommen-
dations about specific elicitation methods or contexts. Sequence
generation and allocation concealment are not necessarily relevant
for within-participant comparison studies but are relevant for be-
tween-participant comparisons, particularly for studies with non-
random allocation of elicitationmethod to participants enrolled at
the same site (Avery 1967, Brent 2009). Where elicitation meth-
ods were allocated by site or study (as for Huskisson 1974 and
Török 1984), it ismore likely that there was inconsistent recording
of AEs, which could also impact the quality of the comparisons. It
is not feasible to blind participants to a questioning method and
this is likely to have affected the reporting of AEs when elicita-
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tion methods were used in sequence, since the data reports were
not independent. There may have been a particular risk of bias
for Wallander 1991 as participants took forms for both question-
ing methods home to complete on their own. However, for the
other studies, if the data were applied consistently and recorded
accurately, then these cumulative comparisons are still useful, as
they reflected the impact of using more than one method together,
compared to one of themethods being used alone. All studies were
limited by a lack of a true gold standard against which to assess the
data reported by participants. Most studies had a low or unclear
risk of attrition bias, but two could be considered of higher risk
because it was not clear if dropouts were related to the questioning
method that they used (Ciccolunghi 1975, Wallander 1991).
Potential biases in the review process
There were practical reasons for limiting the search to studies pub-
lished in English and reporting terms synonymous with AE three
or more times in the title or abstract. However, the review could
have been improved by extending the search to languages other
thanEnglish.Our findings also suggested that the electronic search
missed several publications identified by non-electronic means.
This highlights the importance of conducting a thorough review
of reference lists of both included studies, and other articles that
are relevant to the topic (as we did for this review). This raises the
possibility that we may have missed other eligible studies, which
may have weakened our overall conclusions. However, changes to
the search strategy are unlikely to have overcome these issues with-
out increasing the number of references to an unmanageable level
and this issue could be explored in further research into the review
methodology, such as those suggested within the Study Within A
Review initiative (Anon 2012).
While we excluded studies with objective measures of AEs if the
subjective data could not be extracted separately, some included
studies may have also included objectively measured AEs without
reporting them as such. We included populations taking part in
clinical trials and methods studies outside of a clinical trial, pro-
vided relevance to clinical trials was cited. These environments
may be quite different, in that the trial context may shape be-
haviour, including how AEs are reported (Allen 2013, Heaven
2006, Paterson 2008, Scott 2011). This review focused on clini-
cal trials and methods studies relevant for trials. However, as tri-
als are not the only valuable source of information of harms, and
in fact have inherent limitations on the detection of harms, they
may not always be the best method to evaluate different elicitation
methods. Other types of studies should be also ideally be explored
in this regard. Separating the three-way comparisons of within-
participant studies into two-way comparisons may have distorted
results due to the possible effects of priming of one method on a
subsequent one. In addition, the number of AEs or ADRs in a par-
ticular study or population may have impacted the ability to detect
a difference between questioning methods and the types of items
selected for a checklistmay also influence this.We chose to include
studies regardless of whether they prospectively or retrospectively
addressed the comparison of AE elicitation methods (and this was
not always clear from the reports of studies), although in general it
is less optimal to retrospectively report outcomes. Lastly, we were
not always able to confirm the calculations of the original authors.
Agreements and disagreements with other
studies or reviews
No similar reviews were identified.
A U T H O R S ’ C O N C L U S I O N S
Implication for methodological research
The wide variety and inherent low quality of methods used to
compare elicitation strategies in clinical drug trials limited this re-
view. Although we recognise that this is a complicated area, future
studies would be improved by using and reporting clear defini-
tions and terminology for AEs (and other important variables), the
frequency and time period over which they were ascertained, and
how theywere graded, assessed for a relationship to the study drug,
coded, and tabulated/reported. As is the case with similar work
conducted in other areas of pharmacoepidemiology, this research
is hampered by the lack of a true gold standard against which to
assess the data reported by participants. This means that measures
are likely to be concordant rather than valid (West 2005). How-
ever, improving record linkages, using blood samples for pharma-
cokinetic analysis of commonly used medications to detect non-
study medicines, and comparing new strategies against existing
ones are options to explore. While the many potential AE end-
points in any given trial may preclude the development of general
AE PRO measurement instruments, much could also be learnt
from how these employ both quantitative and qualitative methods
to understand data elicited (FDA 2009).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Allen 2013
Methods Methods study nested in trial. Subset of adults with or without malaria enrolled in 2 open-label artemether-lume-
fantrine/antiretroviral interaction trials (South Africa, N = 16; Tanzania, N = 76). Within-participant comparison
of cumulative data elicited by 2 consecutive methods prior to treatment and after 3 to 7 days. Third method then
applied with participants who reported differently between first 2 methods (South Africa, N = 11; Tanzania, N = 16)
. Participants’ experiences of illness and treatment and reporting behaviour also explored qualitatively
Data Treatment-emergent AEs, severity assessed by investigator. Also, previous and concomitant medications, medical
histories
Comparisons ELICITATION METHOD 1
General open-ended verbal enquiry about health and medicine use without reference to particular conditions, body
systems or treatments
ELICITATION METHOD 2
Immediately after Method 1: verbal enquiry with reference to checklists of potential health issues and medicines
ELICITATION METHOD 3
Within 7 days of Methods 1 and 2: in-depth interview: prompted narrative of the participant’s trial experience,
reflection on previous ill health and medicines used, and photographs of typical over-the-counter and traditional
medicines available to the study populations
Outcomes Number (%) additional AEs,medications, andmedical histories by previousmethod. AE severity description.Themes,
theoretical interpretation of participants’ experiences related to differential reporting between methods. Could dis-
tinguish between treatments and not informative to make a direct comparison between sites due to differences in the
participant populations and trial designs
Notes Amajority of fields in the checklists were common to both trials although they could not be harmonised fully. Answers
probed according to common clinical practice in eliciting a medical and treatment history
Avery 1967
Methods Methods study nested in trial. Subset of depressed inpatients enrolled in pilot study of chlorpromazine with or without
procyclidine versus placebo (US, N = 23). Between-participant comparison of data elicited by 2 randomly allocated
methods prior to treatment and at weekly intervals for 5 weeks
Data Symptoms (unclear if treatment-emergent). Severity estimated by weighting the gross symptoms by a factor derived
from degree of subjective discomfort (0 to 3)
Comparisons ELICITATION METHOD 1
Verbal enquiry “Have you noticed any change in bodily function or had any physical complaints in the past week?”
ELICITATION METHOD 2
Method 1 plus specific questions from a study checklist of possible drug side effects. The question in elicitation
method 1 plus specific questions from a checklist of possible drug side effects
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Avery 1967 (Continued)
Outcomes Means and ranges of number and severity of symptoms by method and treatment (P = 0.05, one-tailed test of
significance using Mann-Whitney U test)
Notes Method 2: National Institute of Mental Health study checklist of possible drug side effects (NB assumed not all were
asked)
Barber 1995
Methods Methods study nested in trial. Subset of adults with ocular hypertension or open-angle glaucoma randomised to 2%
dorzolamide or 2% pilocarpine plus 0.5% timolol in a cross-over trial (US, N = 47 [pilocarpine phase only reported
due to lack of AEs with dorzolamide]). Within-participant comparison of data elicited by 2 concurrent methods 1)
prior to treatment, days 14, 30 and 2) throughout trial
Data Adverse experiences (unclear if treatment-emergent), participant assessment of bothersomeness (6-point scale), quality
of life
Comparisons ELICITATION METHOD 1
Interviewer-administered questionnaire (COMTOL). NB domain scores calculated from average of symptoms
ELICITATION METHOD 2
Participants instructed to call investigator if they experienced an AE and investigator asked participants at each visit
if they had experienced any AE since their last visit (not clear which time-point in relation to Method 1)
Outcomes Number (%), mean scores (SD) AE frequency and bother domain scores for those who did not report any spontaneous
AEs but indicated on questionnaire they had the AE. Relationship between AEs and quality of life
Notes Method 1: validated questionnaire that captured the frequency and bother of common side effects (i.e. ocular and
other local effects, and effects on visual function) of topical therapy for lowering intraocular pressure. In addition,
the questionnaire measured the extent to which these side effects and any associated limitations in routine living
activities interfered with health-related quality of life, medication compliance, and participant satisfaction with the
medication
Barrowman 1970
Methods Methods study nested in class experiment. Healthy medical students administered pentagastrin 6 µg/kg or 0.9%
sodium chloride (UK, N = 24). Within-participant comparison of data elicited by 2 consecutive methods over 10
minutes post treatment
Data Unwanted subjective effects/symptoms (assumed treatment-emergent)
Comparisons ELICITATION METHOD 1
During first 9 minutes post-dose observer, on 3 occasions, asked subject to describe any unusual sensation
ELICITATION METHOD 2
10 minutes post-dose subject asked directly about certain symptoms
Outcomes Number of symptoms by method and treatment.
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Barrowman 1970 (Continued)
Notes Method 2: Symptoms known or suspected to occur after pentagastrin, and some control items (headache, dryness
of mouth, increased salivation). Instructions given to the observer about the questioning methods, including timing,
and how to complete the data elicited according to each method
Bent 2006
Methods Methods study nested in trial. Subset of healthy men with benign prostatic hyperplasia enrolled in a trial of ’saw
palmetto’ (US, N = 214). Between-participant comparison of data elicited by 1 of 3 randomly allocated methods at
the end of a 1-month, single-blind, placebo run-in period
Data AEs (unclear if treatment-emergent), seriousness assessed by investigator
Comparisons ELICITATION METHOD 1
Self-administered open-ended question (“Did you have any significant medical problem since the last study visit?”).
If “yes”, participants asked to identify medical problem (recorded by study assistant on same checklist as Method 3
group)
ELICITATION METHOD 2
Self-administered open-ended explicit question (“Since the last study visit, have you limited your usual daily activities
formore than 1 day because of amedical problem?”). If “yes”, participants asked to identifymedical problem (recorded
by study assistant on same checklist as Method 3 group)
ELICITATION METHOD 3
Self-administered checklist (“Since the last visit, have you experienced any of the following?”: 53 symptoms, grouped
by anatomical region)
Outcomes Number/type of AEs by method. Difference in proportion of participants reporting ≥ 1 AE by method (χ2). SAE
description
Notes Method 3: checklist developed after an unpublished review of checklists used in earlier clinical trials at the same
institution. Self completed, although a study assistant recorded medical problems on the checklist
Borghi 1984
Methods Methods study nested in trial. Adult antihypertensive outpatients enrolled in amulticentre, double-blind, randomised
cross-over trial of oxprenolol versus chlorthiazide with single-blind placebo wash-out periods (Italy, N = 223/227).
Between-participant comparison of data elicited by a conventional approach followed by 1 of 2 randomly assigned
methods throughout the trial
Data Unwanted effects (unclear if treatment-emergent).
Comparisons ELICITATION METHOD 1
Reported signs and symptoms evaluated by physician (suggested filtering of reports depending on judgement about
causality so not data included in review)
ELICITATION METHOD 2
Method 1 plus self-completed checklist of 49 items requiring yes/no (sequence changed each visit)
ELICITATION METHOD 3
Method 1 plus self-completed blank card, same format as Method 2, for participant to report signs and symptoms
experienced
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Borghi 1984 (Continued)
Outcomes Number of participants (%) with ≥ 1 unwanted effect by treatment
Notes Method 2: 49 items consisting of pharmacological unwanted effects linked to the most common antihypertensive
drugs, mainly ß-blockers and diuretics.The investigator was neither informed of the results of the questionnaires, nor
did they help the participant to fill them in, so as not to influence the data collection
Brent 2009
Methods Methods integral to trial. Adolescent outpatients with moderate to severe depressive disorder and taking an SSRI
randomised to another SSRI or venlafaxine with or without cognitive behavior therapy (US, N = 334) . Between-
participant comparison of data elicited by 2 non-randomly allocated methods at each visit over 12 weeks
Data Self-harm AEs (suicidal and non-suicidal self-injury), assumed treatment-emergent, seriousness assessed by investi-
gator
Comparisons ELICITATION METHOD 1
Spontaneous report of self-harm (no details).
ELICITATION METHOD 2
Weekly monitoring using Brief Suicide Severity Rating Scale: 1) rating of suicidal ideation 0 to 5 and 2) rating of
suicidal behavior 0 to 5 using Columbia Classification Algorithm of Suicide Assessment; two-point change on either
scale determined if a suicidal AE occurred
Outcomes Proportion of AEs by method (standard univariate statistics). Times to event per method (Kaplan-Meier). AE versus
SAE description
Notes Method 2 involved standard validated instruments: Brief Suicide Severity Rating Scale and Columbia Classification
Algorithm of Suicide Assessment are published tools
Ciccolunghi 1975
Methods Methods study outside of trial. Adult employees of research company (clinical research and production departments)
. Between-participant comparison of data elicited by 1 of 3 randomly allocated methods on one occasion by group,
healthy versus those taking medication (Switzerland, N = 416)
Data Symptoms (not necessarily treatment-emergent), participant assessment of severity (2-point scale)
Comparisons ELICITATION METHOD 1
Open-ended questionnaire with 3 entry lines.
ELICITATION METHOD 2
Open-ended questionnaire with 10 entry lines.
ELICITATION METHOD 3
Checklist of 38 items.
Outcomes Number of participants with ≥1 symptom (%), range, median by treatment (healthy versus medication). Severity
description
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Ciccolunghi 1975 (Continued)
Notes Methods distributed by internal mail with addressed envelope for return. Anonymity assured
De Vries 2013
Methods Tool validation outside of trial. Subset of adult outpatients dispensed an oral glucose lowering drug (Netherlands, N
= 90). Between-participant comparison of data elicited by 2 randomly allocated methods. Description of feasibility
including self-reported time to completion and ease of use (5-point Likert)
Data ADEs (not necessarily treatment-emergent). Feasibility of completion
Comparisons ELICITATION METHOD 1
Email invite for internet-based self-administered questionnaire with ADEs categorized in 16 body categories (T1),
repeat after 1 week with no body categories (T2)
ELICITATION METHOD 2
Email invite for internet-based self-administered questionnaire with ADEs not categorized in 16 body categories (T1)
, repeat after 1 week with body categories (T2)
Outcomes Number of ADEs bymethod (χ2,Mann-WhitneyU tests). Agreement ofmethods (Z value). Description of feasibility
outcomes
Notes Content validation of common ADEs drafted in layman terms with reference to CTCAE v 4.0, existing symptom and
ADE checklists, then coded, categorised into body categories using MedDRA® classifications. Open-ended option
for “other”, questions relating to duration, frequency, seriousness, and causality based on literature
De Vries 2014
Methods Tool validation outside of trial. Subset of adult outpatients dispensed an oral glucose lowering drug (Netherlands,
N = 78). Between-participant comparison of data elicited by 2 consecutive methods (random allocation of second
method using a 4-week or 3-month recall period)
Data ADEs (not necessarily treatment-emergent), participants’ assessment of nature and causality
Comparisons ELICITATION METHOD 1
Gold standard: paper-based daily diary completed for 3 months: an open-ended question asking for symptoms
experienced and closed-ended question about attribution to any drug taken
ELICITATION METHOD 2
Email invite for internet-based self-administered questionnaire with ADEs (symptoms in lay terms) relating to past
4 weeks
ELICITATION METHOD 3
Email invite for internet-based self-administered questionnaire with ADEs (symptoms in lay terms) relating to past
3 months
Outcomes Sensitivities and positive predictor values (CI) at class and specific ADE levels
Notes Content validation of common ADEs drafted in layman terms with reference to CTCAE v 4.0, existing symptom and
ADE checklists, then coded, categorised into body categories using MedDRA® classifications. Open-ended option
for “other”, questions relating to duration, frequency, seriousness, and causality based on literature
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Downing 1970
Methods Methods study nested in trial. Adults with mild to moderate anxiety or depression or both receiving one of several
antidepressants (amitriptyline, iprindole), tranquillizers (chlordiazepoxide, diazepam, fluphenazine) or placebo in
double-blind trials (US, N = 123) . Within-participant comparison of data elicited by 2 consecutive methods 4 weeks
post-treatment
Data Side reactions/effects, participant assessment of intensity, discomfort, and opinion on relationship to study drug. NB
only those symptoms that the participant related to medication reported
Comparisons ELICITATION METHOD 1
Open-ended question (O) week 2 and 4: “How are you feeling?”. If no reference to drug-related symptomatology:
“How else are you feeling?” then “How does the drug make you feel?”
ELICITATION METHOD 2
Structured (S) question 28-item questionnaire as basis of structured interview at week 4 after Method 1. If AE report,
participant asked to estimate intensity (3-point scale), discomfort (4-point scale) and whether symptom was felt due
to study medicine
Outcomes Incidence of side reactions (0 or ≥ 1 ) per method. Comparative incidence between methods (χ2 using McNemar’s
formula, P < 0.01). Number of side effects per participant per treatment. Number of new side effects by method 2.
Mean intensity and discomfort scores per participant (average all drug-related symptoms reported). Number (%) of
events attributed or not to treatment
Notes Method 2: 23 common medication effects and 5 highly unlikely to be related. The latter were captured in a miscel-
laneous category on coding sheet. Methods applied by the treating physician (extensive training in interviewing and
rating procedures). Reports entered onto data sheet with categories provided for medication-produced disturbances
frequently associated with the medications. Symptoms unlikely to be associated with the medications recorded as
miscellaneous
Greenhill 2004
Methods Methods study outside of trial. Children initiating treatment with 1 or more psychotropic medicines in the past 60
days and attending outpatient visits (US, N = 59) . Within-participant comparison of data elicited by 3 consecutive
sections of an instrument delivered as a scripted interview at a routine follow-up visit
Data AEs (any unfavourable event that occurs during treatment or a clinical trial, regardless of cause), severity, and clinical
relevance assessed by investigator
Comparisons ELICITATION METHOD 1
3-question general inquiry (GI): “Has had any physical or health problems since….? I’m talking about something
that started to become a problem during this time or an old problem that got much worse.”, “Have there been
activities that didn’t do as often or that he/she didn’t do at all because of not feeling well since ?”, “Since
, has said that his/her body feels funny... or that he/she has any aches or pains... or that some part of him/her
hurts or doesn’t feel well?”
ELICITATION METHOD 2
After Method 1: drug-specific inquiry (DSI) - 18 questions about clinically important AEs for various medicines
ELICITATION METHOD 3
After Method 1 and 2: body system review (BSR) - 24 questions
Outcomes Number (%) of AEs first elicited by method (by AE severity and clinical relevance). Time for administration by
method
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Greenhill 2004 (Continued)
Notes Methods 1 and 2 (same instrument): semi-structured interview (SMURF) constructed from an existing instrument
(SAFTEE) as a scripted interview, with instructions, demographic queries, and a glossary of preferred AE terms. Only
AEs where it would be malpractice not to assess were included. Experienced clinicians (95% psychiatrists and 5%
nurses) trained to evaluate and treat children in child psychiatric settings conducted the interviews. They received 1
hour of telephone training in the administration of the SMURF. AEs elicited were captured on another form using
SAFTEE preferred terms and related details
Hermans 1994
Methods Methods integral to trial. Adults with mild to moderate hypertension enrolled in a double-blind, randomised trial
comparing isradipine and amlodipine (Belgium, N = 205). Within-participant comparison of data elicited by 2
consecutive methods at baseline and after 6 weeks
Data AEs, order experienced.
Comparisons ELICITATION METHOD 1
Verbal enquiry “How have you felt since your last visit?”.
ELICITATION METHOD 2
Self-completed written questionnaire: swollen ankles, headache, flushing, palpitations, dizziness, or nausea
Outcomes Number (%) of AEs by method. Incidence of participants with AE by method (χ2)
Notes Method 2: anticipated side effects of dihydropyridine calcium antagonists. Assumed cardiologists and nephrologists
asking questions
Huskisson 1974
Methods Methods study nested in trial. Participants with rheumatoid arthritis enrolled in a RCT of aspirin versus fenoprofen
(UK, N = 60). Between-group non-random comparison of data elicited by 1 or 2 methods over 6 months (timing of
assessments unknown)
Data Side effects, severity (not clear who assessed severity).
Comparisons ELICITATION METHOD 1
Verbal enquiry: “Have you noticed any new symptoms which might be related to the treatment?”
ELICITATION METHOD 2
Method 1 plus checklist of 21 possible side effects recorded as absent, slight, moderate, or severe (0, 1, 2, or 3); side
effect score from sum of values
Outcomes % AE side effect scores by method and treatment (sum of severity 0 (absent), 1, 2, 3 x 100/number of participants).
Cross-tabulation by method. NB those side effects that were not significantly different between treatments (by either
method) were grouped in analysis as ’irrelevant’
Notes Method 2: tinnitus, deafness, gastrointestinal complaints, and others with no obvious relevance
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Jacobson 1987
Methods Tool validation within trial. Adults with schizophrenia, major depressive episode with psychotic features, moderate
or greater anxiety, depression, or insomnia enrolled in inpatient or outpatient trials investigating drug treatments
(US, N = 134). Within-participant comparison of data elicited by 2 consecutive methods within a structure verbal
interview at weekly trial visits
Data AEs.
Comparisons ELICITATION METHOD 1
General inquiry (GI): “Have you had any physical or health problems during the past week (or specified assessment
interval)? Have you noticed any changes in your physical appearance during the past week (or specified assessment
interval)? Have you cut down on the things you usually do because of not feeling well physically during the past week
(or specified assessment interval)?”
ELICITATION METHOD 2
After Method 1: systematic inquiry (SI) which is the GI plus a review of 23 body systems.
Outcomes Number of AEs by method, mean number of AEs per assessment, mean severity, and impairment
Notes SAFTEEdeveloped by theNational Institute ofMental Health. This study part of validation exercise. NB participants
were randomly assigned to different staff applying each elicitation method
Kruft 2007
Methods Methods integral to trial. Retrospective meta-analysis of 4 double-masked, randomised, cross-over ophthalmic trials
involving various drugs or placebo (multinational, N = 223). Within-participant comparison of data elicited by 2
methods
Data Occular AEs.
Comparisons ELICITATION METHOD 1
General query: “How are you doing since your last visit?”.
ELICITATION METHOD 2
Solicited ophthalmic symptom query checklist, including visual analogue scales (VAS)
Outcomes Number (%) ophthalmic symptoms by method.
Notes Method 2: some VAS in trials were validated instruments, not clear if this one was
Landén 2005
Methods Methods study nested in trial. Adults with treatment-refractory depression enrolled in a placebo-controlled RCT of
bupirone-augmentation of SSRI therapy (Sweden and Norway, N = 119). Within-participant comparison of data
elicited by 2 consecutive methods before and 4 weeks post-treatment
Data Sexual side effects.
Comparisons ELICITATION METHOD 1
Non-leading question such as: “Have you felt different in any way since you started the new treatment?”
ELICITATION METHOD 2
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Landén 2005 (Continued)
After Method 1: direct questions from UKU side effect rating scale (none, mild, moderate, severe) for 3 symptoms
of sexual dysfunction
Outcomes Number sexual side effects by method, OR (Pearson χ2, Yates correction as appropriate)
Notes Method 2: UKU is a validated instrument.
Lundberg 1980
Methods Methods study nested in trial. Adult male healthy volunteers enrolled in a double-blind, placebo-controlled, 2-factor
cross-over trial of diphenhydramine versus terfenadine (US, N = 12). Within-participant comparison of data elicited
by 2 consecutive methods on 2 occasions at 3 visits over 9 days
Data Side effects.
Comparisons ELICITATION METHOD 1
Somesthetic Inventory (self-completed): 54 body feelings, 9 fillers assessed through a visual analogue scale (VAS)
ELICITATION METHOD 2
After Method 1: self-completed Side Effects Report of 24 terms assessed with VAS
Outcomes 2-factor, repeated-measures analysis of variance for body feeling or side effect reported by at least 50% of sample
Notes Method 1: compilation and organisation of data on side effects of antihistamines (18 terms also inMethod 1).Method
2: arbitrarily selected terms. Method 1: participants asked to “attune to inner stimuli”, close eyes and determine how
body felt. Method 2: definitions provided to participants
Monteiro 1987
Methods Methods study nested in trial. Adults with severe Obsessive Compulsive Disorder and DSM-III enrolled in a double-
blind RCT of clomipramine versus placebo (UK, N = 33/46). Within-participant comparison of data elicited by 3
methods
Data Sexual side effects.
Comparisons ELICITATION METHOD 1
Spontaneous reports at any time and at week 8.
ELICITATION METHOD 2
Self-rated physical symptom questionnaire (including sexual function items) at weeks 0 and 8
ELICITATION METHOD 3
Stuctured interview enquiry (not clear when conducted, assume at end of study)
Outcomes Number (%) of participants reporting any sexual dysfunction by method. Could not split by trial arm
Notes
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Nicholls 1980
Methods Methods integral to trial. Adults with mild to moderate essential hypertension enrolled in a double-blind, double-
dummy cross-over RCT of labetalol versus propranolol (UK,N = 24). Within-participant comparison of data elicited
by 2 consecutive methods at each visit and end of 8-week treatment period
Data Side effects.
Comparisons ELICITATION METHOD 1
Spontaneous/direct reporting (no details).
ELICITATION METHOD 2
Self-administered questionnaire after assessment and the end of each treatment period
Outcomes % participants reporting each symptom by method and treatment arm. Average number of symptoms per participant
per group
Notes
O’Connell 2007
Methods Methods study nested in trial. Adolescent girls with dysmenorrhoea enrolled in a placebo-controlled RCT of ethinyl
estradiol/levonorgestrel (US, N = 76). Within-participant comparison of data elicited by 2 consecutive methods after
a 3 month treatment period
Data Side effects, including depression.
Comparisons ELICITATION METHOD 1
Open-ended question at one 3 month visit - participants asked to list any side effects or changes they experienced
during the study
ELICITATION METHOD 2
After Method 1: participants asked if they experienced any of 12 specific side effects
Outcomes Number of AEs, % participants reporting ≥ 1 AE, median number of AEs by method and treatment arm
Notes Method 2: AEs commonly attributed to oral contraceptives, including headache, nausea, acne, abdominal pain,
back pain, vomiting, breast tenderness, breast enlargement, mood swings, weight gain, premenstrual syndrome, and
irregular bleeding
Os 1994
Methods Methods integral to trial. Adults withmild tomoderate hypertension enrolled in a double-blind, double-dummyRCT
of lisinopril versus nifedipine (Norway, N = 828). Within-participant comparison of data elicited by 3 consecutive
methods several times during the trial (unclear order)
Data Side effect (cough).
Comparisons ELICITATION METHOD 1
Spontaneous reporting (no details).
ELICITATION METHOD 2
Direct questioning to be answered ’yes’ or ’no’ (no details)
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Os 1994 (Continued)
ELICITATION METHOD 3
Questionnaires consisting of VAS completed by participant and spouse independently
Outcomes Method 1: frequency (%), methods 2 and 3: cumulative incidence after 2, 6, and 10 weeks.Within-treatment changes
by means of McNemar, between-treatment difference using log linear model. VAS between-treatment groups using
ANOVA on ranks of changes from baseline
Notes Method 2: part of the ASPECT Scale - a tool for evaluation of 34 commonly experienced symptomatic side effects
of cardiovascular drugs
Perez-Lloret 2012
Methods Methods study outside trial. Adults with Parkinson’s Disease and post-stroke controls (France, N = 255) receiving at
least 1 drug. Within-participant comparison of data elicited by 2 consecutive methods on 1 occasion
Data AEs (any untoward medical occurrence in a participant who is under any pharmacological treatment; the AE does not
necessarily have to have a causal relationship with this treatment). Causality algorithm, intensity evaluated subjectively
by trial staff
Comparisons ELICITATION METHOD 1
Verbal open enquiry: “Have you noticed any unpleasant effects of your medications during the previous week?”
ELICITATION METHOD 2
After Method 1: verbal structured enquiry about the previous week using a pre-defined list of AEs
Outcomes Number of participants reporting ≥ 1 AE. Total number of AEs by method and population using χ2. Rate (%)
of under-reporting, 95% CI, binomial test for differences of AEs affecting > 10% of participants. Unpaired t-test/
χ2 for comparing numerical or categorical variables, forward regression to identify independent factors related to
spontaneous reporting
Notes Method 2: pre-defined list of most common ADRs to various anti-Parkinsons Disease drugs from a literature search
critically reviewed by a group of PD and pharmacovigilance specialists for consensus: general, gastro-intestinal,
urinary, neuropsychiatric, dermatologic
Rabkin 1992
Methods Method nested within trial. Adults with bulimia, panic disorder, major depression, or dysthymia enrolled in inpatient
or outpatient trials (US, N = 180/226) investigating drug treatments or placebo. Within-participant comparison of
data elicited by 2 consecutive methods within a structure verbal interview pretreatment and after 4 weeks
Data AEs
Comparisons ELICITATION METHOD 1
General inquiry (GI): “Have you had any physical or health problems during the past week (or specified assessment
interval)? Have you noticed any changes in your physical appearance during the past week (or specified assessment
interval)? Have you cut down on the things you usually do because of not feeling well physically during the past week
(or specified assessment interval)?”
ELICITATION METHOD 2
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Rabkin 1992 (Continued)
GI plus Systematic inquiry (SI) which is a review of 23 body systems plus additional 11 items to represent side effects
of MAOIs
Outcomes Number of AEs, type of AE, mean severity (removing comparative data from baseline), functional impairment,
clinical action taken by method. Paired t-tests, OR with 95% CI (2-tailed)
Notes SAFTEE developed by the National Institute of Mental Health. Additional 11 items research team’s own choice.
Severity subjectively graded and action taken noted. SAFTEE applied by either study psychiatrist or research nurse
who had attended training meetings and had had a minimum of 3 practice audio-taped interviews reviewed by first
author to assure adequacy of administration and rating
Reilly 1992
Methods Method nested within trial. Adults with mild to moderate essential hypertension enrolled in a multicentre, ran-
domised, double-blind, placebo-controlled trial of clentiazem (US, N = 92). Within-participant comparison of data
elicited by 2 consecutive methods pretreatment and at the final visit
Data Symptoms (not treatment-emergent), severity (bother on a 5-point scale from which 2 severity scales were created:
symptom severity index checklist and symptom severity index open list. Scores calculated by multiplying no. of days
bothered by ’extent bothered’ for each symptom and summing scores). Secondary - arbitrary 20% change in symptom
severity index checklist score used to represent clinically meaningful change to test a QoL instrument’s responsiveness
Comparisons ELICITATION METHOD 1
Open-question: participants asked if they had any health-related symptoms or problems during the past 7 days
ELICITATION METHOD 2
Same questions with reference to a checklist immediately after Method 1
Outcomes % participants reporting ≥ 1 symptom by method. Methods compared for severity using Kruksal-Wallis Exact Test
and Pearson product moment correlations
Notes Method 2: 24 symptoms associated with hypertension and anti-hypertensive therapy (previously used). The methods
were applied 48 hours prior to the trial medical evaluation visit by a trained, full-time telephone interviewer. Need
for further training was achieved though completed questionnaires being reviewed daily by a supervisor
Rosenthal 1996
Methods Methods integral to trial. Adults with mild to moderate essential hypertension enrolled in a double-blind RCT of
quinapril versus metoprolol (Germany, N = 5559). Within-participant comparison of data elicited by 2 consecutive
methods
Data Adverse effects (those spontaneously elicited were only presented if they matched questions on the questionnaire)
Comparisons ELICITATION METHOD 1
Physician interview concerning general status of symptoms, development of signs (e.g. rash, swelling, bruises)
ELICITATION METHOD 2
After Method 1: self-administered written questionnaire about signs and symptoms
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Rosenthal 1996 (Continued)
Outcomes Number of AEs by method and treatment arm. Number (%) participants reporting AEs by method and treatment
arm
Notes Method 2: formulated to elicit information concerning the appearance of signs and symptoms that could be related
to ACE inhibitors or a beta-blocker, and any other symptoms that might reflect the participant’s well being. All
spontaneously reported AEs were assigned to body systems categories according to COSTART criteria
Sheftell 2004
Methods Methods study outside trial. Adults with migraine aged ≤ 19 years taking triptans at 2 sites (US and Italy, N = 415)
. Within-participant comparison of data elicited by 2 consecutive methods on one occasion
Data Adverse effects (those spontaneously elicited were only presented if they matched questions on the questionnaire)
Comparisons ELICITATION METHOD 1
Physician interview concerning general status of symptoms, development of signs (e.g. rash, swelling, bruises)
ELICITATION METHOD 2
After Method 1: self-administered written questionnaire about signs and symptoms
Outcomes Number of AEs by method and treatment arm. Number (%) participants reporting AEs by method and treatment
arm
Notes Method 2: formulated to elicit information concerning the appearance of signs and symptoms that could be related
to ACE inhibitors or a beta-blocker, and any other symptoms that might reflect the participant’s well-being. All
spontaneously reported AEs were assigned to body systems categories according to COSTART criteria
Spilker 1987
Methods Methods study outside of trial. Pharmacy staff, students and faculty. Between-participant comparison of data elicited
by 1 of 2 randomly allocated methods on one occasion by group, healthy versus those taking medication (US, N =
298)
Data Symptoms (not treatment-emergent), participant assessment of severity
Comparisons ELICITATION METHOD 1
Self-completed questionnaires with 15 blank spaces to complete about demographics, tobacco, and alcohol use,
symptoms experienced in the past 72 hours, treatments used
ELICITATION METHOD 2
Self-completed questionnaire with a checklist of 25 symptoms about demographics, tobacco, and alcohol use, symp-
toms experienced in the past 72 hours, treatments used
Outcomes Number of symptoms/average no. of symptoms per person by method. Compared using T-tests
Notes Method 2: checklist used in a previous study. Handed out on a Thursday (middle of the week) to be completed and
handed back in the same occasion
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Török 1984
Methods Methods study nested in trial. Adults from 46 sites with hypertension, angina, or arrhythmias enrolled in 3 trials
(single-arm or placebo-controlled RCT) of chloranolol (Hungary, N = 2066). Between-participant comparison of
data elicited by 2 non-randomly allocated methods. Data only presented for participants taking chloranolol and for
subjective gastro-intestinal related symptoms
Data AEs.
Comparisons ELICITATION METHOD 1
Complaints reported spontaneously by the participants (in placebo-controlled trial only those symptoms during
active drug phase recorded), or signs/symptoms observed by physician without using a list (objectively determined
AEs not included in review)
ELICITATION METHOD 2
As well as method 1, questions about side effects listed in a questionnaire
Outcomes As objective signs also included, data here are only for gastro-intestinal symptoms, which are likely to be subjective -
side effects per 100 participants by method
Notes
Wallander 1991
Methods Methods study nested in trial. Adults from 23 primary care sites with hypertension, angina, or arrhythmias enrolled
in a double-blind RCT of felodipine versus placebo added to metoprolol (Sweden, N = 191/251). Within-participant
comparison of data elicited by 3 consecutive methods at various visits up to 8 weeks
Data AEs.
Comparisons ELICITATION METHOD 1
Complaint score: “Have you had any of the following symptoms in the past month?” completed the day before
baseline and final visit
ELICITATION METHOD 2
Subjective symptom assessment profile (SSAP): 41-item VAS completed day before the baseline and final visit
Outcomes Number of AEs bymethod. Bivariate relationships usingPitman’s non-parametric permutation test, tests of paired data
(before/after randomisation) using linear, nonparametric permutation, multivariate tests with Pitman’s inmultivariate
form - reporting before randomisation treated as confounding variable
Notes Method 1: used in previous population studies, included depression, tension, head, heart, lung, metabolism, mus-
culoskeletal system, GI and urinary tracts. Patients placed in an envelope and advised the physician would not have
access. Method 2: validated instrument, highly correlated items in 6 domains, rest single items. After completion of
Methods 1 and 2, they were put in an envelope and participants advised that the physician would not have access
to the information. NB A previous method which involved question posed by a physician and then evaluated for
association with the trial drugs was not included in the review comparison
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Wallin 1981
Methods Methods study nested in trial. Patients with gonorrhoea enrolled in a study of bacampicillin (Swedwn, N = 515).
Within-participant comparison of data elicited by 2 consecutive methods
Data Adverse reactions.
Comparisons ELICITATION METHOD 1
“Have you had any troubles from the drug?”.
ELICITATION METHOD 2
Checklist immediately afterMethod 1: “Have you noticed any of the following reactions: diarrhoea, nausea, vomiting,
other gastrointestinal disturbances, skin eruptions, or other troubles?”
Outcomes Number of additional AEs from previous method by method.
Notes
Wernicke 2005
Methods Methods integral to trials. Patients with various conditions enrolled in one of 3 double-blind, placebo-controlled
RCTs of anonymous drugs (N = 653: 219, 167, 267). Within-participant comparison of data elicited by 2 consecutive
methods in participants who attended a visit where both methods were used
Data Treatment-emergent AEs.
Comparisons ELICITATION METHOD 1
Unsolicited AEs by open-ended questioning; participants asked to report experiences since the last visit in their own
words
ELICITATION METHOD 2
ElicitedAEs by standard questionnaires (Side Effects Checklist (child trial) BBAEQ-M (child/adolescent trial AMDP-
5 (adult trial)))
Outcomes AEs reflecting same symptom in spontaneous and solicited methods selected. Ratio between rate reported by drug
versus placebo (D/P) plotted for solicited on x-axis against spontaneous on y-axis. Also ratio of D/P ratios (Sp-
So index): spontaneous D/P ratio divided by solicited D/P ratio (95% CI). Treatment differences compared using
Fisher’s exact test
Notes Method 2: Side Effects Checklist was based on the Subjective Treatment Emergent Symtpoms Scale (US National
Institute of Mental health) - 30 items including general symptoms such as trouble sleeping, diarrhoea, headache,
trouble eating. BBAEQ-M: 24 items rated 0 to 9, AMDP-5: 47 items rated 0 to 3. COSTART III was used to map
actual terms to standard terms
Yeo 1991
Methods Methods integral to trial. Adults with hypertension enrolled in a placebo-controlled double-blind RCT comparing
enalapril with nifedipine (ACE inhibitors) (UK, N = 128). Within-participant comparison of data elicited by 2
methods (method 1 at each visit, method 2 pretreatment, 8 and 24 weeks/withdrawal)
Data Side effect (cough).
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Yeo 1991 (Continued)
Comparisons ELICITATION METHOD 1
“Have the tablets upset you in any way?” at each visit.
ELICITATION METHOD 2
VAS at baseline, 8 weeks, 24 weeks/withdrawal (from “I never cough” to “I am always coughing”)
Outcomes Method 1: frequency of cough. Method 2: changes in mean scores and frequency of cough defined by an increase in
VAS of≥ 8 mm. Between-treatment differences using Kolmogorov-Smirnov 2-sample test, χ2 with Yates correction,
Fisher’s exact, Wilcoxen rand sum tests
Notes
ACE:angiotensin−convertingenzyme
ADE:adversedrugevent
AE: adverse eventAMDP-5: Assessment and documentation of psychopathology
ANOVA: analysis of varience
ASPECT: Assessment of symptoms and psychological effects in cardiovascular therapy
BBAEQ-M: Barkley behavior and adverse events questionnaire-modified
BSR: body system review
CI: confidence interval
COMTOL: comparison on ophthalmic medications for tolerability
COSTART: Coding symbols for a thesaurus of adverse reaction terms
CTCAE: Common terminology ceriteria for adverse events
D: drug
DSI: drug-specific inquiry
DSM-III: Diagnostic and statistical manual of mental disorders 3rd edition
GI: general inquiry
MAOI: monoamine oxidase inhibitor
MedDRA: Medical dictionary for regulatory activities
NB: nota bene
no.: number
O: open-ended question
OR: odds ratio
P: placebo
QoL: quality of life
RCT: randomised controlled trial
S: structured
SAFTEE: Systematic assessment for treatment emergent events
SAE; serious adverse event
SD: standard deviation
SI: structured or systematic inquiry
SMURF: Safety monitoring uniform form
SSAP: subjective symptom assessment profile
SSRI: selective serotonin reuptake inhibitor
T1: time 1
T2: time 2
UKU: Udvalg for Kliniske Undersøgelser
VAS: visual analogue scale
χ2: chi-squared
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Z: zeta (standard score)
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anderson 1994 No comparison of elicited data
Aspinall 2002 Lack of clinical trial focus
Atherton 2012 Included objective measure(s)
Basch 2014 No comparison of elicited data
Bennett 2012 Assessed severity, experience of AEs already reported
Bergh 2013 Not possible to compare data between methods
Bonierbale 2003 Lack of clinical trial focus
Brown 2005 Included objective measure(s)
Byerly 2006 Lack of clinical trial focus
Carreno 2008 Lack of clinical trial focus
Coolbrandt 2011 Lack of clinical trial focus
Costa 1979 Lack of clinical trial focus
De Smedt 2011 Lack of clinical trial focus
Downie 2006 Lack of clinical trial focus
Edwards 1996 Incomplete relevant data reported
Emslie 2006 Not possible to compare data between methods
Fisher 1990 Lack of clinical trial focus
Gelenberg 2013 Not possible to compare data between methods
Glaser 1954 Not possible to compare data between methods
Greenblatt 1964 Incomplete relevant data reported
Hakobyan 2011 Lack of clinical trial focus
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(Continued)
Hanesse 1994 Lack of clinical trial focus
Homsi 2006 Lack of clinical trial focus
Iverson 2011 Incomplete relevant data reported
Jarernsiripornkul 2009 Lack of clinical trial focus
Jonsson 2011 Lack of clinical trial focus
Lambert 2003 Included objective measure(s)
Love 1989 Lack of clinical trial focus
Makaranada 1995 Lack of clinical trial focus
Martys 1982 Lack of clinical trial focus
Mei 2006 Lack of clinical trial focus
Möller 2000 Not possible to compare data between methods
Olsen 1999 Lack of clinical trial focus
Pandina 2007 Included objective measure(s)
Rynn 2015 Not possible to compare data between methods
Sheikh 2013 Not possible to compare data between methods
Thomsen 1997 Lack of clinical trial focus
Tran 1997 Included objective measure(s)
Trindade 1998 Comparison between trials, not within trials
Van Haecht 1990 Lack of clinical trial focus
Waddell 2008 Lack of clinical trial focus
Yusufi 2007 Included objective measure(s)
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Characteristics of studies awaiting assessment [ordered by study ID]
AMIS 1980
Methods Within-participant comparison of data elicited by 2 methods. Adults who had had a myocardial infarction enrolled
in a randomised, double-blind, placebo-controlled trial of aspirin
Data AEs (haematemesis, tarry stools, bloody stools).
Comparisons Open question versus specific enquiry.
Outcomes Proportion of participants reporting AEs by method by trial group
Notes This comparison was referenced by LM Friedman in Fundamentals of Clinical Trials (Springer), however none of
the published papers found so far for this clinical trial reported the comparison data
Mothapo 2015
Methods Within-participant comparison of data elicited by 3 methods. HIV-infected participants on long-term efavirenz in
an observational clinical trial
Data Neuropsychiatric symptoms.
Comparisons The depression-anxiety-stress-scale (DASS), the symptom-checklist (SCL-90) and the outcome-questionnaire (OQ-
45)
Outcomes Not clear.
Notes Awaiting access to full text..
AE:adverseevent
DASS: depression-anxiety-stress-scale
HIV: human immunodeficiency virus
OQ-45: Outcome Measure-45
SCL-90: Symptom Checklist-90
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Overview of questioning methods
Description Application Development
Open questions
Allen 2013 Questions about health
andmedicine use without reference
to particular conditions, body sys-
tems, or treatments
Verbal. Answers probed according
to common clinical practice in elic-
iting a medical and treatment his-
tory
No details
Avery 1967 “Have you noticed any change in
bodily function or had any physical
complaints in the past week?”
Verbal No details
Barber 1995 Participants instructed to call if
they experienced AE and asked at
visits if they had experienced AE
Passive and verbal No details
Barrowman 1970 Asked to describe any unusual sen-
sation.
Verbal No details
Bent 2006 “Did you have any significant med-
ical problem since the last study
visit?”). If “yes”, asked to identify
Self-administered, recorded by
study assistant on checklist.
No details
Bent 2006 “Since the last study visit, have you
limited your usual daily activities
for more than 1 day because of a
medical problem?”). If “yes”, asked
to identify
Self-administered, recorded by
study assistant on checklist.
No details
Borghi 1984 No detail No details No detail
Brent 2009 Spontaneous reports No details No details
Downing 1970 “How are you feeling?”. If no ref-
erence to drug-related symptomol-
ogy: “How else are you feeling?”
then “How does the drugmake you
feel?”
No details No details
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Table 1. Overview of questioning methods (Continued)
Greenhill 2004 “Has had any physical or
health problems since….? I’m talk-
ing about something that started to
become a problem during this time
or an old problem that got much
worse.”, “Have there been activities
that didn’t do as often or that
he/she didn’t do at all because of not
feeling well since ?”, “Since
, has said that his/her body
feels funny... or that he/she has any
aches or pains... or that somepart of
him/her hurts or doesn’t feel well?”
Verbal Constructed from an existing in-
strument (SAFTEE) as a scripted
interview, with instructions, demo-
graphic queries and a glossary of
preferred AE terms
Hermans 1994 “How have you felt since your last
visit?”
Verbal No details
Huskisson 1974 “Have you noticed any new symp-
toms which might be related to the
treatment?”
Verbal No details
Jacobson 1987 “Have you had any physical or
health problems during the past
week (or specified assessment inter-
val)? Have you noticed any changes
in your physical appearance during
the past week (or specified assess-
ment interval)? Have you cut down
on the things you usually do be-
cause of not feeling well physically
during the past week (or specified
assessment interval)?”
Verbal structured interview SAFTEE developed by the Na-
tional Institute of Mental Health.
This study part of validation exer-
cise
Kruft 2007 “How are you doing since your last
visit?”.
No details No details
Landén 2005 Non-leading question such as:
“Have you felt different in any way
since you started the new treat-
ment?”
No details No details
Monteiro 1987 Spontaneous reports. No details No details
Nicholls 1980 Spontaneous reports. No details No details
O’Connell 2007 Asked to list any side effects or
changes experienced.
No details No details
Os 1994 Spontaneous reports. No details No details
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Table 1. Overview of questioning methods (Continued)
Perez-Lloret 2012 “Have you noticed any unpleasant
effects of your medications during
the previous week?”
No details No details
Rabkin 1992 “Have you had any physical or
health problems during the past
week (or specified assessment inter-
val)? Have you noticed any changes
in your physical appearance during
the past week (or specified assess-
ment interval)? Have you cut down
on the things you usually do be-
cause of not feeling well physically
during the past week (or specified
assessment interval)?”
Verbal structured interview SAFTEE developed by the Na-
tional Institute of Mental Health.
Additional 11 items research team’s
own choice. Severity subjectively
graded and action taken noted
Reilly 1992 Asked about any health-related
symptoms or problems.
No details No details
Rosenthal 1996 Physician interview concerning
general status of symptoms, devel-
opment of signs (e.g. rash, swelling,
bruises)
No details No details
Török 1984 Spontaneous reports No details No details
Wallander 1991 “Have youhad any health problems
since we first met?”
No details No details
Wallin 1981 “Have you had any troubles from
the drug?”
No details No details
Wernicke 2005 Asked to report experiences in own
words.
No details No details
Yeo 1991 “Have the tablets upset you in any
way?”
No details No details
Blank forms
Borghi 1984 Blank card to report signs and
symptoms experienced.
Self-completed No details
Ciccolunghi 1975 Open-ended questionnaire with 3
entry lines.
No details No details
Ciccolunghi 1975 Open-ended questionnaire with 10
entry lines.
No details No details
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Table 1. Overview of questioning methods (Continued)
Spilker 1987 Questionnairewith 15blank spaces
to complete about demographics,
tobacco, and alcohol use, symp-
toms experienced, treatments used
Self-completed No details
Sheftell 2004 Asked if they had AEs when using
drug. If yes, asked to list and grade
severity
No details No details
Checklists
Allen 2013 Potential health issues
and medicines by10 body systems,
28 symptoms, 17 medicines in to-
tal for both trials together
Verbal enquiry. Answers probed ac-
cording to common clinical prac-
tice in eliciting a medical and treat-
ment history
A majority of fields were common
between the 2 trials, although they
could not be harmonised fully
Avery 1967 Possible drug side effects No details National Institute of
Mental Health study checklist (NB
assumed not all were asked)
Barber 1995 Common side effects Interviewer-administered Validated questionnaire for captur-
ing frequency and bother of ocular
and other local effects, effects on vi-
sual function of topical therapy for
lowering intraocular pressure. Also,
extent to which side effects and as-
sociated limitations in routine liv-
ing activities interfere with health-
related quality of life, medication
compliance, and participant satis-
faction with the medication
Barrowman 1970 Symptoms Verbal enquiry Symptoms known or suspected to
occur after pentagastrin, and some
control items (headache, dryness of
mouth, increased salivation)
Bent 2006 “Since the last visit, have you expe-
rienced any of the following?”: 53
symptoms, grouped by anatomical
region
Self-administered Developed after a unpublished re-
view of checklists used in earlier tri-
als at same institution
Borghi 1984 49 items requiring yes/no Self-completed (sequence changed
each visit)
Pharmacological unwanted effects
linked to themost common antihy-
pertensive drugs,mainly ß-blockers
and diuretics
Ciccolunghi 1975 38 items No details No details
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Table 1. Overview of questioning methods (Continued)
De Vries 2013 Adverse drug events (ADEs) cate-
gorised in 16 body categories
Email invite for Internet-based self-
administration
Content validation of common
ADEs drafted in layman termswith
reference to CTCAE v 4.0, exist-
ing symptom and ADE checklists,
then coded, categorised into body
categories using MedDRA® clas-
sifications. Open-ended option for
’other’, questions relating to du-
ration, frequency, seriousness, and
causality based on literature
De Vries 2013 Adverse drug events not categorised
in body categories
Email invite for Internet-based self-
administration
Content validation of common
ADEs drafted in layman termswith
reference to CTCAE v 4.0, exist-
ing symptom and ADE checklists,
then coded, categorised into body
categories using MedDRA® clas-
sifications. Open-ended option for
’other’, questions relating to du-
ration, frequency, seriousness, and
causality based on literature
De Vries 2014 Adverse drug events (symptoms in
lay terms)
Email invite for Internet-based self-
administration
Content validation of common
ADEs drafted in layman termswith
reference to CTCAE v 4.0, exist-
ing symptom and ADE checklists,
then coded, categorised into body
categories using MedDRA® clas-
sifications. Open-ended option for
’other’, questions relating to du-
ration, frequency, seriousness, and
causality based on literature
Downing 1970 28-item questionnaire. If AE re-
ported, participant asked to es-
timate intensity, discomfort, and
whether symptom was felt due to
study medicine
Structured interviewusing a coding
sheet
23 common medication effects,
and 5 highly unlikely to be related
captured as miscellaneous
Greenhill 2004 Drug-specific inquiry - 18 ques-
tions
Verbal enquiry Constructed from an existing in-
strument (SAFTEE) as a scripted
interview, with instructions, demo-
graphic queries, and a glossary of
preferred AE terms. Clinically im-
portant AEs for various medicines
Greenhill 2004 Body system review - 24 questions Verbal enquiry Constructed from an existing in-
strument (SAFTEE) as a scripted
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Table 1. Overview of questioning methods (Continued)
interview, with instructions, demo-
graphic queries, and a glossary of
preferred AE terms. Clinically im-
portant AEs for various medicines
Hermans 1994 Symptoms Self-completed written question-
naire
Anticipated side effects of dihy-
dropyridine calcium antagonists
(swollen ankles, headache, flush-
ing, palpitations, dizziness, or nau-
sea)
Huskisson 1974 21 possible side effects No details Tinnitus, deafness, gastrointestinal
complaints, and others with no ob-
vious relevance
Jacobson 1987 Review of 23 body systems Verbal structured interview SAFTEE developed by the Na-
tional Institute of Mental Health.
This study part of validation exer-
cise
Kruft 2007 Ophthalmic symptoms No details No details
Lundberg 1980 Somesthetic Inventory: 54 body
feelings (NB 9 fillers assessed
through a visual analogue scale)
Self-completed - participants asked
to ’attune to inner stimuli’, close
eyes and determine how body felt
Compilation and organisation of
data on side effects of antihis-
tamines
Monteiro 1987 Self-rated physical symptom ques-
tionnaire (including sexual func-
tion items)
No details No details
Nicholls 1980 Side effects Self-administered No details
O’Connell 2007 12 specific side effects AEs com-
monly attributed to oral contracep-
tives, including headache, nausea,
acne, abdominal pain, back pain,
vomiting, breast tenderness, breast
enlargement, mood swings, weight
gain, premenstrual syndrome, and
irregular bleeding
Os 1994 34 symptomatic side effects Direct questioning to be answered
’yes’ or ’no’.
Part of the ASPECT Scale - a tool
for evaluation of 34 commonly ex-
perienced symptomatic side effects
of cardiovascular drugs
Perez-Lloret 2012 Predefined list of AEs Verbal structured enquiry Pre-defined list of most common
ADRs to various anti-Parkinson’s
Disease drugs from a literature
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Table 1. Overview of questioning methods (Continued)
search critically reviewedby a group
of PD and pharmacovigilance spe-
cialists for consensus: general, GI,
urinary, neuropsychiatric, derma-
tologic
Rabkin 1992 23 body systems plus additional 11
items to represent side effects of
MAOIs
Verbal structured interview SAFTEE developed by the Na-
tional Institute of Mental Health.
Additional 11 items research team’s
own choice. Severity subjectively
graded, and action taken noted
Reilly 1992 4 symptoms 4 symptoms associated with hyper-
tension and anti-hypertensive ther-
apy (previously used)
Rosenthal 1996 Signs and symptoms Self-administered written ques-
tionnaire
Formulated to elicit information
concerning the appearance of signs
and symptoms that could be related
toACE inhibitors or a beta-blocker,
and any other symptoms that may
reflect well-being
Sheftell 2004 49 possible AEs Mostly known Triptan side effects
and some confounders (side effects
not expected to be relatedwith trip-
tans)
Spilker 1987 25 symptoms Self-completed No details
Török 1984 Side effects No details 35 anticipated andother side effects
Wallander 1991 “Have you had any of the following
symptoms in the past month?”
No details Used in previous population stud-
ies, includes depression, tension,
head, heart, lung, metabolism,
musculoskeletal system, GI, and
urinary tracts. Participants placed
in an envelope and advised the
physician would not have access
Wallin 1981 “Have you noticed any of the fol-
lowing reactions: diarrhoea, nau-
sea, vomiting, other gastrointesti-
nal disturbances, skin eruptions, or
other troubles?”
No details No details
Wernicke 2005 Side Effects Checklist (child trial),
BBAEQ-M (child/adolescent trial)
, AMDP-5 (adult trial)
No details Side Effects Checklist is based on
the Subjective Treatment Emer-
gent Symtpoms Scale (USNational
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Table 1. Overview of questioning methods (Continued)
Institute of Mental Health) - 30
items including general symptoms
such as trouble sleeping, diarrhoea,
headache, trouble eating. BBAEQ-
M: 24 items rated 0 to 9, AMDP-
5: 47 items rated 0 to -3
Rating scales
Brent 2009 Brief Suicide Severity Rating Scale:
rating of suicidal ideation0 to5 and
rating of suicidal behavior 0 to 5
using Columbia Classification Al-
gorithm of Suicide Assessment
No details Published validated instruments
Kruft 2007 Visual analogue scales (VAS) No details Some VAS were validated instru-
ments, details unknown
Landén 2005 UKU side effect rating scale (none,
mild, moderate, severe) for 3 symp-
toms of sexual dysfunction
No details UKU is a validated instrument
Lundberg 1980 Side Effects Report of 24 terms as-
sessed with VAS
Self-completed - definitions pro-
vided to participants
Arbitrarily selected terms
Os 1994 VAS Completed by participant and
spouse independently
No details
Wallander 1991 41-item VAS No details Validated instrument, highly corre-
lated items in 6 domains, rest single
items
Yeo 1991 VAS (cough) No details No details
Diary
De Vries 2014 Open-ended question asking for
symptoms experienced and closed-
ended question about attribution
to any drug taken
Paper-based
In-depth interview
Allen 2013 Prompted narrative of participant’s
trial experience, reflection on pre-
vious ill health, and medicines
used and photographs of typical
over-the-counter and traditional
medicines available to the study
Verbal interview No details
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Table 1. Overview of questioning methods (Continued)
populations
Monteiro 1987 Stuctured interview Verbal interview No details
ADE:adversedrugevent
ADR: adverse drug reaction
AE: adverse event
AMDP-5: Assessment and documentation of psychopathology
ASPECT: Assessment of symptoms and psychological effects in cardiovascular therapy
BBAEQ-M: Barkley behavior and adverse events questionnaire-modified
CTCAE: Common terminology ceriteria for adverse events
GI: general inquiry
MAOI: monoamine oxidase inhibitor
MedDRA: Medical dictionary for regulatory activities
SAFTEE: Systematic assessment for treatment emergent events
UKU: dvalg for Kliniske Undersøgelser
VAS: visual analogue scale
Table2. Risk of bias (selection, performance anddetection, and attrition) of included studies forwithin-participant comparisons
Selection bias Performance and detec-
tion bias
Attrition bias
Author Random sequence genera-
tion
Allocation concealment Blinding Incomplete outcome data
assessed
Allen 2013 N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. ’Pos-
sible ’prim-
ing” by ear-
lier method,
however cu-
mula-
tive data was
part of the
study
Low risk Appeared all
participants
completed
all methods.
Barber 1995 N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
Low risk A few drop-
outs, un-
likely related
to methods.
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Table2. Risk of bias (selection, performance anddetection, and attrition) of included studies forwithin-participant comparisons
(Continued)
to
the nature of
study. ’Pos-
sible ’prim-
ing” by ear-
lier method
Barrowman
1970
N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. ’Pos-
sible ’prim-
ing” by ear-
lier method
Low risk Appeared all
participants
completed
all methods.
De Vries
2013
Low risk Random se-
quence by
two groups.
High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. ’Pos-
sible ’prim-
ing” by ear-
lier method
Low risk A few drop-
outs, un-
likely related
to methods.
De Vries
2014
N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. ’Pos-
sible ’prim-
ing” by ear-
lier method
Unclear Not clear
whether at-
trition
was related
to method.
Downing
1970
N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
Low risk Appeared all
participants
completed
all method.
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Table2. Risk of bias (selection, performance anddetection, and attrition) of included studies forwithin-participant comparisons
(Continued)
the nature of
study. ’Pos-
sible ’prim-
ing” by ear-
lier method
Greenhill
2004
N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to the nature
of study.
’Priming’ by
ear-
lier method,
however cu-
mula-
tive data was
part of the
study
Low risk Appeared all
participants
completed
all method.
Hermans
1994
N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
Low risk A few drop-
outs, un-
likely related
to methods.
Jacobson
1987
Low risk Random
sequence or-
der of ques-
tions
received by
two groups.
High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
Unclear No informa-
tion
provided.
Kruft 2007 N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
Unclear No informa-
tion
provided.
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Table2. Risk of bias (selection, performance anddetection, and attrition) of included studies forwithin-participant comparisons
(Continued)
likely to be
blinded due
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
Landen
2005
N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
Low risk Appeared all
participants
completed
all methods.
Lundberg
1980
N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
Low risk Appeared all
participants
completed
all methods.
Montiero
1987
N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
Low risk A few drop-
outs, un-
likely related
to methods.
Nicholls
1980
N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
Unclear Not clear
why dif-
ferent num-
bers of par-
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Table2. Risk of bias (selection, performance anddetection, and attrition) of included studies forwithin-participant comparisons
(Continued)
blinded due
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
ticipants for
2 methods
O’Connell
2007
N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
Low risk Appeared
that all par-
ticipants
completed
all methods.
Os 1994 N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
Low risk Some drop-
outs but un-
likely related
to method.
Perez-Lloret
2012
N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
Low risk Appeared
that all par-
ticipants
completed
all methods.
Rabkin
1992
N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
Low risk Appeared
that all par-
ticipants
completed
all methods.
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Table2. Risk of bias (selection, performance anddetection, and attrition) of included studies forwithin-participant comparisons
(Continued)
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
Reilly 1992 N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
Low risk Some drop-
outs but un-
likely related
to method.
Rosenthal
1996
N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
Unclear Not clear
why fewer
participants
for method
2; could
be related to
match-
ing of symp-
toms be-
tween meth-
ods
Sheftell
2004
N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
Low risk Appeared
that all par-
ticipants
completed
all methods.
Wallander
1991
N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
High risk Signifi-
cant number
of dropouts
(45/
236), poten-
tially related
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Table2. Risk of bias (selection, performance anddetection, and attrition) of included studies forwithin-participant comparisons
(Continued)
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method,
especially as
participants
took forms
for both
questioning
meth-
ods home to
complete
to method
(partic-
ipants took
forms for
both
questioning
meth-
ods home to
complete)
Wallin 1981 N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
Unclear No informa-
tion
provided.
Wernicke
2006
N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
Unclear No informa-
tion
provided.
Yeo 1991 N/A High risk Open
by nature of
study.
High risk Partici-
pants/
assessors un-
likely to be
blinded due
to
the nature of
study. Possi-
ble ’prim-
ing’ by ear-
lier method
Low risk Some drop-
outs (3 more
in method
2) but un-
likely related
to method
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AE:adverseevent
N/A: not applicable
O: open question
Table 3. Risk of bias (reporting and other) of included studies for within-participant comparisons
Reporting bias Other biases
Author No selective reporting Explicit application
Allen 2013 Low risk All data appeared
presented.
Unclear Possible variations
in phraseology be-
tween participants.
N/A
Barber 1995 Low risk All data appeared
presented.
Unclear Possible variations
in phraseology be-
tween participants.
.
Unclear Queried if methods ap-
plied in same order for all
participants
Barrowman
1970
Low risk All data appeared
presented.
Low risk Explicit in-
structions for staff
to use.
N/A
De Vries 2013 Low risk All data appeared
presented.
Low risk As-
sumed explicit in-
structions for self-
administration.
N/A
De Vries 2014 Low risk All data appeared
presented.
Low risk As-
sumed explicit in-
structions for self-
administration.
N/A
Downing 1970 Unclear Only presented
data that partic-
ipants related to
medication.
Low risk Explicit in-
structions for staff
to use.
N/A
Greenhill 2004 Low risk All data appeared
presented.
Low risk Explicit in-
structions for staff
to use.
N/A
Hermans 1994 Low risk All data appeared
presented.
Low risk Assumed ex-
plicit instructions,
particularly for self-
administration
N/A
Jacobson 1987 Unclear Some overlap be-
tween data pre-
sented.
Low risk Explicit in-
structions for staff
to use.
N/A
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Table 3. Risk of bias (reporting and other) of included studies for within-participant comparisons (Continued)
Kruft 2007 Unclear Difficult to as-
certain as short
report.
Unclear Not clear from in-
formation
provided.
Unclear Meta-analysis
Landen 2005 Unclear Summary data
presented.
Low risk Assumed ex-
plicit instructions,
particularly for self-
administration
N/A
Lundberg 1980 Unclear Summary data
presented.
Low risk Explicit in-
structions for staff
to use.
N/A
Montiero 1987 Unclear Summary data
presented.
Unclear Not clear from in-
formation
provided.
N/A
Nicholls 1980 Low risk All data appeared
presented.
Unclear Not clear from in-
formation
provided.
N/A
O’Connell 2007 Low risk All data appeared
presented.
Unclear Not clear from in-
formation
provided.
N/A
Os 1994 Low risk All data appeared
presented.
Unclear Not clear from in-
formation
provided.
Unclear Unclear order
Perez-Lloret
2012
Low risk All data appeared
presented.
Low risk Explicit in-
structions for staff
to use.
N/A
Rabkin 1992 Low risk All data appeared
presented.
Low risk Explicit in-
structions for staff
to use.
N/A
Reilly 1992 Low risk All data appeared
presented.
Unclear Not clear from in-
formation
provided.
N/A
Rosenthal 1996 High risk Not all data pre-
sented - those
spontaneously-
elicitedwere only
presented if they
matched
questions on the
questionnaire
Unclear Not clear from in-
formation
provided.
N/A
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Table 3. Risk of bias (reporting and other) of included studies for within-participant comparisons (Continued)
Sheftell 2004 Low risk All data appeared
presented.
Low risk As-
sumed explicit in-
structions for self-
administration.
N/A
Wallander 1991 Low risk All data appeared
presented.
High risk Although could as-
sume explicit in-
structions for self-
adminis-
tration of methods
2 and 3, they were
completed at home
so it was outside of
the control of the
clinic as to comple-
tion, including or-
der
N/A
Wallin 1981 Unclear Not clear from
information pro-
vided.
Unclear May
have been varia-
tions in phraseol-
ogy between partic-
ipants in method 2
N/A
Wernicke 2006 High risk Not all data pre-
sented. AEs re-
flect-
ing same symp-
tom in sponta-
neous and so-
licited methods
were selected for
the comparison
Unclear May
have been varia-
tions in phraseol-
ogy between partic-
ipants in method 1
Unclear Meta-analysis
Yeo 1991 Low risk All data appeared
presented.
Low risk Standard O and as-
sumed explicit in-
structions for self-
administration
N/A
AE:adverseevent
N/A: not applicable
O: open question
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Table 4. Risk of bias (selection, performance and detection, and attrition) of included studies for between-participant com-
parisons
Selection bias Performance and detec-
tion bias
Attrition bias
Author Random sequence genera-
tion
Allocation concealment Blinding Incomplete outcome data
assessed
Avery 1967 Unclear No informa-
tion other
than “ar-
bitrarily as-
signed”.
Unclear No informa-
tion
provided
High risk No infor-
mation
provided,
however
participants
and assessors
unlikely to
be blinded
due to
the nature
of study.
The group
who were
exposed
to both
questioning
meth-
ods may
have been
’primed’
by the first
method
Low risk Dropsouts
were in-
dicated but
ap-
peared sim-
ilar between
groups
Bent 2006 Low risk Computer-
gener-
ated prior to
study. Base-
line charac-
teristics were
sim-
ilar between
groups
Low risk Study per-
sonnel were
blinded
to the alloca-
tion.
High risk Although
participants
were not in-
formed of
their group
and analysts
were
blinded,
study staff
were aware
of groups
and were in-
volved in
completing
some data
Low risk All partici-
pants com-
pleted the
study and
outcome as-
sessment.
Borghi 1984 Unclear No informa-
tion
provided.
Unclear No informa-
tion
provided.
Low risk Little infor-
mation pro-
vided, how-
Low risk Although
group allo-
ca-
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Table 4. Risk of bias (selection, performance and detection, and attrition) of included studies for between-participant com-
parisons (Continued)
ever the in-
vestigator
was neither
informed of
the results of
the self-
reporting,
nor did they
help partici-
pants fill in
the forms
tion of drop-
outs unclear,
there were
only a few
Brent 2009 High risk Non-ran-
dom alloca-
tion
by nature of
study.
High risk Open allo-
cationby en-
rolment pe-
riod and na-
ture of
study.
High risk Participants
and
assessors un-
likely to be
blinded due
to the nature
of study
Unclear No informa-
tion
provided
Chiccol-
unghi 1975
Low risk Predeter-
mined ran-
domisation
list. Baseline
charac-
teristics were
sim-
ilar between
groups
Unclear No informa-
tion
provided.
High risk Participants
and
assessors un-
likely to be
blinded due
to the nature
of study
High risk Signif-
icant miss-
ing data, po-
tentially re-
lated to the
method as
forms were
distributed
in the inter-
nal mail and
it was left to
staff to de-
cide whether
to complete
and return
them, al-
though sim-
ilar numbers
were
returned for
each elicita-
tion type
(57% versus
44%)
Huskisson
1974
High risk Non-
random al-
location by
study centre.
High risk Open
by nature of
study.
High risk Participants
and
assessors un-
likely to be
Unclear No informa-
tion
provided.
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Table 4. Risk of bias (selection, performance and detection, and attrition) of included studies for between-participant com-
parisons (Continued)
blinded due
to the nature
of study; al-
though
groups were
at different
sites there
may still
have been
room for bi-
ased assess-
ments based
on
the method
of question-
ing, and dif-
fer-
ent staff may
have elicited
/recorded
AEs differ-
ently
Spilker 1987 Low risk Table of ran-
dom num-
bers
Unclear No informa-
tion
provided.
High risk Participants
and
assessors un-
likely to be
blinded due
to the nature
of study
Low risk Although
group allo-
ca-
tion of drop-
outs unclear,
there were
only a few
Torok 1984 High risk Non-ran-
dom alloca-
tion
by nature of
study.
High risk Open
by nature of
study.
High risk Participants
and
assessors un-
likely to be
blinded due
to the nature
of study; al-
though
groups were
at different
sites/in dif-
ferent stud-
ies, there
may still
have been
room for bi-
ased assess-
Unclear No informa-
tion
provided.
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Table 4. Risk of bias (selection, performance and detection, and attrition) of included studies for between-participant com-
parisons (Continued)
ments based
on
the method
of question-
ing
AE:adverseevent
CL: checklist
O: open question
Table 5. Risk of bias (reporting and other) of included studies for between-participant comparisons
Reporting bias Other biases
Author No selective reporting Explicit application
Avery 1967 Unclear Summary data
presented.
Low risk Explicit phrase-
ology for O. CL
had specific items
but not all was pre-
sented in laymans
language so may
have had inconsis-
tent phraseology
N/A
Bent 2006 Low risk All data appeared
presented.
Low risk As-
sumed explicit in-
structions for self-
administration.
N/A
Borghi 1984 Low risk All data appeared
presented.
Unclear Not
clear from informa-
tion provided.
N/A
Brent 2009 Unclear Brief summary
data presented.
Unclear Little information
provided, although
method 2 involved
val-
idated scales so as-
sumed had explicit
instructions on ap-
plication
Unclear Unclear whether method
1 was used in both
groups.
Chiccolunghi
1975
Low risk All data appeared
presented.
Low risk As-
sumed explicit in-
structions for self-
administration.
Unclear Large numbers of non-
responders to invitation
which could be related to
methods
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Table 5. Risk of bias (reporting and other) of included studies for between-participant comparisons (Continued)
Huskisson 1974 Unclear Raw data trans-
formed by scor-
ing and some
data grouped.
Unclear Not
clear from informa-
tion provided.
Unclear Unclear whether method
1 used in both groups.
Spilker 1987 Low risk All data appeared
presented.
Low risk As-
sumed explicit in-
structions for self-
administration.
Unclear It was not stated how
many were invited.
Torok 1984 Unclear Relevant AE data
only pre-
sented for par-
ticipants taking
chloranolol
Unclear Not
clear from informa-
tion provided.
N/A
AE:adverseevent
CL: checklist
O: open question
Table 6. Elicitation of the number of AEs reported for between-participant comparisons
Study
Ther-
apy
area
End-
point
Fol-
low-
up
AEs elicited
Number participants Number of AEs (total) Number (%) participants with≥1
AE
O O CL R O O CL R O O CL R
Avery
1967
Psy-
chia-
try
Any
AE
5
weeks
11 N/A 12 N/A N/A N/A N/A N/A N/A N/A N/A N/A
Huskisson
1974**
Rheuma-
tol-
ogy
Any
AE
24
weeks
30 N/A 30 N/A N/A N/A N/A N/A N/A N/A N/A N/A
Torok
1984***
Car-
diol-
ogy
Any
AE
Vari-
ous
600 N/A 537,
929
N/A 7 N/A 75,
365
N/A N/A N/A N/A N/A
Bent
2006
Pro-
static
hy-
Any
AE
< 1
- 24
months
70 70 74 N/A 11 14 238 N/A 10
(14)
9(13) 57
(77)
N/A
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Table 6. Elicitation of the number of AEs reported for between-participant comparisons (Continued)
per-
plasia
Borghi
1984*
Car-
diol-
ogy
Any
AE
16
weeks
106 N/A 117 N/A 496 N/A 1556 N/A Ox-
prenolol
48
(45),
chlorthali-
done
60
(57)
N/A Ox-
prenolol
76
(65),
chlorthali-
done
81
(69)
N/A
Spilker
1987
No
indi-
ca-
tion
Any
AE
1 oc-
ca-
sion
132 N/A 166 N/A 229 N/A 581 N/A 106
(80)
N/A 154
(93)
N/A
Cic-
col-
unghi
1975
No
indi-
ca-
tion
Any
AE
1 oc-
ca-
sion
144 129 143 N/A 88 67 720 N/A 59
(41)
46
(36)
127
(89)
N/A
Brent
2009**
Psy-
chia-
try
Self-
harm
12
weeks
Suici-
dal
181 N/A N/A 153 N/A N/A N/A N/A 16 (8.
8)
N/A N/A 32
(20.9)
Non-
suici-
dal
181 N/A N/A 153 N/A N/A N/A N/A 4 (2.2) N/A N/A 27
(17.6)
Sui-
cide
at-
tempts
181 N/A N/A 153 N/A N/A N/A N/A 7 (3.9) N/A N/A 10 (6.
5)
AE:adverseevent
CL:checklist
N/A:notapplicable
O :openquestion
vs:versus
R:ratingscale
∗AllparticipantsaskedAEsbyanopenquestion(O),butasthisprocesspossiblyinvolved ′f iltering′of reportsbythedoctor,thedatawerenotincludedinthereview
∗∗Huskissonusedacompositemeasureoff requencyandseverity
∗∗∗Aselectionof thetotalAEsarepresentedinthereviewasthoseobjectivelymeasuredwereexcluded
†2−sampletestofproportions
††2−samplettest
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Table 7. Effects of methods on the number of AEs reported for between-participant comparisons
Study Therapy area Endpoint Follow-up Effect (number of AEs)
Overall By drug arm
Proportion with ≥
1 AE†
Description (in-
cluding of other ef-
fect measure if dif-
ferent)
Avery 1967 Psychiatry Any AE 5 weeks N/A Statistically signif-
icant higher mean
number of AEs at
each visit by CL.
See paper for de-
tails
Statistically signif-
icant higher mean
number of AEs at
5 of 6 study visits
by CL in the active
drug arm. See pa-
per for details
Huskisson
1974**
Rheumatology Any AE 24 weeks N/A Unclear scor-
ing; appears higher
total score for AEs
by CL thanO (540
versus 409). AEs
listed on CL were
more frequently re-
ported by CL than
when not listed.
AEs not listed on
CL
more frequently re-
ported by O. See
paper for details
Fenoprofen
auditory, gastroin-
testinal I and all
other (’irrelevant’)
AE scores 2-3 x
more frequently re-
ported by CL than
O, aspirin AE
scores ranged from
no difference (au-
ditory), approx.. 1.
5 x less gastroin-
testinal and 0.60 x
more (’irrelevant’)
using O compared
to CL. See paper
for details
Torok 1984*** Cardiology Any AE Various N/A Lower number of
AEs per 100partic-
ipants by O com-
pared to CL
N/A
Bent 2006 Prostatic hyper-
plasia
Any AE < 1 - 24 months OvsO 0.14 (-0.10;
0.12) P = 0.805,
OvsCL -0.63 (-0.
75; -0.50) P = 0.
000, OvsCL -0.64
(-0.77; -0.52) P =
0.000
Group assigned to
CL reported signif-
icantly
greater number of
AEs than either O.
No difference be-
tween O methods
N/A
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Table 7. Effects of methods on the number of AEs reported for between-participant comparisons (Continued)
Borghi 1984* Cardiology Any AE 16 weeks Only available by
drug arm
N/A % ≥ 1 AE for Ox-
prenolol 0.20 (0.
07; 0.33) P = 0.
0031, Chlorthali-
done 0.13 (0.00; 0.
25) P = 0.05
Spilker 1987 No indication Any AE 1 occasion -0.12 (-0.20; -0.
05) P = 0.013
Group assigned to
CL reported signif-
icantly
greater number of
AEs than O
N/A
Ciccolunghi
1975
No indication Any AE 1 occasion OvsO 0.05 (-0.06;
0.16) P = 0.3676,
OvsCL -0.48 (-0.
57; -0.38) P = 0.
000, OvsCL -0.53
(-0.63; -0.43) P =
0.000
Group assigned to
CL reported signif-
icantly
greater number of
AEs than either O.
No difference be-
tween O methods
%≥ 1 AE for non-
med: OvsO 0.19 (-
0.09; 0.13) P = 0.
7331, OvsCL -0.
66 (-0.77; -0.54) P
= 0.0000, OvsCL -
0.68 (-0.79; -0.56)
P = 0.0000. Med:
OvsO 0.05 (-0.12;
0.22) P = 0.5816,
OvsCL -0.26 (-0.
38; -0.14) P = 0.
001, Ovs CL -0.31
(-0.44; -0.17) P =
0.0000
Brent 2009** Psychiatry Self-harm 12 weeks
Suicidal -0.12 (-0.22; 0.09)
P = 0.0017
Group assigned to
R reported signifi-
cantly
greater number of
suicidal-re-
lated AEs than O.
NB no completed
suicides
N/A
Non-suicidal -0.15 (-0.22; -0.
90) P = 0.0000
Group assigned to
R reported signifi-
cantly greater
number of non-
suicidal AEs than
O
N/A
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Table 7. Effects of methods on the number of AEs reported for between-participant comparisons (Continued)
Suicide attempts -0.03 (-0.07; 0.02)
P = 0.2689
No difference be-
tween R and O for
reporting of sui-
cide attempts
N/A
AE:adverseevent
CL:checklist
N/A:notapplicable
O :openquestion
vs:versus
R:ratingscale
∗AllparticipantsaskedAEsbyanopenquestion(O),butasthisprocesspossiblyinvolved ′f iltering′of reportsbythedoctor,thedatawerenotincludedinthereview
∗∗Huskissonusedacompositemeasureoff requencyandseverity
∗∗∗Aselectionof thetotalAEsarepresentedinthereviewasthoseobjectivelymeasuredwereexcluded
†2−sampletestofproportions
††2−samplettest
Table 8. Elicitiation of the number of AEs reported for within-participant comparisons
Study Ther-
apy
area
End-
point
Fol-
low-
up
AEs elicited
Num-
ber
of
par-
tici-
pants
Number of AEs (total) Number (%) of participants with ≥1 AE
O O CL CL R INT O O CL CL R INT
Bar-
ber
1995
Oph-
thal-
mol-
ogy
Any
AE
4
weeks
92 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Bar-
row-
man
1970
GI Any
AE
1 oc-
ca-
sion
24 31 N/A 57 N/A N/A N/A N/A N/A N/A N/A N/A N/A
Down-
ing
1970
Psy-
chia-
try
Any
AE
4
weeks
123 N/A N/A N/A N/A N/A N/A 45 N/A 65 N/A N/A N/A
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Table 8. Elicitiation of the number of AEs reported for within-participant comparisons (Continued)
Her-
mans
1994
Car-
diol-
ogy
Any
AE
6
weeks
205 W2:
11
W4:
49
N/A W2:
58
W4:
105
N/A N/A N/A W2:
21
(10)
W8:
53
(26)
N/A W2:
39
(19)
W8:
61
(31)
N/A N/A N/A
Ja-
cob-
son
1987
Psy-
chia-
try
Any
AE
NK 106 279 N/A 1871 N/A N/A N/A N/A N/A N/A N/A N/A N/A
Nicholls
1980*
Car-
diol-
ogy
Any
AE
8
weeks
24 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
O’Connell
2007
Dys-
men-
or-
rhoea
Any
AE
12
weeks
76 66 N/A 177 N/A N/A N/A 45
(60)
N/A 57
(77)
N/A N/A N/A
Perez
2012 Parkin-
son’s
Dis-
ease
(PD)
and
post-
stroke
con-
trols
(PSC)
Any
AE
1 oc-
ca-
sion
203
PD,
52
PSC
113+
6
N/A PD
1573,
PSC
167
N/A N/A N/A PD
85
(42)
, PSC
5
(10)
N/A PD
203
(100)
, PSC
47
(90)
N/A N/A N/A
Rabkin
1992
Psy-
chia-
try
Any
AE
4
weeks
180/
226
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Reilly
1992
Car-
diol-
ogy
Any
AE
10
weeks
92 W0
37
W12
46
N/A W0
340
W12
96
N/A N/A N/A W0
27
(29.
5)
W12
33
(35.
2)
N/A WO
84
(90.
9)
W12
74
(80.
7)
N/A N/A N/A
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Table 8. Elicitiation of the number of AEs reported for within-participant comparisons (Continued)
Rosen-
thal
1996
Car-
diol-
ogy
Any
AE
12
weeks
5559 984 N/A 7055 N/A N/A N/A 705
(12.
7)
N/A 2753
(50)
N/A N/A N/A
Wallin
1981
Gon-
or-
rhoea
Any
AE
NK 515 25 N/A 16 N/A N/A N/A N/A N/A N/A N/A N/A N/A
Wer-
nicke
2006
Not
known
Any
AE
NK 635 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
de
Vries
2014
Dia-
betes
Any
AE
1 oc-
ca-
sion
78 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Sheftell
2004
Mi-
graine
Any
AE
1 oc-
ca-
sion
415 N/A N/A N/A N/A N/A N/A 118
(28.
4)
N/A 248
(59.
8)
N/A N/A N/A
Lan-
den
2005
Psy-
chia-
try
Sex-
ual
4
weeks
119 N/A N/A N/A N/A N/A N/A 7 (6) N/A N/A N/A 49
(41)
N/A
Yeo
1991
Car-
diol-
ogy
Any
AE
24
weeks
128 N/A N/A N/A N/A N/A N/A 4 (3.
1)
N/A N/A N/A 12
(20)
N/A
Kruft
2007
Oph-
thal-
mol-
ogy
Oc-
cular
NK NK N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Mon-
tiero
1987
Psy-
chia-
try
Sex-
ual
12
weeks
33 N/A N/A N/A N/A N/A N/A 3 N/A 23 N/A N/A 8
de
Vries
2013
Dia-
betes
Any
AE
1 oc-
ca-
sion
90 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Lund-
berg
1980
Anti-
his-
tamine
Any
AE
9
days
12 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
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Table 8. Elicitiation of the number of AEs reported for within-participant comparisons (Continued)
Wal-
lan-
der
1991
Car-
diol-
ogy
Any
AE
8
weeks
191/
251
N/A N/A 926 N/A 1521 N/A N/A N/A N/A N/A N/A N/A
Allen
2013* Malaria
Any
AE
3-7
days
18,
80
(sites’
data
can-
not
be
com-
bined)
6, 23 N/A +1,
+20
N/A N/A +0,
+1**
N/A N/A N/A N/A N/A N/A
Green-
hill
2004
Psy-
chia-
try
Any
AE
1 oc-
ca-
sion
59 48 N/A +16 +129 N/A N/A N/A N/A N/A N/A N/A N/A
Os
1994
Car-
diol-
ogy
Cough
2
weeks
828 N/A N/A N/A N/A N/A N/A 48
(6)
N/A 185
(22)
N/A NK N/A
ADE:adversedrugevent
AE: adverse event
BSR: body system reviewCL: checklist
D: drug
DSI: drug-specific inquiry
INT: interview
N/A: not applicable
NK: not known
O: open question
O(B): blank page
PD:Parkinson′sDisease
PPV: positive predictive value
PSC: post-stroke control
R: rating scaleSD: standard deviation
SOC: system organ class
Sp-So: spontaneous-solicited index
VAS: visual analogue scale
W0, W2, W4, W8, W12:
χ²: chi-squared
Z: zeta (standard score)
∗T wosites/groupsreportedseparatelyasdiff erentparticipantpopulations
∗∗subsetofparticipantsf romCversusCLcomparisontheninterviewed
†McNemar ′stestofproportions,††2−samplettest
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Table 9. Effects of methods on the number of AEs reported for within-participant comparisons
Study Therapy area Endpoint Follow-up Effect (number of AEs)
Overall By drug arm
Test of proportions
with ≥ 1 AE
Description (includ-
ing of other effect
measure if different)
Barber 1995 Ophthalmology Any AE 4 weeks N/A Average frequency of
do-
main scores (number
(%) mean (SD)) for
those not reporting
AEs by O but indi-
cating AE by CL: oc-
cular symptoms 41
(89.1), 1.18 (0.91)
; taste 3 (6.4), 2.5
(2.18); vision diffi-
culties 33 (70.2), 2.
8 (1.84); accommo-
dation difficulties 20
(42.6), 3.68 (2.27);
browache 12 (25.5)
, 2.75 (1.86). Scores
ranged from partic-
ipants experiencing
AEs rarely to usu-
ally. Average domain
scores increased as
AEs reported by O
and therapy discon-
tinued - participants
reporting AEs to O
reported more AEs
by CL
N/A
Barrowman
1970
GI Any AE 1 occasion N/A CL elicited 1.8 x the
number of AEs than
O
Mean number of
AEs for pentagastrin:
O 2.1 CL 3.2 (range
1-5). For placebo: O
0 CL 1 (range 0-3)
Downing 1970 Psychiatry Any AE 4 weeks OR 3.22 (1.49; 7.
74) P = 0.0017†
While
methods agreed for
85 (69%) of partic-
ipants, CL elicited
a significantly greater
More AEs reported
with am-
plodipine versus is-
radipine when either
O or CL used. No
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Table 9. Effects of methods on the number of AEs reported for within-participant comparisons (Continued)
number of AEs than
O
drug-placebo differ-
ence found when O
used, however, for
CL, a statistically
significant difference
found in proportion
of participants with
≥ 1 AE (χ² 5.76,
P < 0.025). In those
AEs deemedmedica-
tion-related, CL re-
sulted in higher fre-
quency of AEs in ac-
tive arm and pro-
duced a larger drug-
placebo difference in
frequency of AEs
Hermans 1994 Cardiology Any AE 6 weeks W0: -0.10 (-0.17; -0.
03) P = 0.0063, W8:
-0.05 (-0.14; 0.03) P
= 0.2293††
CL elicited 2 x as
many AEs as O
and % of partici-
pants with ≥ 1AE
significantly greater
with CL at W0,
however proportions
similar at W8 be-
tween methods
Between-drugdiffer-
ence in AEs overall
(and for frequency of
ankle oedema) statis-
tically significant (P
= 0.02, 95% CI 3.1
to 26.7) for O, not
for CL. No differ-
ence between meth-
ods for other specific
AEs or for severity of
ankle oedema
Jacobson 1987 Psychiatry Any AE NK N/A CL elicited 6.7 x the
number of AEs than
O. Mean number of
AEs per assessment
5 more by CL com-
pared to O. In over-
lapping group of 88
exposed to O, mean
number of AEs per
assessment was 1.6
x higher than when
O was part of com-
bined tool
N/A
Nicholls 1980* Cardiology Any AE 8 weeks N/A See data by drug
arm.
Statistically signifi-
cant difference in
mean number of AEs
betweendrugs byCL
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Table 9. Effects of methods on the number of AEs reported for within-participant comparisons (Continued)
(5.4 labetolol, 3.6
propranolol P < 0.
05) but not by O (1.
6 labetolol, 1.5 pro-
pranolol)
O’Connell 2007 Dysmenorrhoea Any AE 12 weeks N/A CL elicited 2.7 x the
number of AEs than
O.
Median number of
AEs for contracep-
tive and placebo by
O was 1. By CL, me-
dian for both was 2
Perez 2012 Parkinson’s Dis-
ease (PD) and
post-stroke con-
trols (PSC)
Any AE 1 occasion N/A Sig-
nificantly more par-
ticipants reporting≥
1 AE on CL com-
pared toO (P < 0.01)
in both groups. Only
factor found related
to reporting of ≥ 1
AE by participants in
response to O, was if
participant reported
> 2 AEs by CL (OR
1.2 (1.1 to 3.2)
N/A
Rabkin 1992 Psychiatry Any AE 4 weeks N/A CL elicited 5 x mean
number of AEs than
O.
N/A
Reilly 1992 Cardiology Any AE 10 weeks W0: 0-.65 (-0.75; -
0.54), P = 0.0000,
W12: -0.47 (-0.59; -
0.34), P = 0.0000 ††
% participants with
≥ 1 AE was signif-
icantly greater with
CL at W0 and W12.
Only 6% of symp-
toms reported onCL
were reported on O
N/A
Rosenthal 1996 Cardiology Any AE 12 weeks -0.38 (-0.39; -0.36)
P = 0.0000††
% of participants
with ≥ 1AE was
significantly greater
with CL
Between-drugdiffer-
ence in AEs overall
was statistically sig-
nificant (-0.03 (-0.
07; -0.001), P = 0.
0266) for O, not for
CL.(-0.04 -0.09; 0.
004), P = 0.0776
Wallin 1981 Gonorrhoea Any AE NK N/A 64% in-
crease in number of
N/A
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Table 9. Effects of methods on the number of AEs reported for within-participant comparisons (Continued)
AEs elicited by CL
after O.
Wernicke 2006 Not known Any AE NK N/A See data by drug
arm.
Sp-So index > 1.
0 for 22/29 (75.
9%) AEs but not
significant for most:
O more effective in
detecting difference
between treatments.
More statistically sig-
nificant differences
between treatments
by CL (9 AEs) than
O (5 AEs): differ-
ences in % of AEs
between drug and
placebo (rather than
ratios of AE rates)
more often greater
with CL
de Vries 2014 Diabetes Any AE 1 occasion N/A Sensitivities, PPV of
CL compared with
O (D) at primary
SOC (95% CI): 4-
weeks 33% (4-78)
and 10% (1-30); 3-
months 33% (21-
47) and 51% (34-
69). Sensitiv-
ities at specific ADE
level (95% CI): 4-
weeks 43% (10-92);
3-months 41% (30-
54)
N/A
Sheftell 2004 Migraine Any AE 1 occasion -0.31 (-0.38; -0.25)
P = 0.0000
Sig-
nificantly more AEs
reported throughCL
for those reporting 1,
2, 3 or more AEs
N/A
Landen 2005 Psychiatry Sexual 4 weeks OR 11 (5;26) χ² 45,
P < 0.001
R elicited signifi-
cantly greater num-
ber of AEs than O.
2 women versus 5
men reported AE by
O (χ² 6.7, P = 0.
No statistically
significant difference
found between drugs
by either method
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Table 9. Effects of methods on the number of AEs reported for within-participant comparisons (Continued)
01) and 29 women
versus 20 men by R
(χ²3.7, P = 0.06)
Yeo 1991 Cardiology Any AE 24 weeks -0.08 (-0.15; -0.01)
P = 0.0374.
% participants with
≥ 1AE significantly
greater with R com-
pared to O. Increase
in cough by R less
consistent in men
than women
N/A
Kruft 2007 Ophthalmology Occular NK N/A For 13 of 14 ques-
tions, there was a sta-
tistically greater pos-
itive response to CL
or R than O
N/A
Montiero 1987 Psychiatry Sexual 12 weeks N/A Of 10 participants
(all active) who did
not report AE byCL,
3 reported AE by O
and 8 by INT. 36%
of those with drug-
induced AE at in-
terview did not re-
port at CL despite
concern with it and
even if they were se-
cretly reducing dose
of drug to overcome
it
No AEs in placebo
arm by any method
de Vries 2013 Diabetes Any AE 1 occasion N/A Number of AEs sim-
ilar between the CLs
(Z = -0.049, P = 0.
961)
N/A
Lundberg 1980 Antihistamine Any AE 9 days N/A N/A Two-factor repeated
measure of variance
for AEs reported by
≥
50% sample showed
significant effects of
drug for 6 symptoms
by CL but no differ-
ence by R
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Table 9. Effects of methods on the number of AEs reported for within-participant comparisons (Continued)
Wallander 1991 Cardiology Any AE 8 weeks N/A Higher mean num-
ber AEs through R
versus CL (overall
and sex/age groups).
In addition to mea-
suring frequency, R
also quantified de-
gree of change in
symptoms
N/A
Allen 2013* Malaria Any AE 3-7 days N/A % increase in num-
ber of AEs: Site 1:
16.7% O to CL,
no change with INT.
Site 2: 87.0% O to
CL, 2.3% CL to
INT (subset)
N/A
Greenhill 2004 Psychiatry Any AE 1 occasion N/A Cumulative % in-
crease in number of
AEs: 33% O to first
CL (drug-specific in-
quiry, DSI) followed
by 202% to next CL
(body system review,
BSR)
N/A
Os 1994 Cardiology Cough 2 weeks -0.17 (-0.20; -0.13)
P = 0.0000
% participants with
≥ 1 AE signifi-
cantly greater with
CL compared to O.
Not possible to com-
pare frequency over-
all with R
Cough more fre-
quent with lisinopril
than nifedipine (8.5
versus 3.1%, P = 0.
0009) by O. Similar
change in frequency
with R. Not possible
to present same data
for CL
O: AE 3 x more fre-
quent in female ver-
sus male with lisino-
pril (12.6 versus 4.
4%, P = 0.0027)
, no difference for
nifedipine. 3 fold
difference with CL.
By VAS, participant
and spouse assessed
frequency of lisino-
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Table 9. Effects of methods on the number of AEs reported for within-participant comparisons (Continued)
pril-associated
AE similarly. With
O, similar number
of AEs independent
of smoking, with CL
a statistically signif-
icant difference be-
tween non-smokers
and smokers (16 ver-
sus 7%, P = 0.0018)
ADE:adversedrugevent
AE: adverse event
BSR: body system reviewCL: checklist
D: drug
DSI: drug-specific inquiry
INT: interview
N/A: not applicable
NK: not known
O: open question
O(B): blank page
PD:Parkinson′sDisease
PPV: positive predictive value
PSC: post-stroke control
R: rating scaleSD: standard deviation
SOC: system organ class
Sp-So: spontaneous-solicited index
VAS: visual analogue scale
W0, W2, W4, W8, W12:
χ²: chi-squared
Z: zeta (standard score)
∗T wosites/groupsreportedseparatelyasdiff erentparticipantpopulations
∗∗subsetofparticipantsf romCversusCLcomparisontheninterviewed
†McNemar ′stestofproportions,††2−samplettest
Table 10. Effects of methods on the nature of AEs reported for between-participant comparisons
Study Location Within/
outside trial
Participants Therapy
area
Endpoint Treatment-
emergent
Duration of
follow-up
Effect (na-
ture of AEs)
Avery 1967 US Within Patients Psychiatry Any AE Unclear 5 weeks A statistically
signif-
icant higher
mean severity
AEs at each
visit by CL
overall and in
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Table 10. Effects of methods on the nature of AEs reported for between-participant comparisons (Continued)
just the active
arm. See pa-
per for details
Huskisson
1974**
Europe Within Patients Rheumatol-
ogy
Any AE Unclear 24 weeks Severity was
included as a
composite
measure with
frequency so
presented un-
der ef-
fect (number
of AEs)
Torok
1984***
Europe Within Patients Cardiology Any AE Not necessar-
ily
Various N/A
Bent 2006 US Within Patients Prostatic hy-
perplasia
Any AE Unclear < 1 - 24
months
N/A
Borghi
1984*
Europe Within Patients Cardiology Any AE Unclear 16 weeks N/A
Spilker 1987 US Outside Healthy vol-
unteers
No
indication
Any AE Not necessar-
ily
1 occasion Most com-
mon symp-
toms by CL
were fatigue,
headache,
and
nasal conges-
tion and byO
were
headache,
back or mus-
cle pain, and
nasal conges-
tion
Ciccolunghi
1975
Europe Outside Healthy vol-
unteers
No
indication
Any AE Not necessar-
ily
1 occasion O was asso-
ciated with a
greater sever-
ity of symp-
toms than
CL. The type
of symptoms
reported did
de-
pend to some
81Eliciting adverse effects data from participants in clinical trials (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 10. Effects of methods on the nature of AEs reported for between-participant comparisons (Continued)
extent on the
method
Brent
2009**
US Within Patients Psychiatry Self-harm Yes 12 weeks
Suicidal There was no
difference be-
tween R
and O for re-
porting of se-
rious suicidal
or non-suici-
dal AEs (8.
4% versus 7.
3%, χ² = 0.
03, df = 1,
P = 0.87).
Time to on-
set for suici-
dal and non-
suicidal AEs
earlier for CL
than O: me-
dian 2 versus
5 weeks (χ² =
9.41, df = 1, P
= 0.004)
Non-
suicidal
Suicide
attempts
AE:adverseevent
CL: checklist
df: degrees of freedom
N/A: not applicable
O: open question
R: rating scale
χ²: chi-squared
∗AllparticipantsaskedAEsbyopenquestion(O),butasthisprocesspossiblyinvolved ′f iltering′of reportsbythedoctordatanotincludedinthereview.
∗∗Huskissonusedacompositemeasureoff requencyandseverity
∗∗∗Aselectionof thetotalAEsarepresentedinreviewasthoseobjectivelymeasuredwereexcluded
Table 11. Effects of methods on the nature of AEs reported for within-participant comparisons
Study Location Within /
outside trial
Partici-
pants
Therapy
area
Endpoint Treatment-
emergent
Duration of
follow-up
Effect (na-
ture of AEs)
Barber 1995 US Within Patients Ophthal-
mology
Any AE Unclear 4 weeks Participants
reporting
AEs by O
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Table 11. Effects of methods on the nature of AEs reported for within-participant comparisons (Continued)
and discon-
tinuing ther-
apy reported
more bother
and activity
limitation
compared
to those
who did not
report by O
but did by
CL. Aver-
age global
QoL scores
increased as
participants
reported AEs
by O and
discontinued
therapy;
participants
who re-
ported AEs
by O indi-
cated more
negative im-
pact of side
effects and
activity lim-
itations on
QoL, more
dissatisfac-
tion with
medication,
and more
noncompli-
ance versus
those not
reporting by
O
Barrowman
1970
Europe Within HV Gastroin-
tenstinal
Any AE Yes 1 occasion N/A
Downing
1970
US Within Patients Psychiatry Any AE Unclear 4 weeks Greater pro-
portion of
participants
reporting an
AE by both
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Table 11. Effects of methods on the nature of AEs reported for within-participant comparisons (Continued)
O and CL
(26, 90%)
had high
mean in-
tensity scores
compared to
those only re-
porting by
CL (12, 50%
- predom-
inantly those
taking tran-
quillizers) P
< 0.01. The
former par-
ticipants
more often
reported AEs
at a high dis-
comfort level
compared to
the latter, P <
0.05
Hermans
1994
Europe Within Patients Cardiology Any AE Yes 6 weeks There was no
ap-
parent differ-
ence between
the meth-
ods for sever-
ity and dura-
tion of AEs
Jacobson
1987
US Within Patients Psychiatry Any AE Unclear NK CL detected
a greater va-
riety of AEs
than O while
AEs reported
by O had a
higher mean
sever-
ity compared
to those re-
ported by CL
Nicholls
1980*
Europe Within Patients Cardiology Any AE Unclear 8 weeks N/A
O’Connell
2007
US Within Patients Dysmenor-
rhoea
Any AE Unclear 12 weeks N/A
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Table 11. Effects of methods on the nature of AEs reported for within-participant comparisons (Continued)
Perez 2012 Europe Outside Patients Parkinson’s
Disease,
post-stroke
controls
Any AE Unclear 1 occasion No relation-
ship between
AE sever-
ity and the
O question-
ing method
Rabkin
1992
US Within Patients Psychiatry Any AE Unclear 4 weeks AEs reported
to O signifi-
cantly more
distressing,
more often
interfered
with daily
function-
ing and
elicited more
changes
in clinical
management
versus CL
(NB for
latter addi-
tional 46
participants
assessed). No
medically
serious AEs
elicited by O
alone. Over-
all, and for
participants
on active
drug (but
not placebo)
, mean
severity of
AEs reported
by O sig-
nificantly
greater
versus CL.
However,
61% of AEs
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Table 11. Effects of methods on the nature of AEs reported for within-participant comparisons (Continued)
rated severe/
very severe
elicited by
CL, 65%
AEs causing
severe/
very severe
dysfunction
detected by
CL versus
35% by O
Reilly 1992 US Within Patients Cardiology Any AE Not
necessarily
10 weeks Symptoms
reported
by O more
bothersome
than CL. no
change in
mean degree
of distress
caused by
AEs using
CL, but
increase
in distress
associated
with AEs by
O. Duration
of AEs
similar for
O and CL
but a higher
symptom
severity
score by O
versus CL.
Significant
relationship
between
degree of
bother (P
< 0.0001)
, duration
(P = 0.02),
severity (P =
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Table 11. Effects of methods on the nature of AEs reported for within-participant comparisons (Continued)
0.0003) and
reporting of
AEs by O.
Only 18%
of symptoms
bothering
participants
a lot/ex-
tremely were
first reported
by CL
Rosenthal
1996
Europe Within Patients Cardiology Any AE Unclear 12 weeks N/A
Wallin 1981 Europe Within Patients Gonorrhoea Any AE Unclear NK Conclusions
severity not
supported by
the data.
Wernicke
2006
Not known Within Patients Not known Any AE Yes NK N/A
de Vries
2014
Europe Outside Patients Diabetes Any AE Unclear 1 occasion N/A
Sheftell
2004
Multina-
tional
Outside Patients Migraine Any AE Unclear 1 occasion No differ-
ence between
O and CL
for severity.
However 31
(7.
5%) partici-
pants who
rated AE as
severe in CL
did not re-
port the AE
in O
Landen
2005
Europe Within Patients Psychiatry Sexual Yes 4 weeks
Yeo 1991 Europe Within Patients Cardiology Any AE Unclear 24 weeks N/A
Kruft 2007 Multina-
tional
Within Patients Ophthal-
mology
Occular Unclear NK N/A
Montiero
1987
Europe Within Patients Psychiatry Sexual Yes 12 weeks N/A
87Eliciting adverse effects data from participants in clinical trials (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 11. Effects of methods on the nature of AEs reported for within-participant comparisons (Continued)
de Vries
2013
Europe Outside Patients Diabetes Any AE Unclear 1 occasion N/A
Lundberg
1980
US Within Patients Antihis-
tamine
Any AE Unclear 9 days N/A
Wallander
1991
Europe Within Patients Cardiology Any AE Unclear 8 weeks N/A
Allen 2013* Africa Within Patients,
healthy vol-
unteers
Malaria Any AE Yes 3-7 days All ad-
ditional AEs
were
mild and un-
likely related
to trial drug
Greenhill
2004
US Outside Patients Psychiatry Any AE Unclear 1 occasion 54% of AEs
elicited by O
were moder-
ate to severe
compared to
75% of
those elicited
by DSI and
37%
for BSR. Of
the 17 severe
AEs, 6 (37%)
were elicited
by BSR. 31%
of the AEs
elicited by
O were clini-
cally relevant
compared
with 12% for
the DSI and
15%
for the BSR.
Of the clini-
cally relevant
AEs (N = 37)
, 19 (53%)
were elicited
by BSR
Os 1994 Europe Within Patients Cardiology Cough Yes 2 weeks N/A
AE:adverseevent
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BSR: body system review
CL: checklist
DSI: drug-specific inquiry
INT: interview
N/A: not applicable
NB: nota bene
NK: not known
O: open question/spontaneous
QoL: quality of life
R: rating scale
∗T wosites/groupsreportedseparatelyasdiff erentparticipantpopulations
A P P E N D I C E S
Appendix 1. Appendix 1: final electronic search strategy and results
Database(s): Embase 1980 to 2013 Week 17, Embase 1980 to 2013 Week 27 Searched April 2013
16th July 2013 (used entry week field and selected all from 201317 to latest 201328) - 158 results when limited to human and English
16th March 2015 used Entry field 201327 to 2015 wk 11, retrieved 1405
# Searches Results
1 exp adverse drug reaction/ 303737
2 drug safety/ 210956
3 side effect/ 157758
4 (drug? adj2 (safety or harm? or adverse or undesirable or toler-
ability or toxicity or toxic or effect? or event? or symptom?)).
ti,ab
66980
5 ((adverse or side or undesirable or treatment emergent or treat-
ment related) adj2 (effect? or reaction? or event? or outcome?
or symptom?)).ti,ab
504926
6 (adr or adrs).ti,ab. 8291
7 (drug? adj2 (safety or harm? or adverse or undesirable or tol-
erability or toxicity or toxic or effect? or event? or symptom?
) adj3 (measur$ or assess$ or monitor$ or detect$ or report$
or self report$ or record$ or identif$ or collect$ or notify or
notifie? or notification$)).ti,ab
7902
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(Continued)
8 ((adverse or side or undesirable or treatment emergent or treat-
ment related) adj2 (effect? or reaction? or event? or outcome?
or symptom?) adj3 (measur$ or assess$ or monitor$ or detect$
or report$ or self report$ or record$ or identif$ or collect$ or
notify or notifie? or notification$)).ti,ab
53530
9 ((adr or adrs) adj3 (measur$ or assess$ or monitor$ or detect$
or report$ or self report$ or record$ or identif$ or collect$ or
notify or notifie? or notification$)).ti,ab
2377
10 or/1-9 935536
11 adverse.ab. /freq=3 or adr.ab. /freq=3 or adrs.ab. /freq=3 or ae.
ab. /freq=3 or aes.ab. /freq=3 or (side adj effect$).ab. /freq=3
or elicit$.ab. /freq=3 or symptom?.ab. /freq=3
192692
12 10 and 11 62830
13 (drug? adj2 (safety or harm? or adverse or undesirable or tol-
erability or toxicity or toxic or effect? or event? or symptom?
) adj3 (measur$ or assess$ or monitor$ or detect$ or report$
or self report$ or record$ or identif$ or collect$ or notify or
notifie? or notification$)).ti
1952
14 ((adverse or side or undesirable or treatment emergent or treat-
ment related) adj2 (effect? or reaction? or event? or outcome?
or symptom?) adj3 (measur$ or assess$ or monitor$ or detect$
or report$ or self report$ or record$ or identif$ or collect$ or
notify or notifie? or notification$)).ti
3406
15 ((adr or adrs) adj3 (measur$ or assess$ or monitor$ or detect$
or report$ or self report$ or record$ or identif$ or collect$ or
notify or notifie? or notification$)).ti
159
16 or/12-15 65507
17 ((patient$ or participant$ or subject$) adj2 (elicit$ or evoke$
or solicit$ or unsolicit$ or notify or notifie? or notification$ or
spontaneous$ or prompt or prompted or unprompted or open-
ended or structured or systematic or standardi$)).ti,ab
22183
18 (spontaneous report$ or self report$ or participant report$ or
patient report$ or subject report$ or self administer$).ti,ab
129006
19 ((patient$ or participant$ or subject$) adj2 (enquir$ or inquir$
or complain$ or checklist$ or check-list$ or query or querie$
or form or forms or interview$)).ti,ab
49399
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(Continued)
20 ((elicit$ or evoke$ or solicit$ or unsolicit$ or notify or no-
tification$ or prompt or prompted or unprompted or open-
ended or structured or systematic or standardi$) adj2 (enquir$
or inquir$ or complain$ or checklist$ or check-list$ or query
or querie$ or form or forms or interview$)).ti,ab
41109
21 or/17-20 231691
22 and/16,21 4428
(limit to English and Human gives 3478)
Database(s): Ovid MEDLINE(R) 1946 to April Week 3 2013, MEDLINE(R) 1946 to July Week 1 2013 Searched April 2013
16th July 2013 (searched 201304$.ed,ep,up) - 63 results when limited to Humans and English
16th March 2015 searched to 2015 March wk 2 retrieved 702
# Searches Results
1 Adverse Drug Reaction Reporting Systems/ 5208
2 Drug Toxicity/ 5938
3 (ae or de).fs. 3394970
4 (drug? adj2 (safety or harm? or adverse or undesirable or toler-
ability or toxicity or toxic or effect? or event? or symptom?)).
ti,ab
47522
5 ((adverse or side or undesirable or treatment emergent or treat-
ment related) adj2 (effect? or reaction? or event? or outcome?
or symptom?)).ti,ab
350647
6 (adr or adrs).ti,ab. 5344
7 (drug? adj2 (safety or harm? or adverse or undesirable or tol-
erability or toxicity or toxic or effect? or event? or symptom?
) adj3 (measur$ or assess$ or monitor$ or detect$ or report$
or self report$ or record$ or identif$ or collect$ or notify or
notifie? or notification$)).ti,ab
5193
8 ((adverse or side or undesirable or treatment emergent or treat-
ment related) adj2 (effect? or reaction? or event? or outcome?
or symptom?) adj3 (measur$ or assess$ or monitor$ or detect$
or report$ or self report$ or record$ or identif$ or collect$ or
notify or notifie? or notification$)).ti,ab
35078
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(Continued)
9 ((adr or adrs) adj3 (measur$ or assess$ or monitor$ or detect$
or report$ or self report$ or record$ or identif$ or collect$ or
notify or notifie? or notification$)).ti,ab
1071
10 or/1-9 3567892
11 adverse.ab. /freq=3 or adr.ab. /freq=3 or adrs.ab. /freq=3 or ae.
ab. /freq=3 or aes.ab. /freq=3 or (side adj effect$).ab. /freq=3
or elicit$.ab. /freq=3 or symptom?.ab. /freq=3
132190
12 and/10-11 54020
13 (drug? adj2 (safety or harm? or adverse or undesirable or tol-
erability or toxicity or toxic or effect? or event? or symptom?
) adj3 (measur$ or assess$ or monitor$ or detect$ or report$
or self report$ or record$ or identif$ or collect$ or notify or
notifie? or notification$)).ti
1253
14 ((adverse or side or undesirable or treatment emergent or treat-
ment related) adj2 (effect? or reaction? or event? or outcome?
or symptom?) adj3 (measur$ or assess$ or monitor$ or detect$
or report$ or self report$ or record$ or identif$ or collect$ or
notify or notifie? or notification$)).ti
2241
15 ((adr or adrs) adj3 (measur$ or assess$ or monitor$ or detect$
or report$ or self report$ or record$ or identif$ or collect$ or
notify or notifie? or notification$)).ti
37
16 or/12-15 55859
17 ((patient$ or participant$ or subject$) adj2 (elicit$ or evoke$
or solicit$ or unsolicit$ or notify or notifie? or notification$ or
spontaneous$ or prompt or prompted or unprompted or open-
ended or structured or systematic or standardi$)).ti,ab
16381
18 (spontaneous report$ or self report$ or participant report$ or
patient report$ or subject report$ or self administer$).ti,ab
97507
19 ((patient$ or participant$ or subject$) adj2 (enquir$ or inquir$
or complain$ or checklist$ or check-list$ or query or querie$
or form or forms or interview$)).ti,ab
34835
20 ((elicit$ or evoke$ or solicit$ or unsolicit$ or notify or no-
tification$ or prompt or prompted or unprompted or open-
ended or structured or systematic or standardi$) adj2 (enquir$
or inquir$ or complain$ or checklist$ or check-list$ or query
or querie$ or form or forms or interview$)).ti,ab
30608
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(Continued)
21 or/17-20 172513
22 16 and 21 3699
(limit to English and Human gives 3397)
Database(s): Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations July 15, 2013 Searched 16th July 2013
# Searches Results
1 (drug? adj2 (safety or harm? or adverse or undesirable or toler-
ability or toxicity or toxic or effect? or event? or symptom?)).
ti,ab
2931
2 ((adverse or side or undesirable or treatment emergent or treat-
ment related) adj2 (effect? or reaction? or event? or outcome?
or symptom?)).ti,ab
24324
3 (adr or adrs).ti,ab. 401
4 (drug? adj2 (safety or harm? or adverse or undesirable or tol-
erability or toxicity or toxic or effect? or event? or symptom?
) adj3 (measur$ or assess$ or monitor$ or detect$ or report$
or self report$ or record$ or identif$ or collect$ or notify or
notifie? or notification$)).ti,ab
402
5 ((adverse or side or undesirable or treatment emergent or treat-
ment related) adj2 (effect? or reaction? or event? or outcome?
or symptom?) adj3 (measur$ or assess$ or monitor$ or detect$
or report$ or self report$ or record$ or identif$ or collect$ or
notify or notifie? or notification$)).ti,ab
2684
6 ((adr or adrs) adj3 (measur$ or assess$ or monitor$ or detect$
or report$ or self report$ or record$ or identif$ or collect$ or
notify or notifie? or notification$)).ti,ab
155
7 or/1-6 25915
8 adverse.ab. /freq=3 or adr.ab. /freq=3 or adrs.ab. /freq=3 or ae.
ab. /freq=3 or aes.ab. /freq=3 or (side adj effect$).ab. /freq=3
or elicit$.ab. /freq=3 or symptom?.ab. /freq=3
9705
9 and/7-8 2853
10 (drug? adj2 (safety or harm? or adverse or undesirable or tol-
erability or toxicity or toxic or effect? or event? or symptom?
) adj3 (measur$ or assess$ or monitor$ or detect$ or report$
or self report$ or record$ or identif$ or collect$ or notify or
112
93Eliciting adverse effects data from participants in clinical trials (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
notifie? or notification$)).ti
11 ((adverse or side or undesirable or treatment emergent or treat-
ment related) adj2 (effect? or reaction? or event? or outcome?
or symptom?) adj3 (measur$ or assess$ or monitor$ or detect$
or report$ or self report$ or record$ or identif$ or collect$ or
notify or notifie? or notification$)).ti
196
12 ((adr or adrs) adj3 (measur$ or assess$ or monitor$ or detect$
or report$ or self report$ or record$ or identif$ or collect$ or
notify or notifie? or notification$)).ti
7
13 or/9-12 2975
14 ((patient$ or participant$ or subject$) adj2 (elicit$ or evoke$
or solicit$ or unsolicit$ or notify or notifie? or notification$ or
spontaneous$ or prompt or prompted or unprompted or open-
ended or structured or systematic or standardi$)).ti,ab
990
15 (spontaneous report$ or self report$ or participant report$ or
patient report$ or subject report$ or self administer$).ti,ab
7777
16 ((patient$ or participant$ or subject$) adj2 (enquir$ or inquir$
or complain$ or checklist$ or check-list$ or query or querie$
or form or forms or interview$)).ti,ab
2244
17 ((elicit$ or evoke$ or solicit$ or unsolicit$ or notify or no-
tification$ or prompt or prompted or unprompted or open-
ended or structured or systematic or standardi$) adj2 (enquir$
or inquir$ or complain$ or checklist$ or check-list$ or query
or querie$ or form or forms or interview$)).ti,ab
2547
18 or/14-17 13045
19 and/13,18 219
CINAHL 1980 to April 2013
16th July 2013 searched 201304 in EM field gave 3 extra results
16th March 2015 searched 201304 to 2015* retrieved 154
Search ID# Search Terms Actions
S21 S11 AND S20 870
S20 S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18
OR S19
58,723
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(Continued)
S19 AB ((elicit* or evoke* or solicit* or unsolicit* or notify or
notification* or prompt or prompted or unprompted or
open-ended or structured or systematic or standardi*) N2
(enquir* or inquir* or complain* or checklist* or check-
list* or query or querie* or form or forms or interview*))
15,094
S18 TI ((elicit* or evoke* or solicit* or unsolicit* or notify or
notification* or prompt or prompted or unprompted or
open-ended or structured or systematic or standardi*) N2
(enquir* or inquir* or complain* or checklist* or check-
list* or query or querie* or form or forms or interview*))
200
S17 AB ((patient* or participant* or subject*) N2 (enquir* or
inquir* or complain* or checklist* or check-list* or query
or querie* or form or forms or interview*))
12,113
S16 TI ((patient* or participant* or subject*) N2 (enquir* or
inquir* or complain* or checklist* or check-list* or query
or querie* or form or forms or interview*))
747
S15 AB (“spontaneous report*” or “self report*” or “participant
report*” or “patient report*” or “subject report*” or “self
administer*”)
28,140
S14 TI (“spontaneous report*” or “self report*” or “participant
report*” or “patient report*” or “subject report*” or “self
administer*”)
4,309
S13 AB ((patient* or participant* or subject*) N2 (elicit* or
evoke* or solicit* or unsolicit* or notify or notifie# or no-
tification* or spontaneous* or prompt or prompted or un-
prompted or open-ended or structured or standardi*))
4,297
S12 TI ((patient* or participant* or subject*) N2 (elicit* or
evoke* or solicit* or unsolicit* or notify or notifie# or no-
tification* or spontaneous* or prompt or prompted or un-
prompted or open-ended or structured or standardi*))
548
S11 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8
OR S9 OR S10
16,075
S10 AB ((adr or adrs) N3 (measur* or assess* or monitor* or
detect* or report* or self report* or record* or identif* or
collect* or notify or notifie# or notification*))
125
S9 TI ((adr or adrs) N3 (measur* or assess* or monitor* or
detect* or report* or self report* or record* or identif* or
collect* or notify or notifie# or notification*))
7
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(Continued)
S8 AB ((adverse or side or undesirable or treatment emergent
or treatment related) N2 (effect# or reaction# or event# or
outcome# or symptom#) N3 (measur* or assess* or moni-
tor* or detect* or report* or self report* or record* or iden-
tif* or collect* or notify or notifie# or notification*))
6,586
S7 TI ((adverse or side or undesirable or treatment emergent
or treatment related) N2 (effect# or reaction# or event# or
outcome# or symptom#) N3 (measur* or assess* or moni-
tor* or detect* or report* or self report* or record* or iden-
tif* or collect* or notify or notifie# or notification*))
799
S6 AB (drug# N2 (safety or harm# or adverse or undesirable
or tolerability or toxicity or toxic or effect# or event# or
symptom#) N3 (measur* or assess* or monitor* or detect*
or report* or self report* or record* or identif* or collect*
or notify or notifie# or notification*))
718
S5 TI (drug# N2 (safety or harm# or adverse or undesirable
or tolerability or toxicity or toxic or effect# or event# or
symptom#) N3 (measur* or assess* or monitor* or detect*
or report* or self report* or record* or identif* or collect*
or notify or notifie# or notification*))
364
S4 TI (adr or adrs) 40
S3 TI ((adverse or side or undesirable or treatment emergent
or treatment related) N2 (effect# or reaction# or event# or
outcome# or symptom#))
6,607
S2 TI (drug# N2 (safety or harm# or adverse or undesirable
or tolerability or toxicity or toxic or effect# or event# or
symptom#))
2,176
S1 (MH “Adverse Drug Event”) 3,161
Web of Knowledge strategies
Databases=SCI-EXPANDED, SSCI, CPCI-S, BIOSIS Timespan=All years
(numbers are from SCI/SSCI/CPCI-S)
Searched 26/6/13
Repeated 16th July 2013, re run search with “Records process from” 2013-05-01, retrieved 3 results from Web of Science databases
and 1 from BIOSIS (latter can only do 2013 so may be duplicate)
16th March 2015 pubn date 2013-5 retrieved 271
#13 241 #11 OR #9
# 12 170 #11 NOT #9
# 11 241 #10 AND #8 AND #4
# 10 11,417,480 TS=(measur* or assess* or monitor* or detect* or report* or self report* or record* or identif* or collect* or notify or
notified or notification*)
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# 9 16 #8 AND #5
# 8 52,126 #7 OR #6
# 7 46,392 TS=(patient* NEAR/2 enquir*) or TS=(participant* NEAR/2 enquir*) or TS=(subject* NEAR/2 enquir*) or TS=(patient*
NEAR/2 inquir*) or TS=(participant* NEAR/2 inquir*) or TS=(subject* NEAR/2 inquir*) or TS=(patient* NEAR/2 complain*) or
TS=(participant* NEAR/2 complain*) or TS=(subject* NEAR/2 complain*) or TS=(patient* NEAR/2 checklist*) or TS=(participant*
NEAR/2 checklist*) or TS=(subject* NEAR/2 checklist*) or TS=(patient* NEAR/2 check-list*) or TS=(participant* NEAR/2 check-
list*) or TS=(subject* NEAR/2 check-list*) or TS=(patient* NEAR/2 query) or TS=(participant* NEAR/2 query) or TS=(subject*
NEAR/2 query) or TS=(patient* NEAR/2 querie*) or TS=(participant* NEAR/2 querie*) or TS=(subject* NEAR/2 querie*) or TS=
(patient* NEAR/2 form) or TS=(participant* NEAR/2 form) or TS=(subject* NEAR/2 form) or TS=(patient* NEAR/2 forms) or TS=
(participant* NEAR/2 forms) or TS=(subject* NEAR/2 forms) or TS=(patient* NEAR/2 interview*) or TS=(participant* NEAR/2
interview*) or TS=(subject* NEAR/2 interview*)
# 6 5,972 TS=(patient* NEAR/2 elicit*) or TS=(participant* NEAR/2 elicit*) or TS=(subject* NEAR/2 elicit*) or TS=(patient*
NEAR/2 evoke*) or TS=(participant* NEAR/2 evoke*) or TS=(subject* NEAR/2 evoke*) or TS=(patient* NEAR/2 solicit*) or TS=
(participant* NEAR/2 solicit*) or TS=(subject* NEAR/2 solicit*) or TS=(patient* NEAR/2 unsolicit*) or TS=(participant* NEAR/2
unsolicit*) or TS=(subject* NEAR/2 unsolicit*) or TS=(patient* NEAR/2 notif*) or TS=(participant* NEAR/2 notif*) or TS=(subject*
NEAR/2 notif*) or TS=(patient* NEAR/2 prompted) or TS=(participant* NEAR/2 prompted) or TS=(subject* NEAR/2 prompted)
or TS=(patient* NEAR/2 unprompted) or TS=(participant* NEAR/2 unprompted) or TS=(subject* NEAR/2 unprompted)
# 5 5,551 #4 AND #3
# 4 48,150 #2 OR #1
# 3 2,594,464 TI=(measur* or assess* or monitor* or detect* or report* or self report* or record* or identif* or collect* or notify or
notified or notification*)
# 2 30,484 TI=(“adverse effect*” or “side effect*” or “undesirable effect*” or “adverse reaction*” or “side reaction*” or “undesirable
reaction*” or “adverse event*” or “undesirable event*” or “adverse outcome*” or “undesirable outcome*” or “adverse symptom*” or
“undesirable symptom*” or “treatment emergent” or “treatment related”)
# 1 19,049 TI=(drug* NEAR/2 safety) or TI= (drug* NEAR/2 harm*) or TI= (drug* NEAR/2 adverse) or TI= (drug* NEAR/2
undesirable) or TI= (drug* NEAR/2 tolerability) or TI= (drug* NEAR/2 toxicity) or TI= (drug* NEAR/2 toxic) or TI= (drug* NEAR/
2 effect) or TI= (drug* NEAR/2 effecTI) or TI= (drug* NEAR/2 event) or TI= (drug* NEAR/2 evenTI) or TI= (drug* NEAR/2
symptom) or TI= (drug* NEAR/2 symptoms)
Database(s): CAB Abstracts 1973 to 2013 Week 24
Searched 25/6/13
Searched 16th Jul 2013 (used update code field and selected all for June and July), but no new records
Searched 16th March 2015 update code to 2015 wk10 retrieved 45
# Searches Results
1 adverse effects/ 27215
2 drug toxicity/ 6475
3 (drug? adj2 (safety or harm? or adverse or undesirable or toler-
ability or toxicity or toxic or effect? or event? or symptom?)).
ti,ab
4157
4 ((adverse or side or undesirable or treatment emergent or treat-
ment related) adj2 (effect? or reaction? or event? or outcome?
or symptom?)).ti,ab
67499
5 (adr or adrs).ti,ab. 633
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(Continued)
6 (drug? adj2 (safety or harm? or adverse or undesirable or tol-
erability or toxicity or toxic or effect? or event? or symptom?
) adj3 (measur$ or assess$ or monitor$ or detect$ or report$
or self report$ or record$ or identif$ or collect$ or notify or
notifie? or notification$)).ti,ab
404
7 ((adverse or side or undesirable or treatment emergent or treat-
ment related) adj2 (effect? or reaction? or event? or outcome?
or symptom?) adj3 (measur$ or assess$ or monitor$ or detect$
or report$ or self report$ or record$ or identif$ or collect$ or
notify or notifie? or notification$)).ti,ab
4292
8 ((adr or adrs) adj3 (measur$ or assess$ or monitor$ or detect$
or report$ or self report$ or record$ or identif$ or collect$ or
notify or notifie? or notification$)).ti,ab
87
9 or/1-8 88969
10 adverse.ab. /freq=3 or adr.ab. /freq=3 or adrs.ab. /freq=3 or ae.
ab. /freq=3 or aes.ab. /freq=3 or (side adj effect$).ab. /freq=3
or elicit$.ab. /freq=3 or symptom?.ab. /freq=3
20765
11 9 and 10 3200
12 (drug? adj2 (safety or harm? or adverse or undesirable or tol-
erability or toxicity or toxic or effect? or event? or symptom?
) adj3 (measur$ or assess$ or monitor$ or detect$ or report$
or self report$ or record$ or identif$ or collect$ or notify or
notifie? or notification$)).ti
83
13 ((adverse or side or undesirable or treatment emergent or treat-
ment related) adj2 (effect? or reaction? or event? or outcome?
or symptom?) adj3 (measur$ or assess$ or monitor$ or detect$
or report$ or self report$ or record$ or identif$ or collect$ or
notify or notifie? or notification$)).ti
203
14 ((adr or adrs) adj3 (measur$ or assess$ or monitor$ or detect$
or report$ or self report$ or record$ or identif$ or collect$ or
notify or notifie? or notification$)).ti
1
15 or/11-14 3359
16 ((patient$ or participant$ or subject$) adj2 (elicit$ or evoke$
or solicit$ or unsolicit$ or notify or notifie? or notification$ or
spontaneous$ or prompt or prompted or unprompted or open-
ended or structured or systematic or standardi$)).ti,ab
925
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(Continued)
17 (spontaneous report$ or self report$ or participant report$ or
patient report$ or subject report$ or self administer$).ti,ab
12019
18 ((patient$ or participant$ or subject$) adj2 (enquir$ or inquir$
or complain$ or checklist$ or check-list$ or query or querie$
or form or forms or interview$)).ti,ab
2987
19 ((elicit$ or evoke$ or solicit$ or unsolicit$ or notify or no-
tification$ or prompt or prompted or unprompted or open-
ended or structured or systematic or standardi$) adj2 (enquir$
or inquir$ or complain$ or checklist$ or check-list$ or query
or querie$ or form or forms or interview$)).ti,ab
6044
20 or/16-19 21388
21 15 and 20 167
22 from 21 keep 2, 4, 7-9, 11-12, 15, 17... 75
23 limit 22 to english language 71
Cochrane Library - ran the same strategy and downloaded results from CMR and HTA, then altered to :ti only for AE terms and
downloaded CCTR (since I don’t have the option of reducing the numbers with freq operator in Cochrane).
Limited to 2013 for update search (16th Jul 2013); no results from CMR,
16th March 2015 publication date 2013-5
CMR
Search Name: Elicitation of AE CMR sensitive
Last Saved: 02/05/2013 09:40:00.932
Description:
16th March 2015 re-ran pubn date 2013-5 no results from CMR (not being updated)
ID Search
#1 MeSH descriptor: [Adverse Drug Reaction Reporting Systems] this term only
#2 MeSH descriptor: [Drug Toxicity] this term only
#3 Any MeSH descriptor with qualifier(s): [Adverse effects - AE, Drug effects - DE]
#4 ((drug? near/2 safety) or (drug? near/2 harm?) or (drug? near/2 adverse) or (drug? near/2 undesirable) or (drug? near/2 tolerability)
or (drug? near/2 toxicity) or (drug? near/2 effect?) or (drug? near/2 event?) or (drug? near/2 symptom?)):ti,ab
#5 ((adverse near/2 effect?) or (adverse near/2 reaction?) or (adverse near/2 event?) or (adverse near/2 outcome?) or (adverse near/2
symptom?)):ti,ab
#6 ((side near/2 effect?) or (side near/2 reaction?) or (side near/2 event?) or (side near/2 outcome?) or (side near/2 symptom?)):ti,ab
#7 ((undesirable near/2 effect?) or (undesirable near/2 reaction?) or (undesirable near/2 event?) or (undesirable near/2 outcome?) or
(undesirable near/2 symptom?)):ti,ab
#8 ((”treatment emergent“ near/2 effect?) or (”treatment emergent“ near/2 reaction?) or (”treatment emergent“ near/2 event?) or
(”treatment emergent“ near/2 outcome?) or (”treatment emergent“ near/2 symptom?)):ti,ab
#9 ((”treatment related“ near/2 effect?) or (”treatment related“ near/2 reaction?) or (”treatment related“ near/2 event?) or (”treatment
related“ near/2 outcome?) or (”treatment related“ near/2 symptom?)):ti,ab
#10 (”adverse effect*“ near/3 assess*) or (”adverse effect*“ near/3 measur*) or (”adverse effect*“ near/3 detect*) or (”adverse effect*“
near/3 notify) or (”adverse effect*“ near/3 notification*):ti,ab
#11 (”adverse event*“ near/3 assess*) or (”adverse event *“ near/3 measur*) or (”adverse event *“ near/3 detect*) or (”adverse event *“
near/3 notify) or (”adverse event *“ near/3 notification*):ti,ab
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#12 (”adverse reaction*“ near/3 assess*) or (”adverse reaction *“ near/3 measur*) or (”adverse reaction *“ near/3 detect*) or (”adverse
reaction *“ near/3 notify) or (”adverse reaction *“ near/3 notification*):ti,ab
#13 (”side effect*“ near/3 assess*) or (”side effect*“ near/3 measur*) or (”side effect*“ near/3 detect*) or (”side effect*“ near/3 notify)
or (”side effect*“ near/3 notification*):ti,ab
#14 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13
#15 ((elicit*NEAR/2 questionnaire*) or (evoke* near/2 questionnaire*) or (solicit* near/2 questionnaire*) or (unsolicit* near/2 question-
naire*) or (self-report* near/2 questionnaire*) or (participant-report* near/2 questionnaire*) or (subject-report* near/2 questionnaire*)
or (self-administer* near/2 questionnaire*) or (spontaneous* near/2 questionnaire*) or (prompt near/2 questionnaire*) or (prompted
near/2 questionnaire*) or (unprompted near/2 questionnaire*) or (open-ended near/2 questionnaire*) or (structured near/2 question-
naire*) or (systematic near/2 questionnaire*) or (standardi* near/2 questionnaire*)):ti,ab
#16 ((elicit*NEAR/2 report?) or (evoke* near/2 report?) or (solicit* near/2 report?) or (unsolicit* near/2 report?) or (self-report? near/2
report?) or (participant-report? near/2 report?) or (subject-report? near/2 report?) or (self-administer* near/2 report?) or (spontaneous*
near/2 report?) or (prompt near/2 report?) or (prompted near/2 report?) or (unprompted near/2 report?) or (open-ended near/2 report?
) or (structured near/2 report?) or (systematic near/2 report?) or (standardi* near/2 report?)):ti,ab
#17 ((elicit*NEAR/2 enquir*) or (evoke* near/2 enquir*) or (solicit* near/2 enquir*) or (unsolicit* near/2 enquir*) or (self-report*
near/2 enquir*) or (participant-report* near/2 enquir*) or (subject-report* near/2 enquir*) or (self-administer* near/2 enquir*) or
(spontaneous* near/2 enquir*) or (prompt near/2 enquir*) or (prompted near/2 enquir*) or (unprompted near/2 enquir*) or (open-
ended near/2 enquir*) or (structured near/2 enquir*) or (systematic near/2 enquir*) or (standardi* near/2 enquir*)):ti,ab
#18 ((elicit*NEAR/2 inquir*) or (evoke* near/2 inquir*) or (solicit* near/2 inquir*) or (unsolicit* near/2 inquir*) or (self-report* near/2
inquir*) or (participant-report* near/2 inquir*) or (subject-report* near/2 inquir*) or (self-administer* near/2 inquir*) or (spontaneous*
near/2 inquir*) or (prompt near/2 inquir*) or (prompted near/2 inquir*) or (unprompted near/2 inquir*) or (open-ended near/2
inquir*) or (structured near/2 inquir*) or (systematic near/2 inquir*) or (standardi* near/2 inquir*)):ti,ab
#19 ((elicit*NEAR/2 checklist*) or (evoke* near/2 checklist*) or (solicit* near/2 checklist*) or (unsolicit* near/2 checklist*) or (self-
report* near/2 checklist*) or (participant-report* near/2 checklist*) or (subject-report* near/2 checklist*) or (self-administer* near/2
checklist*) or (spontaneous* near/2 checklist*) or (prompt near/2 checklist*) or (prompted near/2 checklist*) or (unprompted near/2
checklist*) or (open-ended near/2 checklist*) or (structured near/2 checklist*) or (systematic near/2 checklist*) or (standardi* near/2
checklist*)):ti,ab
#20 ((elicit*NEAR/2 check-list*) or (evoke* near/2 check-list*) or (solicit* near/2 check-list*) or (unsolicit* near/2 check-list*) or (self-
report* near/2 check-list*) or (participant-report* near/2 check-list*) or (subject-report* near/2 check-list*) or (self-administer* near/
2 check-list*) or (spontaneous* near/2 check-list*) or (prompt near/2 check-list*) or (prompted near/2 check-list*) or (unprompted
near/2 check-list*) or (open-ended near/2 check-list*) or (structured near/2 check-list*) or (systematic near/2 check-list*) or (standardi*
near/2 check-list*)):ti,ab
#21 ((elicit*NEAR/2 query) or (evoke* near/2 query) or (solicit* near/2 query) or (unsolicit* near/2 query) or (self-report* near/2
query) or (participant-report* near/2 query) or (subject-report* near/2 query) or (self-administer* near/2 query) or (spontaneous*
near/2 query) or (prompt near/2 query) or (prompted near/2 query) or (unprompted near/2 query) or (open-ended near/2 query) or
(structured near/2 query) or (systematic near/2 query) or (standardi* near/2 query)):ti,ab
#22 ((elicit*NEAR/2 querie*) or (evoke* near/2 querie*) or (solicit* near/2 querie*) or (unsolicit* near/2 querie*) or (self-report* near/2
querie*) or (participant-report* near/2 querie*) or (subject-report* near/2 querie*) or (self-administer* near/2 querie*) or (spontaneous*
near/2 querie*) or (prompt near/2 querie*) or (prompted near/2 querie*) or (unprompted near/2 querie*) or (open-ended near/2
querie*) or (structured near/2 querie*) or (systematic near/2 querie*) or (standardi* near/2 querie*)):ti,ab
#23 ((elicit*NEAR/2 form?) or (evoke* near/2 form?) or (solicit* near/2 form?) or (unsolicit* near/2 form?) or (self-report* near/2
form?) or (participant-report* near/2 form?) or (subject-report* near/2 form?) or (self-administer* near/2 form?) or (spontaneous*
near/2 form?) or (prompt near/2 form?) or (prompted near/2 form?) or (unprompted near/2 form?) or (open-ended near/2 form?) or
(structured near/2 form?) or (systematic near/2 form?) or (standardi* near/2 form?)):ti,ab
#24 ((elicit*NEAR/2 complain*) or (evoke* near/2 complain*) or (solicit* near/2 complain*) or (unsolicit* near/2 complain*) or (self-
report* near/2 complain*) or (participant-report* near/2 complain*) or (subject-report* near/2 complain*) or (self-administer* near/
2 complain*) or (spontaneous* near/2 complain*) or (prompt near/2 complain*) or (prompted near/2 complain*) or (unprompted
near/2 complain*) or (open-ended near/2 complain*) or (structured near/2 complain*) or (systematic near/2 complain*) or (standardi*
near/2 complain*)):ti,ab
#25 (”spontaneous report*“ or ”self report*“ or ”participant report*“ or ”patient report*“ or ”subject report*“ or ”self administer*“):
ti,ab
#26 #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25
#27 #14 and #26
100Eliciting adverse effects data from participants in clinical trials (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
CCTR
Search Name: Elicitation of AE narrower
Last Saved: 02/05/2013 09:50:07.597
Description:
16th March 2015 repeated pubn date 2013-5 retrieved 248
ID Search
#1 MeSH descriptor: [Adverse Drug Reaction Reporting Systems] this term only
#2 MeSH descriptor: [Drug Toxicity] this term only
#3 Any MeSH descriptor with qualifier(s): [Adverse effects - AE, Drug effects - DE]
#4 ((drug? near/2 safety) or (drug? near/2 harm?) or (drug? near/2 adverse) or (drug? near/2 undesirable) or (drug? near/2 tolerability)
or (drug? near/2 toxicity) or (drug? near/2 effect?) or (drug? near/2 event?) or (drug? near/2 symptom?)):ti
#5 ((adverse near/2 effect?) or (adverse near/2 reaction?) or (adverse near/2 event?) or (adverse near/2 outcome?) or (adverse near/2
symptom?)):ti
#6 ((side near/2 effect?) or (side near/2 reaction?) or (side near/2 event?) or (side near/2 outcome?) or (side near/2 symptom?)):ti
#7 ((undesirable near/2 effect?) or (undesirable near/2 reaction?) or (undesirable near/2 event?) or (undesirable near/2 outcome?) or
(undesirable near/2 symptom?)):ti
#8 ((”treatment emergent“ near/2 effect?) or (”treatment emergent“ near/2 reaction?) or (”treatment emergent“ near/2 event?) or
(”treatment emergent“ near/2 outcome?) or (”treatment emergent“ near/2 symptom?)):ti,ab
#9 ((”treatment related“ near/2 effect?) or (”treatment related“ near/2 reaction?) or (”treatment related“ near/2 event?) or (”treatment
related“ near/2 outcome?) or (”treatment related“ near/2 symptom?)):ti
#10 (”adverse effect*“ near/3 assess*) or (”adverse effect*“ near/3 measur*) or (”adverse effect*“ near/3 detect*) or (”adverse effect*“
near/3 notify) or (”adverse effect*“ near/3 notification*):ti,ab
#11 (”adverse event*“ near/3 assess*) or (”adverse event *“ near/3 measur*) or (”adverse event *“ near/3 detect*) or (”adverse event *“
near/3 notify) or (”adverse event *“ near/3 notification*):ti,ab
#12 (”adverse reaction*“ near/3 assess*) or (”adverse reaction *“ near/3 measur*) or (”adverse reaction *“ near/3 detect*) or (”adverse
reaction *“ near/3 notify) or (”adverse reaction *“ near/3 notification*):ti,ab
#13 (”side effect*“ near/3 assess*) or (”side effect*“ near/3 measur*) or (”side effect*“ near/3 detect*) or (”side effect*“ near/3 notify)
or (”side effect*“ near/3 notification*):ti,ab
#14 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13
#15 ((elicit*NEAR/2 questionnaire*) or (evoke* near/2 questionnaire*) or (solicit* near/2 questionnaire*) or (unsolicit* near/2 question-
naire*) or (self-report* near/2 questionnaire*) or (participant-report* near/2 questionnaire*) or (subject-report* near/2 questionnaire*)
or (self-administer* near/2 questionnaire*) or (spontaneous* near/2 questionnaire*) or (prompt near/2 questionnaire*) or (prompted
near/2 questionnaire*) or (unprompted near/2 questionnaire*) or (open-ended near/2 questionnaire*) or (structured near/2 question-
naire*) or (systematic near/2 questionnaire*) or (standardi* near/2 questionnaire*)):ti,ab
#16 ((elicit*NEAR/2 report?) or (evoke* near/2 report?) or (solicit* near/2 report?) or (unsolicit* near/2 report?) or (self-report? near/2
report?) or (participant-report? near/2 report?) or (subject-report? near/2 report?) or (self-administer* near/2 report?) or (spontaneous*
near/2 report?) or (prompt near/2 report?) or (prompted near/2 report?) or (unprompted near/2 report?) or (open-ended near/2 report?
) or (structured near/2 report?) or (systematic near/2 report?) or (standardi* near/2 report?)):ti,ab
#17 ((elicit*NEAR/2 enquir*) or (evoke* near/2 enquir*) or (solicit* near/2 enquir*) or (unsolicit* near/2 enquir*) or (self-report*
near/2 enquir*) or (participant-report* near/2 enquir*) or (subject-report* near/2 enquir*) or (self-administer* near/2 enquir*) or
(spontaneous* near/2 enquir*) or (prompt near/2 enquir*) or (prompted near/2 enquir*) or (unprompted near/2 enquir*) or (open-
ended near/2 enquir*) or (structured near/2 enquir*) or (systematic near/2 enquir*) or (standardi* near/2 enquir*)):ti,ab
#18 ((elicit*NEAR/2 inquir*) or (evoke* near/2 inquir*) or (solicit* near/2 inquir*) or (unsolicit* near/2 inquir*) or (self-report* near/2
inquir*) or (participant-report* near/2 inquir*) or (subject-report* near/2 inquir*) or (self-administer* near/2 inquir*) or (spontaneous*
near/2 inquir*) or (prompt near/2 inquir*) or (prompted near/2 inquir*) or (unprompted near/2 inquir*) or (open-ended near/2
inquir*) or (structured near/2 inquir*) or (systematic near/2 inquir*) or (standardi* near/2 inquir*)):ti,ab
#19 ((elicit*NEAR/2 checklist*) or (evoke* near/2 checklist*) or (solicit* near/2 checklist*) or (unsolicit* near/2 checklist*) or (self-
report* near/2 checklist*) or (participant-report* near/2 checklist*) or (subject-report* near/2 checklist*) or (self-administer* near/2
checklist*) or (spontaneous* near/2 checklist*) or (prompt near/2 checklist*) or (prompted near/2 checklist*) or (unprompted near/2
checklist*) or (open-ended near/2 checklist*) or (structured near/2 checklist*) or (systematic near/2 checklist*) or (standardi* near/2
checklist*)):ti,ab
#20 ((elicit*NEAR/2 check-list*) or (evoke* near/2 check-list*) or (solicit* near/2 check-list*) or (unsolicit* near/2 check-list*) or (self-
report* near/2 check-list*) or (participant-report* near/2 check-list*) or (subject-report* near/2 check-list*) or (self-administer* near/
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2 check-list*) or (spontaneous* near/2 check-list*) or (prompt near/2 check-list*) or (prompted near/2 check-list*) or (unprompted
near/2 check-list*) or (open-ended near/2 check-list*) or (structured near/2 check-list*) or (systematic near/2 check-list*) or (standardi*
near/2 check-list*)):ti,ab
#21 ((elicit*NEAR/2 query) or (evoke* near/2 query) or (solicit* near/2 query) or (unsolicit* near/2 query) or (self-report* near/2
query) or (participant-report* near/2 query) or (subject-report* near/2 query) or (self-administer* near/2 query) or (spontaneous*
near/2 query) or (prompt near/2 query) or (prompted near/2 query) or (unprompted near/2 query) or (open-ended near/2 query) or
(structured near/2 query) or (systematic near/2 query) or (standardi* near/2 query)):ti,ab
#22 ((elicit*NEAR/2 querie*) or (evoke* near/2 querie*) or (solicit* near/2 querie*) or (unsolicit* near/2 querie*) or (self-report* near/2
querie*) or (participant-report* near/2 querie*) or (subject-report* near/2 querie*) or (self-administer* near/2 querie*) or (spontaneous*
near/2 querie*) or (prompt near/2 querie*) or (prompted near/2 querie*) or (unprompted near/2 querie*) or (open-ended near/2
querie*) or (structured near/2 querie*) or (systematic near/2 querie*) or (standardi* near/2 querie*)):ti,ab
#23 ((elicit*NEAR/2 form?) or (evoke* near/2 form?) or (solicit* near/2 form?) or (unsolicit* near/2 form?) or (self-report* near/2
form?) or (participant-report* near/2 form?) or (subject-report* near/2 form?) or (self-administer* near/2 form?) or (spontaneous*
near/2 form?) or (prompt near/2 form?) or (prompted near/2 form?) or (unprompted near/2 form?) or (open-ended near/2 form?) or
(structured near/2 form?) or (systematic near/2 form?) or (standardi* near/2 form?)):ti,ab
#24 ((elicit*NEAR/2 complain*) or (evoke* near/2 complain*) or (solicit* near/2 complain*) or (unsolicit* near/2 complain*) or (self-
report* near/2 complain*) or (participant-report* near/2 complain*) or (subject-report* near/2 complain*) or (self-administer* near/
2 complain*) or (spontaneous* near/2 complain*) or (prompt near/2 complain*) or (prompted near/2 complain*) or (unprompted
near/2 complain*) or (open-ended near/2 complain*) or (structured near/2 complain*) or (systematic near/2 complain*) or (standardi*
near/2 complain*)):ti,ab
#25 (”spontaneous report*“ or ”self report*“ or ”participant report*“ or ”patient report*“ or ”subject report*“ or ”self administer*“):
ti,ab
#26 #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25
#27 #14 and #26
C O N T R I B U T I O N S O F A U T H O R S
EA wrote the protocol with input from KB, CC, and NM. EA and NM or CL independently screened titles, abstracts or full texts
for eligibility and KB had input where there was a need for discussion. EA extracted the data which was checked by CL. EA and CL
independently undertook the risk of bias assessment. EA conducted the analysis and review write-up with input from KB and CC. All
authors approved the final analyses and report of the review.
D E C L A R A T I O N S O F I N T E R E S T
The review authors have no interests to declare.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
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External sources
• Bill and Melinda Gates Foundation, USA.
This review was supported by the ACT Consortium
which is funded through a grant from the Bill and Melinda Gates
Foundation to the London School of Hygiene and Tropical Medicine
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The scope of the review was clarified as regards to the definition of AEs in ’Types of data”, effect measures in ’Types of outcome
measures’, that searches were limited to English, and the use of Popay 2006 to guide the narrative synthesis.
N O T E S
None.
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